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ABSTRACT OF DISSERTATION

PHARMACEUTICALLY ENGINEERED NANOPARTICLES FOR ENHANCING
IMMUNE RESPONSES TO HIV-1 TAT AND GAG p24 PROTEINS
These studies were aimed at investigating the potential application of
nanoparticles engineered from oil-in-water microemulsion precursors for enhancing
immune responses to HIV-1 Tat and Gag p24 proteins. Both of the HIV-1 proteins have
been reported to be critical in the virus life cycle and are being evaluated in clinical trials
as vaccine candidates.
Anionic nanoparticles were prepared using emulsifying wax as the oil phase and
Brij 78 and sodium dodecyl sulfate as the surfactants. The resulting nanoparticles were
coated with Tat and were demonstrated to produce superior immune responses after
administration to BALB/c mice compared to Tat adjuvanted with Alum. Similarly,
cationic nanoparticles were prepared using emulsifying wax and Brij 78 and cetyl
trimethyl ammonium bromide as the surfactants. The cationic nanoparticles were
investigated for delivery of immunostimulatory adjuvants, namely three Toll-like
receptor ligands, for obtaining synergistic enhancements in immune responses to a model
antigen, Ovalbumin (OVA).
In vitro and in vivo studies were carried out to elucidate possible mechanisms by
which nanoparticles may result in enhancements in immune responses. In vitro studies
were carried out to evaluate the uptake of nanoparticles into dendritic cells and to assess
the release of pro-inflammatory cytokines from dendritic cells in the presence of
nanoparicles. In vivo studies were carried out using a MHC class I restricted transgenic
mouse model to investigate the potential for nanoparticles coated with OVA to enhance
presentation of the protein to CD8+ T cells compared to OVA alone.
Finally, the preparation of nanoparticles with a low amount of surface chelated
nickel for high affinity binding to histidine-tagged (his-tag) proteins was investigated. It
was hypothesized that this strengthened interaction of his-tag protein to the nickel
chelated nanoparticles (Ni-NPs) would result in a greater uptake of antigen in vivo;
therefore, enhanced immune responses compared to protein bound to anionic
nanoparticles. In vivo evaluation of his-tag HIV-1 Gag p24 bound to Ni-NPs resulted in
enhanced immune responses compared to protein either adjuvanted with Alum or coated
on the surface of nanoparticles.

KEYWORDS: Nanoparticles, HIV-1 Tat, HIV-1 Gag p24, Adjuvants, Toll-like
receptor ligands, Ovalbumin, OT-1 Transgenic mouse model.
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Chapter 1

Introduction and statement of problem

Adjuvants can be defined as any material included as a component in a vaccine to
aid in producing more robust cellular and/or humoral immune responses to the antigen of
interest. Adjuvants can be broadly categorized as immunostimulatory or particulate,
including particulate delivery systems. Many of the early developments in vaccines,
including the use of adjuvants, have been empirically derived on a trial and error basis
without in depth knowledge of the exact mechanisms involved in generating effective
immune responses. As we gain a better understanding of the immune system and its
components, we can design more effective vaccines. An important strategy in designing
more effective vaccines would be to explore the use of novel delivery systems for
effectively eliciting the immune responses necessary for protection from viral and
bacterial pathogens. The need for safe and effective delivery systems is even more
evident with new generation vaccines where peptides, protein subunits, or DNA are the
antigens. Unlike traditional vaccines such as live attenuated or whole killed pathogens,
new generation vaccines are considered to be much safer; however, new generation
vaccines produce poor immune responses when administered alone. Therefore, in many
cases, adjuvants are typically used in conjunction with the antigen to enhance the immune
response [1,2].
Currently, aluminum-based mineral salts (Alum) are the most widely used
adjuvants for human vaccination. Alum has proven to be safe and effective for antibody
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production (humoral response); however, it is not very effective for generating strong
cellular responses with recombinant proteins [3], which are considered to be important in
providing protection from many viruses such as the human immunodeficiency virus
(HIV) [4]. While many new adjuvants have entered clinical trials, most have been
proven too toxic to be used routinely in humans [1]. Ideal adjuvants for routine human
vaccine applications should be safe, cost-effective, relatively simple to manufacture and
scale-up, versatile, and should produce balanced (humoral and cellular) immune
responses.
Particulate delivery systems such as microparticles and liposomes have been
extensively investigated for enhancing immune responses to protein-based vaccines [5-9].
These systems offer several advantages over other adjuvants for enhancing immune
responses since: 1) they are naturally targeted for uptake by APCs due to their similar
size to pathogens; 2) targeting ligands for APCs can be incorporated on the surface of the
particles; and 3) immunostimulatory molecules can be incorporated with the particles for
synergistic enhancements in immune responses. Moreover, a number of studies suggest
that smaller particles (<1 micron) are more effective at generating immune responses
compared to larger particles (>10 microns) [10-13].
Nanoparticles prepared from oil-in-water microemulsion precursors have been
shown to be effective at enhancing immune responses to plasmid DNA [14,15] and a
model protein, β-galactosidase [16].

The present research was focused on further

investigating the utility of these nanopariticles for enhancing immune responses to two
HIV proteins, Tat and Gag p24. Both proteins are of significant interest for HIV vaccine
development since they have been reported to be relatively conserved and critical in the
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HIV life cycle. In addition, both proteins are currently being evaluated in clinical trials
[17-19]. In vitro and in vivo studies evaluating parameters such as uptake and cell
activation by nanoparticles were carried out to gain a better understanding of the
mechanism by which nanoparticles may be enhancing immune responses. These types of
studies are considered to be important as they would have implications on improvements
that could be made to develop of more effective vaccine delivery systems.

Copyright © Jigna D. Patel 2006
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Chapter 2
Plan of research
The overall goal of this research was to investigate the application of pharmaceutically
engineered nanoparticles for HIV-1 Tat and Gag p24 proteins to elicit enhanced as well
as balanced immune responses compared to protein adjuvanted with Alum. This research
was guided by three main hypotheses:

Hypothesis 1. Mice dosed with anionic nanoparticles coated with HIV-1 proteins will
result in enhanced humoral and cellular immune responses compared to those dosed with
protein adjuvanted with Alum.
Hypothesis 2. Increasing the affinity of the protein antigen for the nanoparticles will
result in a more stable attachment and lead to a corresponding enhancement in the
immune responses in vivo compared to antigens coated on anionic nanoparticles by
charge interaction.
Hypothesis 3. Mice dosed with nanoparticles co-formulated with protein antigen and an
immunostimulatory molecule will produce enhanced immune responses compared to
those dosed with protein antigen with nanoparticles or immunostimulatory molecule
alone.

To evaluate these hypotheses, the research plan described in sections 2.1 to 2.4 was
carried out.
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2.1

Formulation and in vivo assessment of anionic nanoparticles
The main objectives of this section were: 1) to demonstrate that stable anionic

nanoparticles could be prepared; 2) to formulate Tat with anionic nanoparticles; and 3) to
evaluate the in vivo responses of Tat-coated nanoparticles compared to Tat adjuvanted
with Alum.

Anionic nanoparticles in this study were prepared from oil-in-water

microemulsion precursors using emulsifying wax as the oil phase and Brij 78 and sodium
dodecyl sulfate (SDS) as the surfactants.

The nanoparticles were characterized by

particle size, charge, and transmission electron microscopy. Tat was formulated with
anionic nanoparticles and further characterized by measuring the resulting size and
charge of the particles. The in vivo immune responses to Tat were evaluated by dosing
BALB/c mice with 0.2 to 5 μg Tat either coated on anionic nanoparticles or adjuvanted
with Alum. The Tat-specific immune responses were evaluated by measuring the serum
IgG levels, the ability of the anti-sera to neutralize extracellular Tat, and mapping the
antibody epitopes generated to Tat.

2.2

Formulation and in vivo assessment of immunostimulatory molecules and
Ovalbumin (OVA) coated on cationic nanoparticles
The immunostimulatory molecules investigated for use with nanoparticles are

classified as Toll-like receptor (TLR) ligands. The aims of this section were as follows:
1) demonstrate the preparation of cationic nanoparticles; 2) demonstrate that OVA could
be coated on cationic nanoparticles; 3) demonstrate that TLR ligands and OVA could be
coated on cationic nanoparticles; 4) evaluate the TLR ligands and OVA formulations in
BALB/c mice to identify the optimal TLR ligand formulation for future studies with
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nanoparticles. Cationic nanoparticles were prepared from oil-in-water microemulsion
precursors using emulsifying wax and Brij 78 and cetyl trimethyl ammonium bromide
(CTAB) as the surfactants. The TLR ligands evaluated in this section were lipoteichoic
acid (LTA), a synthetic double stranded RNA analog (Poly I:C), and a 20-mer synthetic
oligonucleotide containing CpG motifs (CpG). The nanoparticles were characterized
before and after coating with OVA or the TLR ligands by measuring the size and charge
of the particles. Initially, a short-term in vivo study was carried out in mice to identify
the best TLR ligand for further evaluation. For this study, mice were dosed once with 50
μg of the various TLR ligands and 5 μg OVA coated on nanoparticles. The immune
responses were evaluated on day 8 by measuring T cell proliferation in the lymph nodes.
Based on the results of this study, the TLR ligand CpG was chosen for further evaluation
and a follow up in vivo study was carried out to evaluate the immune responses to CpG
(10 μg) and OVA (5 μg) coated on nanoparticles compared to CpG or nanoparticles alone
formulated with OVA. The immune responses in this follow up study were evaluated by
measuring OVA-specific serum IgG titers and OVA-specific splenocyte proliferation.

2.3

In vitro and in vivo assessment of mechanism(s) of immune response
enhancement by nanoparticles
This main objective of this section was to elucidate possible mechanism(s) by

which nanoparticles may be enhancing immune responses to antigens in vivo. These
studies were separated into two parts. In the first part, in vitro studies were carried to
evaluate: 1) the uptake of various types of nanoparticles (neutral, anionic, and cationic)
by murine bone-marrow derived dendritic cells (BMDDCs); 2) the release of pro-
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inflammatory cytokines in human DCs and BMDDCs; and 3) the release of IL-12 from
BMDDCs using CpG-coated NPs compared to CpG alone. The second part of this study
involved the use of a MHC class I restricted OVA transgenic mouse model (OT-1) for
evaluating the uptake and presentation to T cells in vivo of OVA-coated nanoparticles
compared to OVA alone. For these studies, T lymphocytes from the spleens of OT-1
mice were labeled with a green-fluorescent marker and transferred by tail-vein into
C57BL/6 mice. The OVA containing formulations were injected 24 hours later and T
cell proliferation in the lymph nodes was measured after 3 days.

2.4

Formulation and in vivo evaluation of nickel-coated nanoparticles
The goal of this section was to strengthen the interaction of antigens with the

nanoparticles for obtaining greater enhancements in immune responses compared to
simple anionic nanoparticles. The use of chelated nickel for purification of proteins
containing a hexa-histidine tag (his-tag) has been used extensively and this interaction
has been reported to be extremely strong, in the order of magnitude of biotin-avidin
interactions. This approach of incorporating nickel on the nanoparticles for strengthening
the interaction with proteins was investigated. More specifically, the aim of these studies
was to: 1) demonstrate that nanoparticles containing a small amount of chelated nickel
could be prepared; 2) demonstrate that the nickel coated nanoparticles could bind to histag proteins; and 3) evaluate the immune response to his-tag HIV-1 Gag p24 bound on
nickel nanoparticles compared to protein adsorbed on anionic nanoparticles or adjuvanted
with Alum.

Nanoparticles having a small amount of surface-chelated nickel were

prepared using emulsifying wax, Brij 78, and a nickel chelating lipid 1,2-dioleoyl-sn-
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glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic acid)succinyl].

The resulting

nickel nanoparticles (Ni-NPs) were characterized by particle size and the amount of
nickel entrapped in the particles was determined by atomic emission spectroscopy. Initial
studies to demonstrate binding of his-tagged proteins to Ni-NPs were performed using
his-tag green fluorescent protein (GFP). The optimal binding and stability of his-tag GFP
bound to Ni-NPs was determined. Based on the GFP binding results, the optimal binding
ratios for his-tag HIV-1 Gag p24 were determined and further in vivo immune responses
to the protein formulated with Ni-NPs, Alum, and anionic nanoparticles were evaluated.

Copyright © Jigna D. Patel 2006

8

Chapter 3

Background and literature review

3.1

Vaccines

3.1.1

A brief history
Vaccination can be defined as “an overt attempt to use part or all of a microbial

pathogen to protect against that microbe” [20] with the ultimate goal being the induction
of appropriate immune responses to provide protection against a pathogen without
causing serious disease. Vaccines have proven to be highly effective at controlling many
infectious diseases and reducing disease related mortality over the last two centuries. In
fact, vaccines have been regarded as one of the greatest achievements in the reduction of
deaths due to infectious diseases, with the exception of safer water [21].
The introduction of vaccination is accredited to Edward Jenner, an English
physician, for his effort in deliberately inoculating a young boy with cowpox and
demonstrating this as an effective strategy for controlling smallpox infection when it was
introduced to the boy six weeks later [21]. Jenner referred to the inoculum as vaccine
(derived from the Latin word for cow, vacca) and termed this procedure vaccination [22],
entitling Jenner as the father of modern vaccinology in historical records. However, the
idea of protection from infectious diseases was long before recognized in China and India
in the 16th century where a process termed variolation was practiced to reduce severity of
smallpox. This process involved the introduction of dried pus from smallpox pustules
into healthy individuals through the nose or the skin [21]. The process of variolation via
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the skin (cutaneous variolation) eventually spread to through the Middle East, Africa,
Turkey, and finally introduced to Great Britain by Lady Mary Wortley Montagu in 1721
[20,21,23].
The next major advance in vaccination came about in 1879 with Louis Pasteur’s
work on the attenuation of chicken cholera bacterium. Pasteur noted that a culture of
chicken cholera left exposed to air over a long period provided protection against
challenge with non-attenuated cholera in immunized chickens. Based on these initial
observations with the chicken cholera cultures, Pasteur believed that pathogens could be
attenuated by exposure to various environmental factors such as elevated temperatures,
oxygen, and chemicals.

Further experimentation during this period by Pasteur and

colleagues confirmed his hypothesis and led to the development of both a rabies vaccine
and an anthrax vaccine in the 1880’s [21].
These early pioneering efforts by Jenner and Pasteur paved the foundation for
future developments in vaccines. A brief historical outline of the major developments in
vaccines is presented in Table 3.1. As evident from this Table, since the initial discovery
of an effective smallpox vaccination strategy, numerous other vaccines have come into
development. Moreover, vaccination has been effective in controlling many diseases
including: smallpox, diphtheria, tetanus, yellow fever, pertussis, Haemophilus influenza
type b disease, poliomyelitis, measles, mumps, and rubella [21]. However, the ultimate
triumph in vaccinology to date has been the global eradication of smallpox, declared in
1980 by the World Health Organization (WHO) [22].
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3.1.2

Types of vaccines
Vaccines can be classified into three main categories: live attenuated, whole-

killed, or genetically engineered vaccines. The use of live attenuated or whole killed
organisms as vaccine components have been recognized since the 18th century, as
described above. These approaches are typically referred to as traditional vaccines.
Recently, a better understanding of molecular mechanisms and genetic techniques has led
to the development of a new class of vaccines that are comprised of DNA, peptides or
proteins, more commonly referred to as new generation vaccines.

3.1.2.a Traditional vaccines
The first successful vaccines demonstrated by Jenner and Pasteur were based on
live attenuated organisms.

Live attenuated vaccines are composed of pathogens

weakened by passage or culture conditions causing the organism to be non-virulent but
still immunogenic. Examples of the earliest live attenuated vaccines used in humans
include the smallpox and rabies virus vaccines.

It took another 40 years after the

introduction of rabies vaccine by Pasteur for the next major live attenuated vaccine to be
developed, which occurred in 1920’s with the introduction of the Bacille CalmetteGuérin (BCG) vaccine for tuberculosis (TB) by Camille Calmette and Alphonse Guérin.
The first BCG vaccine was developed by repeated passage of the mycobacterium in
bovine bile and after 13 years and approximately 230 passages, the attenuated BCG strain
was obtained and evaluated orally in clinical trials with children in 1921, with the
widespread use in humans initiated in 1927 [21]. The value of BCG vaccines has been
questioned because of the varying effectiveness observed in controlled trials with the
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vaccine where some trials demonstrate benefits while others show no benefit in providing
protection from the bacteria by vaccination. Despite this ongoing controversy over the
use of BCG vaccines, they are still in use throughout the world with the exception of a
few industrialized countries such as United States and Netherlands [24]. Moreover,
renewed interests in these vaccines have been stimulated with the emergence of
tuberculosis associated in human immunodeficiency virus (HIV) infected patients.
Perhaps the most significant achievement in the use of live attenuated vaccines is the
introduction of an oral poliovirus vaccine (OPV) in 1962, resulting in a dramatic decrease
in poliomyelitis – one of the diseases targeted of eradication by WHO [25]. Additional
examples of live attenuated vaccines that have made significant contributions in reducing
disease rates include the mumps, rubella, and measles vaccines, which have become the
foundation of routine pediatric immunization and were licensed as combination vaccines
(MMR) in 1971 [26,27] . Although live attenuated vaccines have been used widely and
are generally more effective than inactivated vaccines, a major disadvantage of these
types of vaccines is that they tend to pose numerous safety concerns as the organisms
could revert back to a more virulent strain and cause disease.
The use of whole-killed vaccines began soon after Pasteur’s initial success in
generating attenuated strains of chicken cholera. Daniel Salmon and Theobald Smith are
credited for demonstrating that whole-killed pathogens retained their immunogenicity
[28].

In 1896, the work by Wilhelm Kolle demonstrated that agar-grown, heat

inactivated Vibrio cholerae could be used as a human vaccine for cholera. Around the
same time Richard Pfeiffer and Almroth Wright demonstrated that cultures of Salmonella
typhi could be inactivated with heat and preserved in phenol. This demonstration led to
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the development of a typhoid fever vaccine in 1896 that eventually (1915) became widely
used in the military in Europe [29]. Some examples of vaccines to infectious agents that
have been developed in this category include the inactivated poliovirus (IPV) vaccine,
Hepatitis A vaccine, and the influenza vaccine. The use of IPV vaccine has replaced the
more effective OPV vaccine in the U.S. and many European countries due to some safety
concerns raised by some reported cases of paralysis due to the live attenuated vaccine and
more importantly, because the disease is very rare in these countries [30].

3.1.2.b New generation vaccines
The majority of early vaccines developed were based on live attenuated or whole
killed organisms. However, the growing knowledge of infectious diseases during late
19th and early 20th century paved the pathway for the identification of pathogen
components and exploring the use of these individual components for developing
vaccines. In the late 1880s, Roux, Yersin, Behring, and Kitasato realized that diphtheria
bacillus produced an extracellular toxin and that sera from infected animals contained an
antitoxin able to neutralize the diphtheria toxin in culture. These discoveries paved the
foundation for future developments of inactivated toxins, referred to as toxoids, as
vaccine components. In fact, as early as 1923 it was realized that the diphtheria toxin
could be inactivated by formalin and enabled Gaston Ramon to develop the earliest
subunit vaccines, namely diphtheria and tetanus vaccines [21].

With additional

technological advancements, the ability to separate and extract bacterial components led
to the development of polysaccharides, components of bacterial cell walls, as viable
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vaccine strategies in cases such as the early pneumococcal and meningococcal vaccines
[31].
From these early discoveries, it is apparent that advancements in technology as
well as an understanding of both pathogens and immune functions have contributed
immensely to the development of safer, more effective vaccines throughout their history.
This is even more apparent in the recent years where genetic engineering techniques have
contributed immensely in developing safer vaccines.

For example, the use of

recombinant DNA has enabled production of large quantities of well-defined, purified
proteins that have been used for a variety of applications including the development of
safer protein-based vaccines. In fact, the earliest success in using genetic engineering for
vaccine development came about in the early 1980’s with the introduction of a yeast
derived Hepatitis B subunit vaccine, which had previously been obtained from
purification of infected individual’s plasma [32,33]. Genetic engineering techniques have
also opened up avenues in the rational design of proteins using site-directed mutagenesis
to produce proteins with altered properties that are not naturally occurring in the
pathogen and thus, may be less detrimental or reactogenic in the host, i.e. toxoids. One
example of this application is in the improvement of an existing pertussis vaccine, where
pertussis toxin was detoxified by a double mutations to the protein which rendered it
safer while still retaining its antigenic conformation and immunogenicity in vivo [34,35].
This protein-based pertussis vaccine is approved for human use and has replaced the
whole-cell pertussis vaccine in many countries [36].
Another advancement in vaccines permitted by genetic engineering technology
occurred in 1992 when Johnston’s group reported that plasmid DNA (pDNA) was

14

effective for immunization, referred to as genetic immunization [37]. Genetic vaccines
take advantage of the use of plasmid DNA for expression of a gene encoding for a
specific antigen(s) under the control of a eukaryotic or viral promoter (such as a CMV
promoter) [38]. DNA vaccines, once administered, allow for the expression of protein
inside the cells leading to processing and presentation by the major histocompatability
(MHC) class I pathway and generating strong cellular responses.

Indeed, strong

cytotoxic T lymphocyte (CTL) responses have been reported with genetic vaccines in
several different animal models [39-41]. Genetic vaccines enable the delivery and coexpression of multiple antigens or epitopes of a pathogen on one plasmid [42].
Moreover, the delivery of antigen-cytokine fusions encoded on the same plasmid has also
been investigated as a method for obtaining robust enhancements in immune responses
[43-45]. The most common route of administration for delivery of genetic vaccines has
been via intramuscular injection; although, many new devices and alternative approaches,
such as topical application and use of gene gun delivery devices, have been investigated
more recently in effort to enhance immune responses by targeting dendritic cells (DCs)
[14,42,46-48]. Unlike many of the approaches to vaccines discussed so far, genetic
immunization has proven to be successful in mice; however, it has demonstrated limited
effectiveness in non-human primates and humans after conventional intramuscular
administration, requiring extremely high doses of pDNA and in some cases failing to
induce antibody responses [38]. More recently, genetic immunization using low doses of
DNA in humans has been reported with the use of gene gun devices as an alternative to
intramuscular injection by PowderMed, Inc. (http://www.powdermed.com). This success
has been brought about by the PMED™ technology, which involves the delivery of DNA
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coated onto gold particles (1-3 micron in size) into the epidermis using a high pressure
helium gene gun. Phase I clinical trials with PMED™ for influenza vaccine resulted in
100% seroconversion with as little as 4 μg dose of DNA. This approach is currently
being explored for cancer, genital herpes, Hepatitis B, and HIV vaccines in phase I
clinical trials. In addition, genetic immunization show promising applications in primeboost vaccine strategies, where the pDNA vaccine may be used for initial immunization
followed by boosting with another type of vaccine, i.e. viral vectors or subunit-based
vaccines [49]. Thus, genetic immunization may prove successful with the development
of more effective delivery devices in combination with heterologous prime-boost
immunization strategies. A major safety concern raised with the use of pDNA based
vaccines is the potential of the plasmid to integrate into the host genome [42].
The candidate subunit or pDNA based vaccines deem themselves much safer than
traditional approaches as they are purified and well-defined entities; however, they are
less immunogenic than their counterparts due to removal of various components of the
whole pathogen which can function as recognition elements in the body and trigger the
innate immune system – naturally mediating enhanced immune responses. Therefore,
one downfall of new generation vaccines is that they are not very immunogenic when
administered by themselves and many of these approaches require the use of adjuvants to
generate strong immune responses.

3.1.3

Trends and future developments in vaccines
Although significant developments have been made in vaccines, a number of

challenges still lie ahead for the prevention of numerous diseases.
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The growing

knowledge and technological advancements in various areas of vaccinology have made
this an exciting and prevailing field. It has become evident from past experiences that a
greater understanding of immunological functions and viral pathogenesis for many
organisms will be essential in developing effective vaccines for chronic infections such as
HIV, human cytomegalovirus, herpes simplex virus (HSV) and hepatitis C virus (HCV).
Moreover, vaccines have been traditionally used for preventing infectious diseases;
however, current trends demonstrate a shift in their application as there is a great deal
effort being focused on designing vaccines for non-infectious diseases such as
Alzheimer’s, cancer, autoimmune diseases, and for therapeutic applications for
controlling progression on to disease as in the case of HIV, HSV, and human
papillomavirus (HPV) [28].
Whereas the historical basis for vaccines was largely empirical, technological
advancements, in particular genetic engineering techniques, can potentially lead to a
more rational approach in design of vaccines. Several examples of the application of
genetic engineering techniques in generating safer, more effective vaccines have already
been presented in the previous section in the discussion of new generation vaccines.
Additional examples of the benefits of these techniques include, 1) attenuation of live
vaccines via gene deletions or mutations, 2) engineering bacterial or viral vectors to
express foreign proteins of interest, 3) generating reassortant viruses (i.e. influenza
vaccines) by combination of genes from two or more different viral strains, and 4)
generating T cell epitope based vaccines [50]. In spite of the successes of generating
more stable, less virulent live attenuated vaccines with these techniques, there is still a
significant concern in using this approach for many diseases. Moreover, the growing
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requirement for safer and molecularly well-defined entities imposed by regulatory
agencies lends future developments in this area towards the use of subunit based
vaccines. Therefore, a great deal of focus in this area has been placed on identifying the
key antigens in preventing or controlling infection as well as on finding newer, more
effective adjuvants due to their inherent need for enhancing immune responses with these
purified antigens [51]. Other key considerations for developing new vaccines include:
storage, stability, ease of manufacture and scale up, ease of administration or needle free
administration, and feasibility of single dose. The use of needle-free devices and singledose vaccination are particularly important for increased patient compliance.

3.2

Vaccinology and key mediators of immunity
Despite the successes of some of the earliest vaccines such as smallpox and polio,

many of these developments have been made empirically without much knowledge on
the functions of immune system and its components in regard to generating an effective
immune response. The most successful vaccines developed to date have been made for
pathogens that cause acute infections and that could be potentially cleared from the body
by the host’s immune system. Moreover, the effectiveness of many of these vaccines has
largely relied on the generation of high levels of neutralizing antibodies.

An

understanding of the immune system and its components has greatly advanced with
emerging chronic infections such as HCV, HIV etc. that cause persistent infections that
cannot be cleared by the body’s immune system even in the presence of strong immune
responses. Many, if not most, of these infections are intracellular and offer additional
challenges due to mutations in the virus, giving rise to varying strains. Thus, with the
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aim of developing effective vaccines for these more challenging infections, a greater
understanding of the immunological functions has been and continues to be gained. The
contributions of immunology to this area will be necessary for developing safer and more
effective vaccines, adjuvants, and delivery systems.
The immune systems and its functions can be divided into two categories: the
innate and adaptive immune system [52,53]. Both are essential in providing protection
from organisms and have specialized components that are involved in generating an
immune response. Although both systems are generally thought of as distinct, there is
considerable interplay in the two systems in fighting infections and they in fact share
some of components (i.e. antigen presenting cells). Key features of each system are
presented in Table 3.2.

3.2.1 Innate immune system
The innate immune system is often referred to the non-specific component of the
immune system [53]. This system is the first line of defense against pathogens and is
activated through recognition of non-specific, conserved molecular structures commonly
present on pathogens or groups of pathogens, but not found in the host, called pathogenassociated molecular patterns (PAMPs) [54,55]. Some examples of PAMPs include the
lipopolysaccharides (LPS) found in gram-negative bacteria and double-stranded RNA
produced by many viruses.

These PAMPs are recognized by a limited number of

pathogen recognition receptors (PRR), which are germline-encoded receptors present in
cells comprising the innate immune system [55,56]. Activation of the innate immune
system occurs within hours of encountering an organism and results in the production of
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pro-inflammatory cytokines such as interferons (IFN-α, β, and γ), interleukins (ILs), and
activation of complement pathway [52,55]. The immune response generated mediates
the clearance of the pathogen from the host; however, the immune response to the
pathogen is constant – no heightened immune response is generated with successive
exposures to the pathogen [52,53].
The activation of innate immune system is mediated by the recognition of
pathogens by PRR including Toll-like receptors (TLRs), scavenger receptors, and Fc
receptors.

A detailed review of the recognition, binding, and signaling processes

involved in the innate immune response is presented elsewhere (see references
[55,57,58]).

3.2.2

Adaptive immune system
Hallmarks of the adaptive immune system include high specificity and memory of

the specific immune responses generated [52]. Unlike the innate immune system, the
adaptive immune system is capable of generating stronger and higher immune responses
with successive exposures to the pathogen. Thus, it is possible to prevent or reduce the
course of infection upon re-exposure to the same pathogen – via the generation of a
memory response. This branch of the immune system is composed of three main cells:
antigen presenting cells (APCs), B lymphocytes (B cells) and T lymphocytes (T cells).
The APCs provide a key bridge between the innate and adaptive immune systems,
whereas, the lymphocytes are the mediators of the high specificity and memory
components unique to the adaptive immune system. Both lymphocytes involved in the
adaptive immune response are derived from a common lymphoid progenitor cell in the
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bone marrow; however, their maturation at different sites in the body raises these two cell
types [52].

Moreover, both naïve lymphocytes are located in specialized areas in

secondary lymphoid organs (i.e. the mucosal lymphoid tissues, draining lymph nodes and
spleen) where antigen recognition by these cells occurs, generating effector cells that can
participate in the antigen-specific response. Therefore, unlike innate immune system
which initiates responses at the site of infection, the adaptive immune responses are
initiated in the secondary lymphoid organs.

In addition, memory cells that are able to

respond more robustly to subsequent exposures to the same pathogen are generated
during adaptive immune responses. One major difference between the two lymphocytes
for antigen recognition is that B cells can directly recognize the antigen or pathogen
through receptors present on the cell surface, whereas T cells do not have the ability to
directly recognize the antigen and one of the functions of APCs is to process the antigen
and present peptide fragments bound to cell surface molecules for recognition by T cells.
The main interactions between the cells of the adaptive immune system leading to the
production of antigen specific immune responses are summarized in Figure 3.1. A brief
description of the various functions of the cells in generating an adaptive immune
response is given in the sections below (see references [52,53] for a comprehensive
review).

3.2.2.a Antigen presenting cells
Pathogens taken up and processed by APCs initiate a sequence of events that
ultimately leads to the activation of APCs and naïve T cells. APCs are found on most
tissues (i.e. skin and mucosa) and circulating throughout the body, constantly surveying
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the environment for invading organisms. The ingested pathogens are then processed into
peptide fragments (peptides of 9-15 amino acids), are conjugated to molecules encoded
by genes of the major histocompatability complex (MHC) and are presented on the
surface of APCs for T cell recognition.

This process is referred to as antigen

presentation. Two types of MHC molecules are present: MHC class I, which are present
on all cell types, and MHC class II, which are specifically expressed on APCs. MHC
class I molecules bind peptides of 9-10 amino acids, whereas MHC class II molecules
bind to longer peptide fragments of 10-15 amino acids in length.

The processing

pathway for the peptide fragments binding to these two MHC molecules is also distinct.
MHC class I molecules are generally thought to bind to processed fragments of a protein
synthesized in the cytoplasm, such as those resulting from infection from a virus. On the
other hand, MHC class II molecules primarily bind to peptide fragments of exogenously
derived proteins, which have been processed in the lysosomes. Naïve T cells possessing
receptors of the same specificity as the epitopes presented on these peptide-MHC
complexes can then bind to the cell surface; however, this interaction alone will not result
in activation of naïve T cells. Recognition of other cell surface molecules on the APCs
commonly referred to as co-stimulatory molecules by the T cell receptors is also
necessary to result in activation of the naïve T cells. While all APCs have the potential of
stimulating naïve T cells by up-regulating expression of MHC class II and co-stimulatory
molecules during infection, the most efficient APC and the primary APC responsible for
activation of naïve T cells are the dendritic cells (DCs) (discussed in detail in section
3.4).
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3.2.2.b T lymphocytes
Immature lymphocytes that leave the bone marrow and mature in the thymus give
rise to mature T lymphocytes or T cells. These cells can be further subdivided into two
categories depending on the expression on cell surface markers as CD4 and CD8 positive
T lymphocytes.

Both T cells also express the T cell receptor (TCR), which has

specificity for certain peptides and is involved in recognition of the MHC-peptide
complex presented on APCs. Immune responses mediated by T cells are generally
referred to as cell-mediated immune (CMI) responses.
The CD8 positive (CD8+) T cells also called cytotoxic T lymphocytes (CTLs) are
activated by the recognition of peptides presented on MHC class I molecules. Activation
of CTLs results in lysis of infected cells by recognition of the MHC class I-peptides on
these cells. The CD4 positive (CD4+) T cells are referred to as the T helper cells (Th)
and these cells can be further subdivided into Th1 and Th2 cells. T helper cells are
activated by the recognition of peptides presented on MHC class II molecules and the
type of Th cell formed is influenced by various factors (i.e. cytokines) during an
infection. For example, the release of pro-inflammatory cytokines such as IL-12 by
APCs during the innate immune response causes differentiation of naïve Th cells into
Th1 cells. The two Th cell types also result in production for distinctly different cytokine
profiles which are associated with mediating either cellular or humoral based immune
responses. Th1 cells release IL-2, IL-3, and IFN-γ and are associated with enhancing
cellular responses, which are necessary for combating intracellular pathogens. On the
other hand, Th2 cells mediate humoral responses by releasing the cytokines IL-4, IL-5,
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IL-6 and IL-10. Th2 responses are most effective at eliminating extracellular pathogens
such as bacteria.

3.2.2.c B lymphocytes
B lymphocytes, more commonly referred to as B cells, mature in the bone marrow
and are primarily responsible for producing antibodies (immunoglobulin, Ig) referred to
as the humoral immune response. Mature B cells express two types of Ig receptors on
their cell surface: IgM and IgD, which can directly recognize and bind to antigens. The
binding of an antigen to the B cell receptor results in endocytosis of the antigen-receptor
complex and processing of the antigen.

This process also ultimately leads to the

activation and differentiation of B cells into plasma cells, which are able to secrete
antigen specific antibodies that can circulate in the blood. The initial antibodies secreted
in an immune response are IgM and upon interaction with cytokines released from
activated Th cells, the isotypes of antibody produced by plasma cells can be varied to
IgG, IgE or IgA (a process referred to as isotype switching).
The uptake and processed antigen can also be presented on the surface of MHC
class II molecules on B cells. Although they are not very efficient stimulators of naïve T
cells, B cells that have been induced to express the necessary co-stimulatory molecules
can function as APCs, stimulating naïve T cells.

3.3

Adjuvants and mechanism of action
Adjuvants, derived from the Latin word adjuvare which means to help, have been

described as any material used with antigens in immunization that aid in enhancing the
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cellular and/or humoral immune responses [2,59].

The use of adjuvants was first

introduced by Ramon in 1925, who demonstrated that immune responses to diphtheria
and tetanus toxoid could be enhanced by injection with other compounds such as agar,
tapioca, lecithin, starch oil, saponin, and breadcrumbs [60]. In the recent years, a great
deal of attention has focused on the development and application of new adjuvants. This
trend has been introduced partially by the interest in using new generation vaccines,
which are purified and lack many of the components of pathogens recognized by the
innate immune system and therefore, tend to produce poor immune responses when given
alone. Adjuvants can also be used to modulate the type of immune response generated to
the antigen. Appropriate selection of the adjuvant with the antigen can result in primarily
cellular (CTL and Th1) or humoral based immune responses. For example, aluminum
salts (commonly referred to as Alum) tend to produce predominantly humoral based
immune responses [61-63] where as bacterial derived components such as Lipid A and
Saponins (QS21) are associated with producing cellular type responses [1,64]. Thus, the
selection of the appropriate adjuvant has to be made based on the type of immune
response desired or that is necessary for providing protection. However, the selection is
often empirical in many cases because the exact immune responses necessary to provide
protection from pathogens in many diseases are not known.
Alum was first introduced as an adjuvant in 1926 and continues to be the only
FDA approved adjuvant for routine human vaccination in the U.S. [65]. It has been used
widely and proven effective for enhancing humoral immune responses. Although Alum
has been used extensively in vaccines for over 70 years, the exact mechanisms by which
they enhance immune responses have not been fully elucidated. Proposed mechanisms
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include: 1) enhancing the uptake of associated antigen into APCs, 2) forming a depot in
macrophages present in muscle, and 3) causing a local inflammatory response due to
necrosis at the injection site possibly resulting in the release of inflammatory cytokines
and activation of APCs [66-69]

Alum is a weak adjuvant for mediating cellular

immunity and is associated with generating the production of immunoglobulin E
associated with allergic reactions [3,62,70]. Thus, there is a great need for more effective
adjuvants to enhance cell-mediated responses with protein-based vaccines, as these are
regarded to be important for many chronic infections such as HIV. Many new adjuvants
have been evaluated in clinical trials; however, most have proven too toxic for routine
human vaccination. In addition to demonstrated safety and biocompatibility, other ideal
adjuvant properties for consideration include ease of manufacture, wide applicability,
cost effective, and stability.
Although the exact mechanisms by which adjuvants enhance immune responses
are not completely understood, the three general mechanisms proposed by which
adjuvants enhance immune response [2,65,71] are listed below.
1. Adjuvants may be used to form a depot of the antigen at the site of injection,
avoiding rapid clearance of the antigen from the body. The antigen can then be
slowly released over a period of time. Some examples of adjuvants that are
thought to enhance immune responses by depot formation include water-in-oil
emulsions (CFA and IFA), Alum, and PLGA microparticles (>10 microns in
size).
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2. Adjuvants can promote uptake of the antigen by APCs leading to higher
antigen-specific immune responses. Adjuvants of particulate nature, as in the
case of pathogens, are naturally targeted for uptake by APCs.
3. Adjuvants can induce release of pro-inflammatory cytokines and induce
expression of cell-surface molecules on APCs, causing them to become more
efficient at stimulating naïve T cells. Some examples of adjuvants exerting their
effects via this mechanism include: PAMPs or cytokines such as IL-2 or IL-12,
which is induced during inflammation.
A general list of adjuvants used for enhancing immune responses is presented in
Table 3.3. These adjuvants can be more generally classified as immunostimulatory or
particulate.

3.3.1

Immunostimulatory adjuvants
Immunostimulatory

adjuvants

enhance

immune

responses

by

initiating

intracellular signaling pathways that lead a number of events including: maturation of
APCs, the release of pro-inflammatory cytokines or upregulation of cell surface
molecules such as MHC class II and co-stimulatory molecules on APCs.

3.3.1.a Cytokines
Cytokines are small, secreted proteins that are naturally found in the body and
play a critical role in antigen-presentation, activation and proliferation of antigen-specific
lymphocytes during an immune response. In addition, many cytokines are involved in
biasing an immune response to Th1 or Th2 and can be used to selectively modulate the
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immune response generated. For example, IL-12 released by APCs during an innate
immune response is associated with biasing the development of naïve CD4+ T cells into
Th1 cells. Moreover, the release of IFN-γ by Th1 cells mediate cellular responses by
causing activation and proliferation of CD8+ T cells [72,73]. On the other hand, the
presence of IL-4 or IL-10 during an immune responses directs development of Th2 cells
[74]. Thus, the use of cytokines has been attractive for manipulating or directing the
types of immune responses obtained. In addition, cytokines may also enhance immune
responses via recruitment of APCs at the site of injection for antigen uptake and
influencing expression of MHC II and co-stimulatory molecules on these cells.

The

most extensively evaluated cytokines include: IFN-γ and IFN-α, IL-2, IL-4, IL-7, IL-12,
IL-15, IL-18, TNF-α, and granulocyte-macrophage colony-stimulating factor (GM-CSF)
[75].

The main disadvantages in using cytokines are that the proteins can be degraded

rapidly in vivo and/or dose-related toxicity is associated with cytokine use [76,77]. To
overcome these issues, the use of particulate delivery systems for slow release at the site
of injection as a means to minimize toxicity has been investigated [78-82]. In addition,
cytokines encoded on pDNA alone or encoded along with an antigen have been
investigated for enhancing immune responses [43,44,77].

3.3.1.b Bacterial derived adjuvants: PAMPs and TLRs
PAMPs are naturally recognized by cells of the innate immune system and upon
binding to the PRRs initiate a signaling pathway resulting in the production of cytokines
or upregulation in the expression of costimulatory molecules. This activation of the
innate immune system subsequently triggers adaptive immune responses. TLR ligands
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have been evaluated as adjuvants for enhancing immune responses [56]. Currently, there
are 10 identified TLRs and they are located either intracellularly (TLR3, 7, 8, 9) or
expressed on the cell surface (1, 2, 6, 4, 5, 11). Ligands for many of the TLRs have been
identified [57]. The binding of ligands to TLRs on DCs modulates the expression of
chemokine receptors and causes immature DCs to undergo maturation as well as
migration from peripheral tissues into the draining lymph nodes where they can stimulate
naïve T cells and initiate the adaptive immune responses. Many of the TLR ligands are
associated with generating strong cellular type immune responses [56,83-85].

Two

bacterial derived immunostimulatory adjuvants that have been extensively investigated
will be discussed. Both mediate their effects via binding to TLRs, initiating the innate
immune response.

Lipopolysaccharide derivatives
LPS is derived from the cell wall of gram negative bacteria and is composed of
two domains: a hydrophilic polysaccharide portion which extends out from the cell
surface and a hydrophobic domain known as Lipid A embedded in the cell wall [86].
LPS binds to TLR 4 and has shown to be extremely strong adjuvant for generating
cellular responses [56,87,88]. However, LPS can cause septic shock and this severe
toxicity limits it’s use as an adjuvant for humans [56,88]. The adjuvant activity of LPS is
contributed to Lipid A and a chemically modified derivative of LPS called
monophophosphoryl Lipid A (MPL) has demonstrated to retain the adjuvant properties
with dramatically decreased toxicity [89]. MPL has been shown to generate strong Th1
type responses [90] and has been extensively investigated in clinical trials [91-93]. MPL
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is currently under investigation for use with Leishmania, malaria, TB and cancer antigens
and has been evaluated in more than 30,000 humans. Moreover, MPL is approved for
use in Canada for a melanoma vaccine called Melacine®. Synthetic MPL derivatives
(RC-529) have also been evaluated in phase II clinical trial for Hepatitis B vaccine.
Additionally, the Lipid A derivative OM-174 has been evaluated in cancer patients and
demonstrated acceptable safety profile [77,94].

CpG
Bacterial DNA has demonstrated potent immunostimulatory activity due to the
presence of unmethylated CpG (cytosine phosphate guanosine) dinucleotides in a
particular sequence context, referred to as CpG motifs. Unlike bacterial DNA, CpG
motifs are not as prevalent or usually methylated in mammalian DNA, making them
unable to stimulate the immune system [95]. Bacterial DNA containing CpG motifs are
recognized by TLR9, which is expressed in the endoplasmic reticulum. Recognition by
TLR9 results in signal transduction once the receptor translocates to the lysosomal
compartment, where it can bind to bacterial DNA taken up by cells [96]. The binding of
CpG motifs to TLR9 triggers the production of various pro-inflammatory cytokines such
as IL-6, TNF-α as well as the Th1 promoting cytokine, IL-12, and induces the expression
of co-stimulatory molecules on APCs, enabling them to mature into professional APCs
and become more efficient at antigen presentation [97].

More importantly, the

identification of synthetic oligodeoxynucleotides (ODN) containing CpG motifs (referred
to as CpG ODNs) that mimic the potent immunostimulatory properties of bacterial DNA
has generated considerable interest to investigate them as potential adjuvants. Extensive
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in vivo experiments in mice have shown that CpG ODNs provide significant
enhancements in immune responses to various antigens using various routes of
administration [98-104] . In addition, studies with CpG ODNs demonstrate the ability to
generate strong Th1 and cellular immune responses [105-107].

As with most

immunostimulatory adjuvants, adverse side effects such as enlarged spleen [108] and
lymph nodes [109] have been reported in mice; however, these were reported to be
sequence- and dose-dependent [108]. Moreover, some concern has been raised that CpG
ODN use may generate autoimmune diseases due to over stimulation of the innate
immune system; however, repeated doses administered in vivo in mice and non-human
primates to date have shown no toxicity [110]. Therefore, the concerns raised with the
use of CpG ODNs may be prevented by judicious selection of the appropriate CpG
sequence and dose. It is important to note that the strength of the immune response
generated by each CpG ODN can vary and the optimal sequences differ from species to
species. However, optimal CpG ODN have been identified for a number of different
species including mice, rabbit, sheep, goat, cattle, swine, horse, rhesus monkey,
chimpanzee, and humans [111]. Clinical trials evaluating the use of CpG ODNs for
adjuvants in hundreds of patients have reported no adverse reactions due to CpG [110].
In fact, Phase I clinical trials have demonstrated that hepatitis B surface antigen (HBsAg)
adjuvanted with CpG ODN resulted in stronger, more robust immune responses
compared to the HBsAg alone [94,112].
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3.3.1.c Saponins
Saponins, isolated from the tree Quillaja saponaria Molina, have demonstrated to
possess potent immunostimulatory activity.

Saponins are amphipathic molecules

possessing a hydrophilic carbohydrate and hydrophobic steroid or triterpene moiety
[113]. A major disadvantage of saponins is their surface-active character which causes
hemolysis of red blood cells in vitro [114]. Quil A, the active component of saponins,
has been widely investigated as adjuvants in veterinary vaccines for years; however, its
hemolytic activity has limited its use in human vaccines [2,115]. HPLC analysis of
saponins led to the identification of a heterogeneous group of triterpene glycosides with
varying adjuvant activity and toxicity [113]. Among these highly purified saponins, QS21 has been the most extensively evaluated and has demonstrated to possess reduced
toxicity (considerably reduced hemolytic activity) while retaining the potent adjuvant
properties [113,116-120]. QS-21 has been demonstrated as a strong adjuvant for both
cellular, CTL and Th1, and humoral immune responses including enhancements in IgG2a
isotype with subunit-based vaccines [114,121-123]. The application of QS-21 with HIV1 DNA for systemic and mucosal immune response enhancements has also been
demonstrated [124].
The adjuvant activity of QS-21 has not been fully elucidated. Saponins can
interact with cholesterol on cell membranes resulting in pore formation, which may be
one way antigens could gain access to the cytoplasm for antigen presentation via the
MHC class I pathway to generate CTL responses [125].

In vitro studies have

demonstrated that murine macrophages stimulated with QS-21 result in cytokine
production [77]. Moreover, in vivo evaluation in BALB/c mice has demonstrated the
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ability of QS-21 to initiate innate immune responses by enhancing the activity of natural
killer cells in a dose-dependent manner [77]. QS-21 has been evaluated in numerous
clinical trials as an adjuvant for cancer [126-129], malaria [130], HIV-1 [131], and
pneumococcal [77] vaccines. QS-21 has now been administered to over 3500 patients in
over 90 clinical trials, including some children [77,94] and the most common side effect
is reported to pain or tenderness at the site of injection [131,132]. Doses of QS-21
equivalent to or greater than 200 μg have been reported with significant local reactions
raising concerns of adverse effects with this adjuvant [77,133]. Hence, a fine balance
between the QS-21 dose and the adverse effects must be determined for each antigen and
taken into consideration for each vaccine application.

3.3.2 Particulate delivery systems
Particulate delivery systems have been investigated extensively for enhancing
immune responses with new generation vaccines. This class of adjuvants exerts their
effect mainly through formation of an antigen depot at the site of injection or by
enhancing the uptake of the associated antigen by APCs. Particulate delivery systems are
passively targeted for uptake by APCs since they have dimensions that are comparable to
naturally occurring pathogens (Table 3.4) [125].

The use of emulsions, immune

stimulating complexes, liposomes, microparticles, and nanoparticles as adjuvants will be
reviewed.
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3.3.2.a Emulsions
Emulsions are one of the oldest adjuvants investigated for enhancing immune
responses, with the first reported use in 1916 [134]. Emulsions are generated by mixing
antigen solubilized in the aqueous phase with an oil phase in the presence of surfactant.
Emulsions can be classified into two types depending on the continuous phase: oil-inwater emulsions are oil droplets dispersed in the water phase and water-in-oil emulsions
are water droplets dispersed in the oil phase. Interest in using emulsions as adjuvants was
stimulated by the initial demonstration of Freund in 1937 that a water-in-oil emulsion
composed of mineral oil mixed with killed mycobacteria could serve as a potent adjuvant.
This adjuvant is more commonly referred to as complete Freund’s adjuvant (CFA) and it
has been used extensively in laboratory animal research for generating strong cellular and
humoral immune responses. However, the use of CFA is associated severe side effects
[135-138] and is too toxic to be used as an adjuvant in humans. An alternative adjuvant
preparation without killed mycobacteria, incomplete Freund’s adjuvant (IFA), has been
used in a number of veterinary vaccines and has been evaluated in humans with influenza
and killed poliomyelitis vaccines [134,139].

However, localized toxicity such as

formation of abscesses and granulomas at the site of injection prevented further
evaluation of IFA for human vaccines.

It is thought that many of these localized

reactions were due to impurities in the antigen or the formulation components, i.e. the oil
or emulsifier, and that the use of highly purified mineral oils and surfactants available
may reduce the side effects of IFA [139].
In attempt to replace Freund’s adjuvant, the use of an oil-in-water emulsion based
on the biodegradable oil squalene was reported in the 1980s [1].
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One adjuvant

formulation based on this system, syntax adjuvant formulation (SAF), induced strong
cellular responses [140-142]; however, it was too toxic for human vaccination due to the
inclusion of an immunostimulatory muramyl dipeptide (MDP) derivative [1]. These
studies led to the development of MF59, a squalene-in-water emulsion without MDP, as
an adjuvant (see refs [143,144] for detailed review). MF59 has been investigated with
numerous antigens including influenza [145-148], hepatitis B [149,150], HIV-1 [151],
HSV [152] and HPV [153]. In vivo studies in mice suggest that MF59 is taken up by
macrophages and DCs at the site of injection and in the draining lymph nodes [154];
however, a second study evaluating the distribution of the co-administered antigen
demonstrated that clearance of the antigen from the injection site was independent of
MF59 [155]. MF59 was shown to be safe and well tolerated with several vaccines in
clinical trials involving over 32,000 patients, including elderly patients, toddlers, and
infants [143]. MF59 is currently approved as an adjuvant (in the influenza vaccine
FLUAD®) in many European countries – the only other adjuvant besides Alum to be
approved for use in routine human vaccination [156].

3.3.2.b Liposomes
Dispersion of phospholipids and other polar ampiphiles in aqueous buffers result
in the formation of closed, concentric bilayer vesicles called liposomes. These systems
contain an aqueous core and a lipid bilayer, thus allowing for delivery of both hydrophilic
and hydrophobic molecules. Liposomes can vary in size from 20 nm to several microns
and can be classified into two groups depending the number of concentric lipid bilayers:
small or large unilamellar vesicles (SUV or LUV, respectively) consist of one lipid
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bilayer and large multilamellar vesicles (MLV) consist of multiple lipid bilayers [7]
Liposomes have been investigated for numerous drug delivery applications, are marketed
for delivery of cancer drugs [157] and have demonstrated to be relatively safe with no
reports of granulomas after parenteral administration [7,134].

The application of

liposomes as adjuvants was first reported with diphtheria toxoid in 1974 [158] and have
since been shown to be effective for enhancing immune responses to numerous other
antigens [6,159-161] . Moreover, liposomes have been reported to generate good CTL
responses with various antigens in animal models [162-166]. Studies to elucidate the
mechanism of immune response enhancement using liposomes suggest that liposomes
taken up into endosomes release part of the encapsulated antigen directly in the
cytoplasm, allowing the antigen to gain access to the MHC class I pathway and leading to
stronger CTL responses [167].
The stability of liposomes in vivo is dependent on the fluidity of the lipid bilayer,
which is determined by the type of phospholipids used in preparation. Many preparations
include the use of cholesterol to improve stability of the liposome formulations.
However, the use of phospholipids also poses limitations because they can be rapidly
degraded in the host by phospholipases [2]. In addition, the composition and physical
characteristics of liposomes are critical parameters influencing particle uptake by
macrophages [168] and dendritic cells [169] and could potentially affect the immune
responses obtained in vivo [170]. The use of stable polymerized liposomes have been
investigated for enhancing immune responses to encapsulated antigens via the oral route
[171]. More recently, different types of liposomes have been prepared using alternative
amphipathic molecules to phospholipids and are classified based on their composition as
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[172]: Virosomes (fusogenic liposomes), Transferosomes, Archaeosomes, Niosomes,
Chochleates, and Proteosomes. These systems have been evaluated in animal models and
demonstrate to be as effective or superior to conventional liposomes at enhancing
immune responses [160,173-179].

In some cases, these alternative liposomes show

enhanced stability compared to the conventional liposome formulations [179,180]. Of
these alternative liposomes, virosomes, which resemble SUVs and contain influenza
hemagglutinin (HA), have demonstrated greatest potential for use in human vaccines
[51,164,176].

3.3.2.c Immune stimulating complexes (ISCOMS)
Immune stimulating complexes, ISCOMS, were introduced by Morein et al. in
1984 as an antigen delivery system with immunostimulatory properties [181]. ISCOMS
form spontaneously upon mixing appropriate ratios of phospholipids, cholesterol, Quil A,
and an amphipathic antigen (i.e. viral membrane proteins). Electron micrographs of
ISCOMs demonstrate characteristic, rigid cage-like structures of about 40 nm size [172].
This adjuvant has been shown to be effective at enhancing immune responses by both the
parenteral and mucosal routes [182,183]. The use of ISCOMs has been investigated in
small animals with antigens for measles [184-186], influenza [187,188], and HIV
[189,190] vaccines and both humoral and cell mediated immunity were induced. More
importantly, these strong, protective immune responses were maintained when tested in
larger animal models including non-human primates [182] and ISCOMs has been
licensed for use in an anti-influenza vaccine for horses [172]. The hemolytic activity and
toxicity normally associated with Quil A is greatly reduced in this system due to the
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hydrophobic interactions with cholesterol, preventing significant interactions with the cell
[191]. Recent studies suggest that IL-12 plays a vital role in the strong cell mediated
responses observed in vivo with ISCOMs and found that the main APCs involved in
priming CD4+ and CD8+ T cells are DCs [192,193].

ISCOMs are currently being

evaluated in phase I clinical trials with influenza, HPV, and human cytomegalovirus
[94,172]. The major limitation of this approach is its applicability to different antigens.
ISCOMs typically involve the use of membrane proteins; however, inclusion of antigens
that do not possess this hydrophobic character may prove difficult and require extensive
modification for efficient incorporation into ISCOMS.

3.3.2.d Nanoparticles and microparticles
Solid colloidal particles can be classified depending on their size as nanoparticles
for particles in the 10-1000 nm in size range or microparticles for those particles greater
than 1 μm in size. The preparation of nanoparticles and microparticles has been reported
using a wide range of materials [194]. Moreover, numerous methods have been reported
for preparation of nanoparticles and microparticles; however, the most commonly
practiced techniques include emulsion and interfacial polymerization, high-pressure
homogenization, solvent extraction/evaporation (including the double-emulsion-solvent
evaporation technique used for entrapping proteins) and microemulsion precursor
technology. In addition to parameters such as cost-effectiveness, applicability, ease of
scale up, the method used for preparing the particulate delivery system is extremely
critical and must be carefully selected as this can potentially influence the stability of the
antigen and ultimately affect the quality of immune response obtained.
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The interest in using solid colloidal particles for enhancement in immune
responses was stimulated by studies reported by Kreuter and Speiser on the adjuvant
properties of polymeric nanoparticles [195-197].

These studies reported the use of

poly(methyl methacrylate) (PMMA) nanoparticles for enhancing immune responses to
both adsorbed and entrapped vaccines. Although the use of PMMA nanoparticles was
shown to enhance immune responses to a number of different antigens by Kreuter [198],
the utility of these particles is limited by their accumulation in the body due to the
extremely slow rate of degradation of the polymer [199]. The use of biodegradable
poly(alkylcyanoacrylates) (PACA) for preparing nanoparticles was introduced by
Couvreur et al. [200] and their use has been investigated for delivery of various
hydrophilic and lipophilic drugs; however, the use of these nanoparticles has not been
reported in vaccines and controversy over the toxicity due to alkylcyanoacrylate
monomers exists.
The idea of using solid colloidal particles was further advanced by O’Hagan et al.
[201,202] and Eldridge et al. [11,203] by demonstrating that antigens entrapped in
poly(lactide-co-glycolide) (PLGA) microparticles resulted in similar enhancements in
immune responses as the antigen emulsified with Freund’s adjuvant. Although other
polymeric materials such as chitosan [48,204,205], poloxamers [206], polyphosphazenes
[207], and polyanhydrides [208,209] have been investigated for enhancing immune
responses, the use of PLGA polymers has been most preferred due to the extensive
history of use and biocompatibility in humans.

PLGA polymers have been found

numerous applications in humans for medical purposes such as surgical sutures, have
demonstrated excellent biocompatibility and safety, and have been approved for use as
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drug delivery devices for a number of therapeutic products [210]. A detailed review of
the various methods used for preparation of PLGA microparticles and nanoparticles is
presented elsewhere [211]. PLGA microparticles have been effective at entrapping a
range of different antigens and in vivo evaluation in animals have demonstrated them to
be effective at enhancing both cellular (Th1/CTL) and humoral immune responses using
various routes of administration [8,212-217].

More recently, the utility of PLGA

microparticles has been attractive for enhancing immune responses to pathogens that may
be used as potential biowarfare agents [218]. In addition, PLGA microparticles have also
been investigated for enhancing mucosal immune responses, which are regarded to be
important for many diseases as the nasal, rectal, and vaginal sites are the routes of entry
for most pathogens [171,219,220].

The potential of PLGA microparticles for oral

delivery of entrapped antigens has also been evaluated and shown to induce both
systemic and mucosal immune responses [213,217,221-225]. This enhanced immune
response via the oral route is speculated to be due to uptake of the microparticles by
mucosal associated lymphoid tissue (MALT) [226].

Although microparticles have

demonstrated good enhancements in mucosal immune responses in small animal models,
generating these responses non-human primates and humans has been challenging [227].
The use of PLGA polymer for preparation of controlled release drug delivery
systems has been of great interest and currently there are a number of products on the
market using this technology. The release rate of the entrapped molecule from the
microparticle can be modified by altering the co-polymer composition, molecular weight,
crystallinity of the polymer, and the size of the microparticles [228,229]. This property
has made PLGA microparticles extremely attractive for development of single-dose
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vaccines [230-234].

The concept of oral delivery and single-dose vaccines using

microparticles rely on the antigen being entrapped within the microparticle. However, it
must be realized that a great deal of work is necessary to ensure the stability of the
entrapped antigen as this can influence the in vivo results [235]. The entrapment of the
protein in microparticles is associated with a number of issues such as protein stability
during encapsulation, storage and hydration, as well as the environment experienced in
vivo during antigen release [229].
As an alternative to antigen entrapment, the surface characteristics of PLGA
microparticles have been modified by incorporation anionic or cationic surfactant during
the microparticle preparation for adsorption of the antigen on the surface of the particle
via electrostatic and van der waals interactions [9,212,236]. Antigens adsorbed to the
surface of microparticles have shown enhanced immune responses in vivo in mice
[237,238] and these systems are undergoing evaluation in phase I clinical trials
(http://www.iavireport.org/trialsdb/vaccinedetail1.asp?i=82).
As noted before, one of the main mechanisms by which particulate delivery
systems are thought to enhance immune response is by enhanced uptake into APCs. In
vitro studies demonstrate both nanoparticles [239,240] and microparticles [241,242] are
taken up by APCs. In addition, the efficiency of antigen presentation was found to be
enhanced by 10-100 fold using PLGA microparticles [241]. The uptake of particles by
APCs is influenced by several factors including charge, hydrophobicity/hydrophilicity,
and size [168,242]. The increase in hydrophobicity of particles was reported to have
greater adjuvant activity in vivo in one study [243]. Interestingly, in vivo studies have
demonstrated that smaller particles are taken up into lymphatics better than larger
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particles [11,12,244]; thus, having greater chances of being taken up by residing APCs.
Combined, these two factors, size and drainage into the lymphatics, correlate with
enhanced immunogenicity of smaller microparticles compared to larger microparticles
[11-13]. The inverse correlation of particle size and immune response has also been
reported by Kreuter with nanoparticles in the 62-306 nm range [10].
The superior immune responses obtained in vivo using smaller particles have
stimulated a great deal of interest in further investigating nanoparticles for subunit-based
vaccines.

To this end, PLGA nanoparticles have been shown to enhance immune

responses in mice [245-247]. The potential of cationic nanoparticles adsorbed with
hepatitis B surface antigen and β-galactosidase to induce antigen-specific systemic (IgG,
Th1/Th2) and mucosal (IgA) responses was demonstrated after intranasal administration
[248]. More recently, a novel method for preparation of nanoparticles from oil-in-water
microemulsion precursors was demonstrated by Mumper et al. [14-16,249,250]. The
microemulsion precursors are prepared by mixing appropriate ratios of oil, water, and
pharmaceutically acceptable surfactant(s) at an elevated temperature and by simply
cooling these microemulsions to room temperature nanoparticles approximately 100 nm
in size are obtained. These nanoparticles have the advantage of being prepared in a
single step, one vessel process without the use of organic solvents and with relative ease
in modifying the physical characteristics of the particles by choosing the appropriate
surfactants. In addition, the nanoparticles are potentially biocompatible as the oil phase
used for preparation of these nanoparticles is comprised of cetyl alcohol and polysorbate
60, both found in many pharmaceutical products. More importantly, these nanoparticles
are hemocompatible [251] and shown to be degraded via the alcohol dehydrogenase
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system [252]. In vivo evaluation in mice have demonstrated enhanced Th1 and humoral
responses to the model antigen β-galactosidase [16] and HIV-1 Tat protein [253] coated
on the surface of anionic nanoparticles after subcutaneous administration.

3.3.3

Combined adjuvant formulations
With the exception of ISCOMs and CFA, the adjuvants described up to this point

involve the use of individual systems, i.e. particulate or immunostimulatory, for
enhancing immune responses. Many researchers have investigated the combination of
various adjuvant systems as a means for obtaining synergistic enhancements in immune
responses. For example, the use HIV-1 gp120 and Gag p24 entrapped in microparticles
that were dispersed in MF59 demonstrated significantly stronger antigen-specific
humoral and Gag p24-specific CTL responses compared to either adjuvant alone [254].
Alving et al. reported the use of lipid A entrapped liposomes adsorbed to Alum as a safe
and effective method for enhancing humoral and antibody responses to surface bound or
co-entrapped antigen in human clinical trials [166]. The use of QS-21 with low doses of
IL-12 was effective for synergistic enhancement in immune responses to respiratory
syncytial virus, demonstrating the combined adjuvant formulation was effective while
reducing the dose-related systemic toxicity of IL-12 [82]. Moreover, the addition of
MPL to QS-21 adjuvant was effective at directing immune responses to HIV-1 gp120
from a Th2 to a Th1 type response [255]. The adsorption of IL-12 on Alum has also been
investigated to enhance Th1 type immune responses to several antigens [78,81,256].
In the quest for developing safer, more potent adjuvants, a great deal of interest
has turned towards the investigation of various delivery systems for co-delivery of the
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antigen and immunostimulatory adjuvants [8,79,246,257-260].

The use of delivery

systems entrapping an immunostimulatory adjuvant may provide an avenue for reducing
the dose of antigen or the dose of immunostimulatory adjuvant by targeting uptake by
APCs, providing a controlled release environment, and most importantly, decreasing
toxic side effects, as in the case of ISCOMs. The entrapment of the immunostimulatory
adjuvant MDP in microparticles was shown to reduce the toxicity [261] while still
providing potent immune responses to entrapped antigen [262].

Furthermore, CpG

entrapped in PLGA nanoparticles was reported to generate potent cellular responses
using a ten-fold lower dose compared to unentrappped CpG [263].

A particularly

attractive approach for many investigators involves the use of immunostimulatory
adjuvants with particulate systems for modulating the immune responses to obtain
enhanced cellular based responses. Table 3.5 lists several particulate systems that have
been investigated with immunostimulatory adjuvants for improving immune responses to
various antigens.

3.4

Dendritic cells and targeting
The body’s defense mechanism relies on a coordinated set of actions involving

the components of the innate and adaptive immune system to generate strong, longlasting immune responses to pathogens. As described in section 3.2, one of the key cells
involved in this process are the APCs such as DCs. DCs are regarded as professional
APCs as they are the only cells capable of inducing primary immune responses [264].
Although macrophages can function as APCs, their primary function involves
phagocytosis and clearance of the pathogens from the body. On the other hand, DCs
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primarily function to sense, ingest, and process invading pathogens (innate immune
response) and present them to naïve T cells present in the secondary lymphoid organs
(adaptive immune response). DCs are also considered to play a vital role in naïve CD4+
T cell differentiation into Th1 or Th2 type and therefore, controlling both the quality of
the immune response as well as the strength of the immune response [72,265].
Moreover, studies have demonstrated that DCs have the ability to present exogenous
antigens (i.e., from non-replicating pathogens and apoptotic or necrotic cells) on MHC
class I molecules resulting in stimulation of CD8+ T cells. This process, referred to as
cross-priming, demonstrates a non-classical or alternative pathway present in DCs for
processing and complexing exogenously derived peptides to MHC class I molecules and
for inducing CTL responses [266]. In addition to the antigen presenting function, DCs
play an important role in the viability, growth, and differentiation of activated B cells
[267]. Consequently, the key link DCs provide between the innate and adaptive immune
responses combined with their ability to cross-prime exogenous antigens have made these
cells particularly attractive targets for manipulating immune responses and for targeting
vaccines.

3.4.1

Types of dendritic cells
DCs are derived from hematopoietic progenitor cells in the bone marrow that give

rise to DC precursors, which circulate the blood and lymphatics. These DC precursors
further develop into a heterogeneous population of DCs that can be classified into
different subsets based on origin, phenotype, localization, and function. In mice and
humans, DC precursors can be derived from two different types of hematopoietic
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progenitor cells classified as the myeloid and lymphoid progenitors [268]. Furthermore,
the DC precursors generated from these two progenitor cells give rise to phenotypically
distinct subsets of DCs that have been identified in both mice and humans (described in
detail in [264,268,269]). For example, three phenotypically distinct DC subtypes have
been identified in humans:

1) Langerine+ DCs, more commonly referred to as

Langerhans cells (LCs), 2) myeloid DCs, and 3) plasmacytoid DCs. Cell culture studies
with human CD34+ hematopoetic progenitor cells suggest that LCs and myeloid DCs are
derived from a common myeloid progenitor cell, whereas plasmacytoid DCs are thought
to be derived from a lymphoid progenitor cell [268]. The complex nature of the DC
subtypes is even more evident in mice, where DCs can be classified into six subtypes
based on the expression of different cell surface markers [269].

Regardless of the

species, the different DC subtypes contain both immature and mature DCs and they
differentially express PRRs, which affects their ability to recognize and respond to
pathogens and ultimately influence the quality of immune response generated.

For

example, plasmacytoid DCs express TLR7 and 9 only, while both the LCs and myeloid
DCs express TLR1, 2, 3, 4, 5, 8 but not 7 and 9. Moreover, further differences have been
reported between LCs and myeloid DCs. Myeloid DCs have about a 10-fold higher
efficiency of antigen capture and are more potent stimulators of CD4+ T cells compared
to LCs [264]. Taken together, these differences in the DC subsets enable them to greatly
influence the adaptive immune responses generated to various pathogens.
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3.4.2

Maturation of DCs into professional APCs
DC precursors in the blood can migrate to various tissues and in the presence of

certain cytokines, such as GM-CSF and IL-4, they differentiate into immature DCs,
which reside in the peripheral tissues surveying for invading pathogens. Immature DCs
are extremely efficient at capturing antigens and can do this by the following pathways:
macropinocytosis, receptor-mediated endocytosis, and phagocytocysis [266]. The uptake
of the antigen causes immature DCs to undergo a maturation process which involves
phenotypic and morphological changes, migratory capability from the tissue into draining
lymph nodes, upregulation of co-stimulatory molecules, and enhancement MHC class II
molecule synthesis as well as transportation to cell surface. This entire process ultimately
leads to the immature DCs being converted into mature DCs that possess antigen
presentation capability and are referred to as professional APCs. Morphological changes
that are associated with mature dendritic cells include the formation of fine, long veils
(>10 μm) extending from the cell body [267]. Functionally, the mature DCs become less
phagocytic, migrate to T cell areas of in the secondary lympoid organs, and are highly
efficient at stimulating the antigen-specific naïve T cells. The main features of immature
and mature DCs are summarized in Figure 3.2. Several factors can trigger immature DCs
to undergo maturation including binding of bacterial or viral components to TLRs (LPS
or dsRNA), inflammatory cytokines (TNF-α, IL-1, IL-6), T cell derived signals (CD40),
binding of immune complexes to Fc receptors, and other endogenous factors or cell
death. The presence of IL-10 during an immune response inhibits the maturation of DCs;
thus, they become less efficient stimulators of naïve T cells and could lead to antigenspecific tolerance [270].
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3.4.3

Receptor-mediated targeting of DCs
The unique properties of DCs (discussed in the previous sections) have made

them attractive and widely investigated for targeting antigens to obtain enhanced immune
responses. In addition to TLRs, DCs express several endocytic receptors, such as the Clectin and Fc receptors [74] that could be utilized for enhancing immune responses to
protein-based vaccines. The main challenge in targeting DCs is that many of these
receptors have only been recently identified and therefore, have not been extensively
studied. In addition, the ligands that could be utilized for targeting some of these
receptors are yet to be determined.

3.4.3.a C-lectin receptors
The various DC subsets express a family of C-lectin type receptors that recognize
their targets via single or multiple carbohydrate recognition domains (CRDs). C-lectin
receptors bind to their ligands in a calcium-dependent manner [271]. There are two types
of C-lectin receptors: Type I consisting of the mannose and DEC-205 receptors; Type II
consisting of Langerin, DC-SIGN and Dectin-1 receptors [272].

Mannose receptor
The mannose receptor (MR) has been most investigated for targeting antigens to
DCs and macrophages for obtaining enhanced immune responses [273-276]. The MR
contains 8 carbohydrate recognition domains (CRD), of which CRD 4-8 are involved in
binding and recognition of terminal mannose containing ligands [277,278].

The

captured antigen is transported to early endosomes and the MR is recycled back to the
cell surface, allowing large amounts of antigen to be captured via the MR [279].
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Mannosylation of proteins resulted in a 200-10,000 fold increase in simulation of CD4+ T
cells compared to non-mannosylated proteins in vitro [280]. Many groups reported the
use of hydrophobized mannan for enhancing cellular and humoral immune responses to
antigens when formulated with particulate delivery systems such as liposomes and
nanoparticles [15,163,281-283].

Moreover, mannan conjugated to the cancer antigen

HER2 was reported to induce strong enough CTL responses to reject HER2+ tumors in
vivo [284]. One limitation reported to using mannan is its in vivo toxicity (in mice by iv)
and high immunogenicity [283].

More recently, Mizuochi et al. have investigated

various alternative oligosaccharide ligands and demonstrated that mannopentaose [has
five mannose (Man) residues linked in the following order: Manα1-6(Manα1-3)Manα16(Manα1-3)Man] attached to the surface of liposomes generated enhanced cellular
responses compared uncoated liposomes [283,285,286]. Therefore, alternative mannose
type ligands may have potential applications for targeting antigen uptake into DCs and
for enhancing cellular immune responses with particulate delivery systems.

DEC-205
DEC-205, composed of 10 CRDs, is significantly homologous to the MR
[287,288]; however, no specific ligands have been defined for DEC-205 [287]. Targeting
to DEC-205, similar to MR, results in the antigen-receptor complex being endocytosed
and recycled back to the cell surface; however, endocytosis via DEC-205 targets the
antigen to the late endosomal compartment [279]. In vitro and in vivo targeting to DEC205 using an anti-DEC 205 antibody-antigen complex was reported to enhance the
antigen presentation on MHC class I and II molecules (by 100 to 400 fold) compared to
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non-targeted antigens [279,289]. Moreover, targeted liposomes coated with an anti-DEC
205 antibody were reported to induce strong CTL responses to an anti-tumor antigen
when co-delivered with immunostimulatory adjuvants [290]. Furthermore, a more recent
study reported that DEC-205-targeted HIV-1 Gag p24 was effective at inducing potent
CD4+ T cell responses and long-lived memory T cells in mice compared to untargeted
protein or adenovirus expressing Gag p24 [291].

3.4.3.b Fc receptors
DCs express surface immunoglobulin receptors called Fc receptors (FcR) that
recognize the constant portion (Fc) of IgG. One type of FcR, FcγR, has been investigated
for targeting antigens to DCs. Unlike MR and DEC-205 receptor, FcγR is not transported
back to the cell-surface after endocytosis and thus, have a lower uptake capacity
compared to MR and DEC-205 [275].

In vitro studies demonstrating that antigen

presentation can be enhanced by 100-1000 fold by targeting them to the FcR have been
reported [292,293].

In addition, antigen entrapped in FcγR-targeted liposomes was

reported to be 1000 to 100,000 fold more efficient at stimulating antigen-specific T cells
in vitro compared to free antigen or untargeted liposomes [294,295].

In vivo studies

targeting FcγR using a antibody-antigen conjugate demonstrate enhanced cellular and
humoral immune responses compared to antigen alone [296,297]. Moreover, targeting
FcγR has been demonstrated to result in efficient cross-priming of the antigen [298,299]
and thus, have the potential to enhance CTL responses to antigens. Targeting antigens to
FcγR could be limited by potential competition with other IgG and B cells present in
vivo.
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3.4.4

Targeting DCs by route of immunization
Traditionally, vaccines have been administered by the parenteral route, with

intramuscular (i.m.) and subcutaneous (s.c.) routes being most utilized. The choice in
immunization route is of important consideration as it can significantly affect the type of
immune responses generated and side effects, such as local reactions [124,300-304]. The
immunization route may influence the uptake of the antigen by APCs, affecting the
strength and type of responses obtained. For example, i.m. injection is considered to
enhance immune responses by offering a depot site for the antigen as few APCs are
present at the muscle sites [301]. The use of s.c. route has been investigated for targeting
colloids to draining lymph nodes, with the size of the colloid being a major factor in
determining drainage [244].

Therefore, antigens formulated with nanoparticles, as

described previously in section 3.3.2.d, are potentially targeted for passive uptake into
APCs residing in the lymphatic system after s.c. injection.
The use of mucosal routes for immunization has been of particular interest as it
can generate both systemic and mucosal immune responses (secretory IgA), providing an
additional barrier of protection at the site of infection for pathogens that are transmitted
via mucosal routes.

Traditionally, the oral and nasal routes have been the most

investigated for mucosal immunization [124,220,305]. Non-toxic derivatives of cholera
toxin (CT) and heat labile enterotoxin (LT) adjuvants have been often investigated for
enhancing immune responses to antigens via mucosal immunization [306]. Moreover,
the use of a genetically modified LT, LTK63, is being evaluated for intranasal delivery of
an influenza vaccine human clinical tirals [94].

Although the oral route has been

investigated extensively with antigens entrapped in particulate delivery systems, the nasal
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route is more attractive since it avoids many challenges associated with oral delivery,
such as the harsh acidic environment of the GI tract experienced by antigens [125,227].
More recently, there has been a great deal of interest in using the skin as an immunization
site, referred to as transcutaneous immunization (TCI) [307-310]. As described in the
earlier section, LCs reside in the viable epidermis and although they compose only 1-4%
of the cells in the viable epidermis, they cover over 20% of the surface area of the skin
due to their characteristic DC-like veils that extend from the cell body [308]. Therefore,
immunization via the skin can be used to passively target the uptake of antigens by LCs,
potentially leading to strong systemic and mucosal immune responses.

The main

challenge in targeting the LCs in the viable epidermis is penetration through the stratum
corneum layer [309]. One system reported the use of a Macroflux® skin, which consists
of titanium microprojections (~330 μm in length), for delivery of protein-based vaccines
through the skin [311]. Macroflux® skin patch coated with OVA demonstrated 50-fold
higher IgG titers compared to i.m. or s.c. routes and comparable to the intradermal route
(i.d.) at the lowest dose investigated in hairless guinea pigs.

The ability of the

Macroflux® patch to co-deliver an immunostimulatory adjuvant, resulting in augmented
OVA-specific antibodies, was also reported [311].

In other animal studies the use of

detoxified LT and CT mutants is most often investigated to obtain enhanced systemic and
mucosal immune responses to an antigen after direct application to shaven skin [310,312314]. Moreover, TCI using a patch was demonstrated to be safe in phase I clinical trials
for immunizing humans with LT, generating robust systemic and mucosal antibodies for
protection against travelers diarrhea [315]. This technology has been further extended for
evaluation in numerous clinical trials including anthrax, hepatitis B, and influenza
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vaccines using a patch infused with the adjuvant LT [94]. This technology may be a
viable strategy for advancing the idea of needle-free immunization; however, the
variability in immune responses generated among individuals due to differences in
penetration across the stratum corneum layer in larger populations needs to be evaluated.
Another delivery technology which bypasses the conventional needle-based
immunization approach involves the use of a high powered helium device (PowderJect®)
to deliver the antigen of interest into the epidermis, where an abundant population of LCs
are present [316].

This system has been reported to significantly enhance immune

responses to hepatitis B surface antigen [317,318], influenza [317], and HIV-1 gp 120
[319]. Moreover, the hepatitis B surface antigen could be co-formulated with CpG ODN
and delivered to the epidermis for further enhancements in immune responses, including
Th1 type responses [318]. The use of this technology has also been extended for delivery
of DNA coated on gold particles to LCs in the epidermis [316]. Unlike traditional
approaches for genetic immunization which rely on transfecting muscle cells after
intramuscular administration, this system allows for direct delivery of the DNA into the
LCs responsible for generating the immune response. This technology termed, PMED™,
has demonstrated success in recent phase I clinical trials with influenza vaccine and is
currently

in

phase

I

clinical

trials

for

a

number

of

additional

vaccines

(www.powdermed.com).

3.5

HIV vaccine development
Although the cause of acquired immunodeficiency syndrome (AIDS), HIV [320],

was identified and fully sequenced in the early 1980’s [321], there is still no effective
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HIV vaccine and HIV continues to infect millions of people. The worldwide prevalence
of AIDS has focused attention on the urgent need to develop a safe and effective vaccine.
The difficulties in developing an effective HIV vaccine are mainly due to: 1) rapid
mutations; 2) genetic variability; 3) formation of latent proviral DNA and 4) lack of
knowledge on the immune correlates of protection [19,322,323].

3.5.1 HIV infection
HIV is classified as a retrovirus and more specifically grouped with lentiviruses
that are characteristic of long incubation periods following infection which eventually
lead to immunosupression and diseased states [52]. It is thought to have evolved from
the less pathogenic simian immunodeficiency virus (SIV) [324] and studies of SIV in
simian species have been useful in developing an understanding of the pathogenesis of
HIV [325,326]. There are two types of HIV viruses identified: HIV-1, the more common
and main cause of AIDS worldwide, and HIV-2, the less pathogenic strain of HIV and
more closely related strain to SIV [324]. Rapid mutations in the virus are caused by the
error prone nature of the reverse transcriptase giving rise to genetically varying strains of
HIV-1 throughout the world [327]. Currently, there are three main categories of HIV-1:
group M, N, and O. Group M is prevalent worldwide and consists of various HIV-1
strains classified as subtypes or clades denoted A to J. The presence of groups N and O
are less prevalent and are predominantly identified in Africa and eastern Europe [324].
HIV can be transmitted by sexual intercourse, exposure to contaminated blood, or
maternal transmission (mother to child). The hallmark of HIV infection is depletion of
CD4+ T cells, which are critical in mediating cellular immunity. There are several stages
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in HIV infection correlated with the presence of specific events during infection
demonstrated in Figure 3.3 [52,327]. In the early or acute phase of infection (2-8 weeks),
a burst in viral replication is observed, correlated with a dramatic decrease in the number
of CD4+ T cells. During this phase, the first immune responses to emerge are HIVspecific CTL responses, which eliminate HIV-infected cells and help decrease the viral
load. CTL responses are followed by an increase in circulating levels of anti-HIV
antibodies and the patient is said to have undergone seroconversion at this point.
Following this phase, an asymptomatic phase is observed during which viral replication
persists and a gradual decrease in CD4+ T cells occurs. When the CD4+ T cells drop
below a certain level (< 200-400 cells/μL) necessary to generate effective immune
responses to other infections, the onset of AIDS begins [328] and the patient becomes
susceptible to numerous opportunistic infections – infections that normal, healthy
individuals can fight but prove fatal in AIDS patients. These opportunistic infections are
the ultimate cause of death in AIDS patients.
The asymptomatic phase in HIV-infected patients is highly variable, lasting from
a few months to over 16 years. Individuals that are able to control the infection (>12-16
years) and progression to disease are referred to as long-term non-progressors (LTNP)
[327]. Studies of these patients have been of great interest to many scientists in this area
to gain a better understanding of the immune correlates necessary to prevent onset of
AIDS. To this end, many studies with LTNP and HIV-infected patients report an inverse
correlation between disease progression and the presence of strong CTL responses to
multiple HIV antigens, suggesting the importance of CTL responses in controlling viral
replication [329-331].
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3.5.2

HIV life cycle
The HIV viral genome consists of nine genes flanked by long-terminal repeats

(LTRs) that are composed of the transcription regulatory elements (Figure 3.4A). These
genes translate for the HIV structural, regulatory, and accessory proteins that have
various functions in the viral life cycle (Table 3.6) [52,327]. A schematic representation
of the mature HIV virus is presented in Figure 3.4B. The various stages in the HIV life
cycle have been described in detail elsewhere [332,333] and are highlighted in Figure 3.5.
HIV infection of CD4+ T cells leads to a productive infection of the cell and
subsequently their demise. Two receptors, CD4 and chemokine, are necessary for viral
infection.

The envelope protein first binds to CD4 receptors found on T cells,

macrophages, and DCs causing conformational changes that allow it to bind to
chemokine co-receptors (CCR5 or CXCR4) also present on the cells. The majority of
HIV infections occur through the use of CCR5 co-receptor; however, viral strains
utilizing CXCR4 are more pathogenic and the use of this receptor has been observed after
long periods of infection [324,334]. The differential use of the two receptors during HIV
infection is likely due to the variability in the envelope proteins, which mediate binding
to these receptors. It is important to note that the spread of the virus is also mediated by
infecting DCs and macrophages, which posses CD4 receptors. Infection of DCs does not
result in viral replication. Instead, they harbor the virus allowing for spread to CD4+ T
cells by cell to cell contact upon migration into LNs [333]. Moreover, DCs abundantly
express the C-lectin receptor called DC-SIGN which binds strongly to the envelope
protein, enabling the virus to enter the cell [335]. Thus, LNs can harbor the virus and act
as reservoirs for the virus [333].
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3.5.3

Vaccine status
Initially, it was believed that neutralizing antibodies to HIV would provide

protection from the virus (sterile immunity) [3]. Therefore, early HIV vaccines were
based on the env gene encoding for the envelope proteins, gp 160 and gp 120, which
harbor the neutralizing epitopes. Envelope based vaccines seem to provide neutralizing
antibodies strain specific, and thus, broad, cross-reactive neutralizing antibodies are not
generated [19,322,336-338]. The ineffectiveness of neutralizing antibodies in providing
protection from infection was even more evident after the reported failures of bivalent
envelope-based vaccines in two different phase III clinical trials [339]. This is due to the
high variability in the envelope proteins, which gives rise to the various groups and
subtypes of HIV mentioned in section 3.5.1. The envelope proteins can vary by more
than 30% in their amino acids among the various subtypes [340], with differences greater
than 50% reported between group M and O [341]. Also, few or no CTL responses are
observed with the envelope based vaccines [19,322,338].
Difficulties thus far in achieving sterile immunity based on the envelope vaccines
have prompted an alternative avenue for developing an HIV vaccine – disease
prevention. Studies of LTNP and HIV-infected patients suggest that CTL responses are
important in preventing disease. The presence of strong CTL responses correlates with
low viral loads. Although it is realized that CTL responses alone will not prevent virus
entry or replication, many studies suggest that they will aid in maintaining low viral loads
and controlling viral replication. Thus, CTL responses may delay or prevent the onset of
the disease [19,322,337,338,342]. In order to develop a vaccine for controlling infection
and blocking the onset of disease against various HIV subtypes, the candidate antigen
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should be immunogenic, conserved (to produce cross-reactive responses), and critical in
the virus life cycle. Currently, numerous candidate HIV vaccines are being evaluated in
human clinical trials [343].

The vaccine components, unlike early approaches, are

targeted towards multiple HIV antigens.

Two HIV proteins that have received

considerable interest for inclusion in potential HIV vaccines are Gag [323,343] and Tat
[18,344-346].

3.5.4 HIV-1 Gag
The gag gene encodes for the positively charged Gag poly-protein precursor, p55.
Non-replicating, non-infectious virus like particles are formed by p55 in the absence of
viral proteins or RNA. Gag p55 is composed of four domains, individually known as the
mature Gag proteins: p24 capsid (CA), p17 matrix (MA), p7 nucleocapsid (NC), p6 and
p1. After virus budding from the host cell, p55 is cleaved by the HIV protease into the
mature Gag proteins.

The Gag precursor is involved in virus assembly and membrane

targeting, whereas the mature Gag proteins are involved in virus uncoating and
disassembly. In the mature virus, MA is associated with the inner viral protein coat,
while NC complexes with the viral RNA in the core and CA forms a shell around the
RNA and core-associated proteins [17]. The Gag proteins are well conserved among
diverse HIV strains and subtypes. Furthermore, strong Gag-specific CTL responses have
been found to correlate with low viral loads in LTNP and HIV-infected patients
[337,347-349]. In fact, a recent study using peripheral blood mononuclear cells from
chronically infected patients found that 96% of the patients responded to challenge by
Gag peptides, found to be the highest response out of all proteins used (Env, Pol, and
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Nef). In addition, the magnitude of the T cell responses to Gag was inversely correlated
with the viral load in plasma and directly with the CD4+ T cell counts in the patients
[350].

Numerous studies performed by O’Hagan have demonstrated the ability of

recombinant Gag p55 or pDNA adsorbed to poly[d,l-lactide-co-glycolide] (PLGA)
microparticles to induce potent CTL and antibody responses in animals [13,238,351] and
these microparticles coated with Gag p55 pDNA are being further evaluated in phase I
clinical trials (http://www.iavireport.org/trialsdb/vaccinedetail1.asp?i=82).
One of the most conserved domains of Gag is found in the CA protein, referred to
as Gag p24 [352-354]. In fact, this Gag p24 contains a region (the major homology
region) that is conserved among different genera of retroviruses [17]. Cytotoxic T, B,
and T helper cell eptiopes have been identified in the Gag p24 protein by Ikuta et al.
[355]. Moreover, other groups have demonstrated Gag p24 to be the target of Gagspecific CTL responses [238,354,356].

The importance of Gag p24-specific CTL

responses in controlling viral replication and CD4+ cell counts was further demonstrated
in a recent study of HIV-infected patients [357].

Combined these features of Gag

proteins have made them extremely attractive for including them in HIV vaccines.
Indeed, numerous clinical trials are investigating Gag as vaccine component including a
phase I clinical trial that is exploring the use of microparticles with Gag (pDNA) [343].

3.5.5 HIV-1 Tat
The two exons of the tat gene of HIV encode for a small regulatory protein of 86102 aa.

The first exon is comprised of the first 72 aa necessary for the HIV

transactivating activity [358,359] and is composed of four domains: the amino-terminal
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(aa 1-21); the cysteine-rich domain (aa 22-37) representing the transactivation domain;
the core (aa 38-48); and the basic domain (aa 49-72) containing nuclear localization
signals and regions mediating cellular uptake of Tat [360]. In addition, the second exon
contains an RGD sequence required for the interaction with cell surface intergin receptors
[361] and mediates cellular uptake of extracellular Tat [362]. HIV-1 Tat is expressed in
the early stages of infection [363] and reported to be necessary for production of an
infectious virus, with only minute amounts of the structural proteins (Env, Gag, and Pol)
expressed in the absence of Tat [364,365]. Moreover, Tat released from infected cells is
found in the extracellular milieu and shown to be taken up by uninfected cells, where it
can have numerous effects in addition to enhancing virus gene expression. Biologically
active Tat was reported to be taken up by APC’s, particularly DCs, more efficiently than
other cells and promote Th1 type responses [366]. In addition, conjugation of proteins to
Tat has been shown to be an effective method in presenting exogenous proteins in context
of MHC class I, and generating antigen-specific CTL responses [367]. Tat induces the
expression of the chemokine receptors CCR5 and CXCR4, which facilitate the
transmission of macrophage-tropic and T cell-tropic strains of HIV-1, respectively [368].
In addition, Tat binds to CXCR4 receptor and prevents viral infection of cells expressing
this receptor, which may potentially cause the virus to adapt to using the CCR5 receptors
in the early phase of HIV infection [369].

Tat also plays an important role in

development of diseases such as AIDS-related Kaposi sarcoma [370], AIDS-related
vasculopathy [371] and HIV-dementia [372] in infected patients. Tat has been shown to
be both immunogenic as well as well conserved among different HIV subtypes [23,26].
Both antibody [373-376] and CTL responses [377,378] to Tat have been inversely
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correlated with disease progression. In fact, a high frequency of CTL responses to Tat is
observed in 80% of HIV-infected patients that were able to effectively control the viral
replication (< 1000 RNA copies/mL) [378]. Extensive work by Ensoli’s group has
demonstrated Tat to be immunogenic, safe, and effective in inducing humoral and
cellular responses to Tat [18]. In addition, they reported that 9 out of 12 cynomolgus
monkeys vaccinated with Tat (protein or DNA) were protected upon challenge with a
highly pathogenic strain (SHIV89.6P) and the protection correlated with the presence of
anti-Tat CTLs [379,380]. Studies done by other groups have also found Tat to be safe
and immunogenic [381-383]; however, two groups have reported failure in controlling
viral replication upon challenge with SHIV89.6P [382,383]. The authors caution that the
conflicting results obtained could be due to differences in the study designs including
different monkey species, dose, immunization schedules, adjuvants, and dose and route
of challenge with viruses [382-384]. Despite the conflicting data reported in non-human
primate studies, many researchers agree on the potential of Tat-based vaccines [368,385387] and results from phase I clinical trials evaluating Tat for preventative and
therapeutic vaccines are being compiled [388].

3.5.6

Therapeutic vaccines for HIV-infected patients
It is estimated that 14,000 new HIV infections occur every day and even more

astounding is that greater than 95% of these new infections are in underdeveloped nations
[389]. Although the use of highly active anti-retroviral therapy (HAART) has been
greatly effective in controlling viral replication and disease progression, it has not been
effective at eliminating the virus completely and there are numerous challenges faced
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with this therapy regimen. The regimen itself is complex, often required multiple drugs
to be taken every day. Moreover, drug-resistant viruses have been found to develop
during HAART that require alternative drug combinations for effectively controlling
HIV, which may ultimately limit the effectiveness of the therapy. The regimens are also
often accompanied by complicated side effects such as increased plasma lipids,
hyperglycemia, and metabolic abnormalities [324]. More importantly, the high cost and
limited availability of HAART to individuals in underdeveloped countries, where the
majority of new emerging infections are occurring, is extremely concerning.
As an alternative to HAART, a great deal of interest has been generated in the
concept of using therapeutic vaccines for controlling disease progression in HIV-infected
patients (reviewed in reference [390]). The goal of therapeutic vaccines would be to
stimulate appropriate cellular and humoral immune responses in the infected patient
capable of controlling the viral replication and therefore, eliminating or decreasing the
need for HAART. This approach is especially attractive for regions where accessibility
to HAART is costly and limited because a single dose of the vaccine could be
administered at appropriate intervals, aiding to reduce viral loads and possibly decrease
HIV transmission and thus, the number of new infections. Many therapeutic vaccines
have demonstrated to be effective in animal models and have entered human clinical
trials; however, so far the results from these trials have failed to demonstrate significant
benefits in using this approach. Some of the challenges that are faced in developing and
evaluating therapeutic vaccines include: 1) little is known on the immune correlates
necessary for viral control, 2) the appropriate time to administer the vaccine and to initial
or cease HAART if used in combination with the vaccine, and 3) limitations in the
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current assays available to evaluate responses from patients after vaccination.
Nonetheless, current work continues to evaluate therapeutic vaccines as a viable
alternative to HAART due to the potential benefits that could be reaped from this
approach. In this respect, the important roles Gag and Tat play in the viral life cycle have
targeted these antigens as components in therapeutic vaccines [384,390-392].

Copyright © Jigna D. Patel 2006
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Table 3.1. Historical outline for the major developments in vaccines. (Adapted from
Plotkin and Plotkin [21] and Bramwell [23])
Vaccine
Introduced
Smallpox
Rabies
Anthrax
Typhoid
Cholera
Plague

Type of
Vaccine

Major Achievements

18th Century
The idea of vaccination introduced using a
Live attenuated
closely related animal virus (cowpox)
19th Century
Live attenuated

First demonstration of chemical attenuation of
pathogens for live vaccines

Whole-killed

Demonstration that inactivated organisms could
retain their immunogenicity
20th Century
(1920s-1940s)

Whole-cell
Pertussis
BCG
Yellow-Fever
Influenza
Tetanus
Diphtheria
Injected polio
(IPV)
Oral Polio (OPV)
Measles
Rubella
Influenza
Pneumococcal
Meningococcal
H. Influenzae
type b
Hepatitis B
Acellular
Pertussis

Whole-killed

-

First demonstration of in vitro passage for
attenuation using artificial media (bile)
In vitro passage using mouse brain and chick
Live-attenuated
embryo
Whole-killed
Production in chick embryo
First use of inactivated protein vaccines –
Protein
Toxoids
(1950s-1970s)
Live-attenuated

Whole-killed
Cell culture introduced for producing vaccines
Live-attenuated
Whole-Killed

Introduction of reassortants – RNA segments
from attenuated strain combined with RNA
from circulating strain.

Purified
Polysaccharide use for vaccination
Polysaccharides
(1980s to date)
Conjugation of protein (i.e. bacterial toxins) to
Protein
polysaccharides for enhancing immune response
First protein-based vaccine produced by genetic
Protein
engineering technology
Genetic engineering for protein modification
Protein
and avoiding side effects associated with
bacterial cell walls
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Table 3.2. Features of innate and adaptive immune systems. (Adapted from Janeway
and Medzhitov [55]).
Feature

Innate immune system

Adaptive immune system

Action Time

Rapid (hours)

Slow (days-weeks)

Immune response

Invariant

Progressive

Macrophages
Dendritic cells
Mast cells
Neutrophils
Eosinophils
NK Cells

Antigen presenting cells
B lymphocytes
T lymphocytes

Receptor
variability

Germ-line encoded and not
variable

Encoded in gene segments and
variable by rearrangement

Recognition

Conserved molecular
patterns present on
pathogens recognized by
PRR

Details of molecular structure
and sequences recognized by
highly specific receptors

1) Pathogen is cleared
2) Adaptive immune system
is initiated

1) Antigen-specific effector
and memory cells generated
2) Antigen-specific antibodies
generated
3) Pathogen is eliminated or
infection is controlled

Cells

Outcome of
Immune Response
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Table 3.3. Examples of commonly investigated adjuvants for vaccines.

Class of Adjuvant

Examples

Immunostimulatory

Cytokines: IL-2, IL-12, IFN-γ, GM-CSF
QS21
Bacterial DNA (CpG)
Lipid A
Bacterial Toxins: cholera toxin,
heat labile enterotoxin

Particulate

Emulsions: CFA, MF59
ISCOMs
Liposomes
Microparticles
Nanoparticles
Virus-like particles (VLPs)
Mineral Salts: Aluminum hydroxide, Aluminum
phosphate and Calcium phosphate
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Table 3.4. Comparison of relative sizes of pathogens with commonly investigated
particulate delivery systems for vaccines. (Adapted from O’Hagan et al. [125])
Pathogens
Bacteria
~0.5-3 μm
Herpes virus
~250 nm
HIV;
~100 nm
Influenza virus
Poliovirus
~20-30 nm

Particulate delivery systems
Microparticles
1-10 μm
Nanoparticles
10-1000 nm
Liposomes
50 nm – 10 μm
MF59
ISCOMs
VLPs
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~200 nm
~40 nm
~20-50 nm

Table 3.5.
Examples of combined adjuvant formulations investigated for
enhancement in immune responses.
Particulate
System

Immunostimulatory
Adjuvant

Antigen

References

Malaria antigen

[256]

HIV-1 gp 120

[81]

Respiratory syncytial virus

[78]

CpG

Hepatitis B surface antigen

[107]

Lipid A derivative

Herpes simplex virus

[91]

Ovalbumin

[393,394]

IL-12
Alum

Influenza
CpG

Hepatitis B surface antigen

[258]

Hepatitis C antigen (NS3)

[159,162]

HIV-1 gp 140

[99]

HIV-1 gp 140

[99]

Influenza

[395]

IL-6

HIV-1 gp 120

[79]

IL-2

Influenza

[80,396,397]

Liposomes
Lipid A derivative

IFN-γ

CpG

Influenza hemagglutinin:
T and B cell epitopes
HIV-1 gp120

[398]

HIV-1 Gag p55

[398]

Neisseria meningitides type
B

Nanoparticles
and
Microparticles

[237]

Anthrax

[260]

Tetanus toxoid

[111,263]

Neisseria meningitides
serotype B (Men B)

Lipid A derivative

[45,79]

[257]

HIV-1 gp 120

[257]

Hepatitis B core antigen

[246]
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Table 3.6. HIV proteins and their main functions in viral life cycle.
Gene
gag

Structural

pol

env
tat
Regulatory
rev

nef
vif
Accessory

vpr

vpu

Protein encoded
Gag p55 precursor;
capsid (p24); matrix
(p17); nucleocapsid
(p7); p6; p1

Major Function(s)
Virus assembly and structure

Viral genome transcription,
Reverse transcriptase
integration into host genome,
(p66/51); Integrase
and cleavage of precursor
(p32); Protease (p11)
proteins in immature virus
gp 160 Envelope
Glycoproteins (gp) required for
precursor;
binding and internalization of
gp 120; gp 41
virus
Promotes infection of cells and
Transactivator (Tat) LTR-mediated viral gene
transcription
Binds to Rev responsive
element on HIV mRNA,
Regulator of viral
allowing transport of unspliced
RNA from nucleus to
expression (Rev)
cytoplasm and production of
structural proteins
Down regulates expression of
Negative-regulation
cell surface molecules (CD4
factor (Nef)
and MHC I) in infected cells
Involved in viral replication by
Viral infectivity
stabilizing DNA intermediate
(Vif)
and
Plays a role in transporting
Viral protein R (Vpr) HIV-preintegration complex to
nucleus
Down regulates CD4
expression and forms ion
Viral protein U
channels in cell membranes to
(Vpu)
allow release of virons from
infected cells
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Figure 3.1

Dendritic
Cell
(APC)

IFN-γ
B cell

+

CD8+

T cell

Th1

IL-4

Th2

MHC II

MHC I

IgG2a

CD4
T cell

IgG1, IgM,
IgA, IgE

IL-4, IL-5
IL-6, IL-10

IL-2, IL-3,
IFN-γ, TNF-α

Cellular
Responses

Humoral
Responses

Figure 3.1. Adaptive immune response. The key cellular interactions involved in
generating antigen-specific immune responses are depicted.

Cellular responses are

mediated by CD8+ and CD4+ T cells and humoral responses are mediated by B cells with
additional help provided by T helper 2 (Th2) cells. The cytokines released by the CD4+
T cell influence the isotype of antibodies produced by B cells (Adapted from Singh and
O’Hagan [1]).
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Figure 3.2

IL-10

Pathogens
Cytokines
T-cells

Immature DC

Mature DC

↑ intracellular MHC II
↑ endocytic receptor expression
↑ uptake capacity
↓ costimulatory molecule expression
↓ migration

↑ surface MHC II
↓ endocytic receptor expression
↓ uptake capacity
↑ costimulatory molecule expression
↑ migration

Figure 3.2. Features of dendritic cells. Immature DCs are triggered to mature by
environmental factors such as encountering a pathogen or release of inflammatory
cytokines. Immature and mature DCs possess different structural, phenotypical and
functional features. (Adapted from Banchereau and Steinman [267]).
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Figure 3.3

Neutralizing Antibodies to HIV
HIV-specific CTL
CD4+ T cells

Plasma HIV

2-8 weeks

2-12 years

Acute
Infection

Asymptomatic phase (clinical latency)

Figure 3.3.

2-3 years
Symptomatic
phase (AIDS)

Adaptive immune responses during HIV infection.

An increase in

circulating virus correlates with decrease in the CD4+ T cells in the initial phase of
infection. The induction of HIV-specific CTL responses helps to maintain CD4+ T cells
in the asymptomatic phase of infection. However, the immune system is unable to
replace the dying CD4+ cells and their subsequent depletion leads to AIDS.
from Girard and Excler [327] and Parham [52]).
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(Adapted

Figure 3.4

A)
rev1

rev2
3’

5’
LTR

tat1 vpu

vif

gag

vpr

pol

LTR

tat2
env

nef

B)
p7 (nucleocapsid)

Protease

p24 (capsid)
Reverse
Transcriptase

p17 (matrix)

gp 120
gp 160

gp41

RNA Genome

Integrase
Lipid Membrane

Vpr

Figure 3.4. HIV genome and schematic representation of the HIV viron. A) The
viral genome consists of nine genes flanked by LTR regions.

B)

Schematic

representation of HIV viron, showing the location of the various proteins in the mature
virus.

(Adapted from Girard and Excler [327] and http://hivinsite.ucsf.edu/

InSite?page=kb-02-01-01#S2X).
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Figure 3.5
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Figure 3.5. HIV life cycle. 1) gp120 interacts with CD4 and chemokine co-receptors
present on the cell. 2) The virus membrane fuses with cell membrane. 3) Viral contents
are emptied into cell cytoplasm. 4) The viral RNA is transcribed into double stranded
DNA by the reverse transcriptase. 5) Viral DNA is transported into the nucleus and
integrated into host genome by integrase. 6) The DNA is transcribed into RNA. 7) RNA
is transported to the cell cytoplasm. 8) The viral proteins are synthesized in the
cytoplasm. 9) The structural proteins are transported to the cell membrane and virus
assembly begins. 10) The immature virus buds from the cell membrane. 11) The
protease enzyme cleaves the polyproteins to give the mature virus. (Adapted from Freed
[17]).
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Chapter 4

HIV-1 Tat-coated nanoparticles result in enhanced humoral immune responses and
neutralizing antibodies compared to Alum adjuvant

4.1

Summary
HIV-1 Tat has been identified as an attractive target for vaccine development and

is currently under investigation in clinical trials as both a therapeutic and preventative
vaccine for HIV-1. It is well known that protein based vaccines produce poor immune
responses by themselves and therefore require adjuvants to enhance immune responses.
We have previously reported on the use of anionic nanoparticles for enhancing cellular
and humoral immune responses to Tat (1-72). The purpose of this study was to further
evaluate the immune response of HIV-1 Tat (1-72) coated on anionic nanoparticles (NPs)
compared to Alum using various doses of Tat (1-72). Nanoparticles were effective at
generating comparable antibody titers at both 1 μg and 5 μg doses of Tat (1-72), whereas
the antibody titers significantly decreased at the lower dose of Tat (1-72) using Alum.
Anti-sera from Tat (1-72) immunized mice reacted greatest to the N-terminal and basic
regions of Tat, with the NP groups showing stronger reactivity to these regions compared
to Alum. Moreover, the anti-sera from all Tat (1-72) immunized groups contained Tatneutralizing antibodies and were able to significantly inhibit Tat-mediated long terminal
repeat (LTR) transactivation.
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4.2

Introduction
Ideally, an HIV vaccine would be effective at blocking viral entry and thus,

provide sterilizing immunity. However, recent failures with the envelope (Env) based
HIV vaccine have demonstrated that this may be a difficult goal to attain [339]. These
experiences have prompted investigators to look at alternative strategies in developing an
HIV vaccine; for example, to limit viral replication and thereby block or delay
progression onto AIDS. In pursuit of this secondary goal, it is well recognized that the
candidate antigen must be conserved among different HIV subtypes, as this is a major
drawback for Env based vaccines. In addition, the antigen should be immunogenic and
play a critical role in the virus life cycle. To this end, the HIV-1 regulatory protein Tat
has received considerable interest as a potential HIV vaccine or as a component in a HIV
vaccine [384,385,399,400].
Tat, a small regulatory HIV protein, is encoded by two exons, with the size of the
full length protein varying from 86 to 102 amino acids (aa) depending on the viral strain.
The first exon of Tat encodes the first 72 aa of the protein, which includes: the aminoterminal (aa 1-21); the cysteine-rich domain (aa 22-37) representing the transactivation
domain; the core (aa 38-48); and the basic domain (aa 49-72) containing nuclear
localization signals and regions mediating cellular uptake of Tat [360]. This region of
Tat has been shown to be necessary for Tat-mediated transactivation of HIV-1 gene
expression [358,359] and is highly conserved among different viral subtypes [401,402],
with the cysteine-rich domain (aa 25-38) being conserved among human, bovine and
simian species [403]. While the second exon, encoding the C-terminal domain of Tat is
not required for the transactivation, it contains an arginine-glycine-aspartic acid (RGD)
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sequence that mediates the binding of extracellular Tat to integrin receptors [361].
Additionally, the C-terminal domain of Tat is of significant importance in the cellular
uptake of extracellular Tat [362].
Tat plays a vital role in the viral life cycle and mediates many processes allowing
for spread of the virus throughout the body and potentiating disease. Of these, possibly
the most significant role of Tat in the virus life cycle is the enhancement of HIV gene
expression. Tat is expressed in the very early stages of infection before the expression of
the structural components (Env, Gag, Pol) [363]. In fact, Tat is necessary for efficient
viral gene expression and in the absence of Tat, no or only minute amounts of the
structural proteins are expressed, preventing the production of an infectious virus
[364,365].

In addition to promoting viral gene expression in HIV-infected cells,

extracellular Tat released from infected T lymphocytes has numerous effects on
uninfected cells that aid in the progression of disease. Tat induces the expression of the
chemokine receptors CCR5 and CXCR4, which function as co-receptors for HIV-1 and
facilitate the transmission of macrophage and T cell tropic HIV-1 strains [368]. Some in
vitro studies have demonstrated that Tat induces the production of Interferon-α,
inhibiting T cell proliferation, [400] and also promotes apoptosis of T cells by increasing
the expression of CD95L/Fas ligand on macrophages [381]. Fanales-Belasio et al. have
demonstrated that biologically active Tat at high concentrations is taken up by antigen
presenting cells (APCs), particularly monocyte-derived dendritic cells, inducing
expression of MHC II, co-stimulatory molecules, and causing production of Th1 type
cytokines such as IL-12 [366]. On the contrary, Izmailova et al. did not observe DC
activation or maturation in the presence of HIV infection or Tat expression; however,
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they reported that Tat was involved in up-regulation of chemoattractant proteins in
immature DC which are involved in recruiting of T cells and macrophages thus, aiding in
the spread of infection [404]. The ability of Tat to be efficiently taken up by cells has
become attractive for the delivery of proteins into cells [405] and conjugation of proteins
to Tat has been shown to be an effective method in presenting exogenous proteins in
context of MHC class I, and generating antigen-specific CTL responses [367].
The importance of Tat in the progression to diseased states has been demonstrated
in numerous reports [373-378,406-408]. In fact, both strong antibody [373,374,376] and
CTL responses [377,378] to Tat have been inversely correlated with viral loads and
disease progression.

Moreover, Tat is involved in the progression of AIDS-related

Kaposi sarcoma and high serum levels anti-Tat antibodies have been correlated with
reduced Kaposi sarcoma in HIV-infected patients [387]. Extensive studies carried out in
mice and non-human primates have demonstrated that immunization with Tat is safe and
effective at generating humoral and cellular immune responses [18].

However,

conflicting data exists on the effectiveness of a Tat-based vaccine in controlling infection
upon challenge with a highly pathogenic strain (SHIV-89.6P) in non-human primates
[379,381,383,409,410]. In spite of these data, many researchers agree that the potential
of Tat based vaccines warrant further investigation and Phase I clinical trials evaluating
Tat for preventative and therapeutic vaccines are currently ongoing in Italy [18,407].
Moreover, a Tat toxoid (chemically modified Tat) vaccine has already been evaluated in
both HIV negative and positive patients and was shown to be safe and effective [387].
Futhermore, other ongoing clinical trials evaluating preventative HIV-1 vaccines include
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Tat as component of the vaccine in addition to other HIV-1 antigens (IAVI Report,
February 2005).
We have previously reported on the preparation and purification of the first exon
of Tat protein (referred to as Tat (1-72)) [362]. We have demonstrated that Tat (1-72) is
immunogenic and that Tat (1-72) coated anionic nanoparticles were effective at
generating humoral and cellular immune responses to Tat [253]. In the present study, the
use of nanoparticles for generating immune responses to various doses of Tat (1-72) was
further investigated. More specifically, we sought to determine the lowest effective dose
of Tat (1-72) that could produce immune responses when administered with anionic
nanoparticles. In addition, the antibody epitopes generated in mice immunized with Tat
(1-72) were mapped and the Tat-neutralizing activity in the sera from immunized mice
was evaluated.
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4.3

Materials and methods

Materials
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of
20:1), was purchased from Spectrum (New Brunswick, NJ). Sodium dodecyl sulfate
(SDS), PBS/Tween 20 buffer, bovine serum albumin (BSA), triethanolamine, and
mannitol were purchased from Sigma Chemical Co. (St. Louis, MO). Brij 78 was
purchased from Uniqema (New Castle, DE). Sheep anti-mouse IgG, peroxidase-linked
species specific F(ab’)2 fragment was purchased from Amersham Pharmacia Biotech
(Piscataway, NJ).

Goat anti-mouse IgG2a and IgG1 horseradish peroxidase (HRP)

conjugates were purchased from Southern Biotechnology Associates, Inc. (Birmingham,
AL). Tetramethylbenzidine (TMB) substrate kit was purchased from Pierce (Rockford,
IL). Incomplete Freund’s adjuvant and mycobacterium tuberculosis were purchased from
Fisher Scientific (Hampton, NH). Lipid A from Salmonella Minnesota R595 (Re) was
purchased from List Biological Laboratories (Campbell, CA). HIV-1 Clade B consensus
Tat peptides (15 aa) were obtained through the AIDS Research and Reference Reagent
Program (Division of AIDS, NIAID, NIH, Bethesda, MA). Recombinant HIV-1 Tat (172 aa) was prepared as previously described [362].

Preparation of anionic NPs
Nanoparticles from oil-in-water microemulsion precursors were prepared as
previously described previously [253] with slight modification.

Briefly, 2 mg of

emulsifying wax and 3.5 mg of Brij 78 was melted and mixed at ~60-65oC. Deionized
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and filtered (0.2 μm) water (980 μL) was added to the melted wax and surfactant while
stirring to form an opaque suspension. Finally, 20 μL of sodium dodecyl sulfate (50
mM) was added to form clear microemulsions at 60-65oC. The microemulsions were
cooled to room temperature, while stirring, to obtain NPs (2 mg/mL).

The final

concentration of components in the NP suspension was emulsifying wax (2 mg/mL), Brij
78 (3 mM), and SDS (1 mM). The NP sizes were measured using a Coulter N4 Plus SubMicron Particle Sizer (Coulter Corporation, Miami, FL) at 90o. The overall charge of the
NPs was measured using Malvern Zeta Sizer 2000 (Malvern Instruments, Southborough,
MA).

Coating of the anionic NPs with Tat
Varying amounts of Tat were added to NPs (1000 μg/mL) in 5% (v/v) mannitol.
The suspension was vortexed gently and placed on a horizontal shaker at room
temperature for a minimum of 30 min to allow for coating. The coated NPs were diluted
appropriately in de-ionized water for measuring the size and charge of the particles.

Mouse immunization study
Two animal studies were carried out to determine the immune response to
different doses of Tat. A summary of the experimental design is presented in Table 4.1.
For both studies, female BALB/c mice (8-10 weeks old) obtained from Harlan SpragueDawley Laboratories (Indianapolis, Indiana) were immunized subcutaneously with 100
μL of the formulations. In the initial mouse study (Study 1), mice (n=5-6/group) were
dosed on day 0, 21 and 28 with 1 μg or 5 μg of Tat-coated NPs or 1 μg or 5 μg of Tat
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adjuvanted with Alum. The dose of NPs and Alum administered in both cases was 100
μg. As a positive control, mice were immunized on day 0 with 5 μg of Tat adjuvanted
with complete Freund’s adjuvant (CFA) followed by boost with 5 μg Tat adjuvanted with
incomplete Freund’s adjuvant (IFA). On day 35, mice were bled by cardiac puncture and
sera were separated. All sera collected were stored at -20oC.
In the follow up study (Study 2), mice (n=6-8/group) were dosed on day 0, 14 and
28 with 0.2 μg or 1 μg of Tat-coated NPs or 0.2 μg or 1 μg of Tat adjuvanted with Alum.
Again, the dose of NPs and Alum given to animals was 100 μg. Mice were immunized
with 1 μg of Tat adjuvanted with Lipid A (50 μg) as a positive control. To assess the
kinetics of Tat specific antibodies generated using the different treatments, mice were
bled on day 13 and 34 by tail vein and sera were collected. On day 42, all mice were bled
by cardiac puncture and sera were collected. All sera were stored at -20oC.

Determination of antibody titers
Tat-specific serum IgG, IgG1 and IgG2a antibody titer were determined using an
ELISA. Briefly, 96-well plates (Costar) were coated with 50 μL of Tat (5-8 μg/mL in
0.01 M phosphate buffered saline, pH 7.4) overnight at 4oC. The plates were blocked for
1 hr at 37oC with 200 μL of 4% BSA prepared in PBS/Tween 20. The plates were then
incubated with 50 μL per well of mouse serum diluted appropriately in 4%
BSA/PBS/Tween 20 for 2 hr at 37oC. The plates were washed with PBS/Tween 20 and
incubated with 50 μL/well anti-mouse IgG HRP F(ab’)2 fragment from sheep (1:3000 in
1% BSA/PBS/Tween 20) for 1 hr at 37oC. For IgG1 and IgG2a determination, the plates
were similarly incubated with goat anti-mouse IgG1-HRP or goat anti-mouse IgG2a-HRP
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diluted 1:8000 (1% BSA/PBS/Tween 20). After washing the plates with PBS/Tween 20,
the plate was developed by adding 100 μL of TMB substrate and incubating for 30 min at
RT. The color development was stopped by addition of 100 μL of 2 M H2SO4 and the
OD at 450 nm was read using a Universal Microplate Reader (Bio-Tek Instruments, Inc.).
The OD at 450 nm versus log serum dilution for each animal was plotted and fit to a four
parameter logistic equation using GraphPad Prism software. The titer was defined as
0.5*ODmax.

B cell epitope mapping
Tat anti-sera were tested by ELISA to determine reactivity to various regions of
Tat. Tat peptides (50 μL of 1 μg/mL Tat peptide in 0.05 M carbonate buffer, pH 9.6)
were coated onto 96-well Costar plates by incubating overnight at 4oC. The plates were
blocked for 1 hr at 37oC with 200 μL of 4% BSA prepared in PBS/Tween 20. Tat antisera diluted at 1:100 in 4% BSA/PBS/Tween 20 were added to the wells and incubated
for 2 hr at 37oC. The wells were washed, reacted with anti-mouse IgG HRP F(ab’)2
fragment from sheep, and developed as described for total IgG titer.

Tat-mediated LTR-transactivation assay
SVGA LTR-chloramphenicol acetyltransferase (CAT) was produced by stable
transfection of the astrocytic cell line SVGA with pHIV-CAT [411]. SVGA LTR-CAT
cells were seeded into 6-well plates a minimum of 24 hr prior to use in Dulbecco’s
Modified Eagle Medium (DMEM; GibcoBRL) with 10% heat-inactivated fetal bovine
serum (FBS; Sigma) and 1% antibiotic-antimycotic solution (penicillin G sodium,
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streptomycin sulfate, and amphotericin B in 0.85% saline; GibcoBRL) (DMEM+10%
FBS+Ab). Ten (10) µL of sera was mixed with 2 μL (1000 μg) recombinant Tat (1-72)
derived from the first exon of the HIV-1 tat gene and incubated for 30 min at 37oC in a
water bath. During the incubation, medium was replaced on the SVGA LTR-CAT cells
with 2 mL fresh DMEM+10% FBS+Ab. The sera/Tat mixtures were then added to the
cells. Cells were then lysed at 24 hr post-treatment and CAT levels were quantitated by
ELISA according to the manufacturer’s directions (Roche).

Statistical analysis
Statistical analysis was performed using one-way analysis of variances (ANOVA)
followed by pair-wise comparisons using Newman-Keuls multiple comparison test using
GraphPad Prism software.
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4.4

Results and discussion
Many researchers have reported on the potential of HIV-1 Tat-based vaccine or

supported the idea including Tat as a component in a cocktail for vaccine development
[384,385,399,400]. As new targets for HIV vaccine development are identified, it is also
important to investigate novel delivery systems for effectively enhancing immune
responses to the target antigen(s). Our laboratory has reported on the use of anionic and
cationic NPs for effectively enhancing immune responses to plasmid DNA and protein
based vaccines [14-16].

These NPs are prepared from oil-in-water microemulsion

precursors and form solid stable particles. The emulsifying wax oil phase used to prepare
the NPs is comprised of cetyl alcohol and polysorbate 60 (20:1 molar ratio) which are
both employed as components in parenteral products and are potentially non-toxic
materials. We have recently shown that these nanoparticles are hemocompatible and
metabolized via endogenous alcohol dehydrogenase enzyme systems [251]. In addition,
these NPs have the advantage of being prepared in a single step, one vessel process with
relative ease in modifying the physical characteristics of the particles by using
appropriate surfactants. We recently reported the use of anionic NPs as effective delivery
systems for enhancing immune responses to Tat (1-72) [253]. In the present studies, the
dose-response to Tat (1-72) using NPs compared to standard Alum adjuvanted protein
was further evaluated. In addition, the humoral immune responses to Tat (1-72) were
characterized for reactivity to various regions of Tat and for activity in a LTRtransactivation assay.
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Adsorption of Tat (1-72) on anionic NPs
The NPs prepared in these present studies are stabilized by the inclusion of Brij
78 and made to be negatively-charged by the use of the anionic surfactant SDS. The net
charge of the NPs prior to coating with Tat is approximately -56 mV (Table 4.2). Tat, a
cationic protein, is expected to be coated on the surface of the NPs via ionic interactions.
It is thought that the negatively charged amino acids of Tat are exposed on the surface of
NPs while the positively charged amino acids interact with the negatively charged NPs.
As demonstrated in Table 4.2, there is a slight increase in the zeta potential with
increasing amounts of Tat coated on NPs; however, the Tat-coated NPs continue to have
a net negative charge possibly due to the exposed negatively charged amino acids. The
coating of Tat on NPs at a 1:100 w/w ratio was found to be approximately 85% by SDSPAGE/densitometry (data not shown).

Dose response to Tat in immunized mice
We previously reported that Tat (5 μg) coated on anionic NPs result in similar
Tat-specific IgG levels as Alum and Lipid A adjuvanted with Tat [253]. Thus, a dose
response of Tat was evaluated in these present studies to determine the minimum Tat
dose that could be administered while maintaining the Tat-specific IgG response. In the
first study, use of 1 μg and 5 μg of Tat coated on NPs or adjuvanted with Alum was
investigated. Tat (5 μg) with CFA adjuvant was used as a positive control. The results
shown in Figure 4.1 demonstrate that Tat-specific IgG antibody titers are maintained at
both the 1 μg and 5 μg of Tat coated on NPs, while Tat (1 μg) adjuvanted with Alum
produced significantly lower titers compared to Tat (5 μg) adjuvanted with Alum.
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Moreover, both the 1 μg and 5 μg Tat-coated NPs produced comparable Tat-specific IgG
titers compared to CFA. Only the higher dose of Tat adjuvanted with Alum produced
comparable Tat-specific IgG levels to CFA adjuvant. These results suggested that a
lower dose of Tat using NPs compared Alum was still effective at eliciting a strong Tatspecific antibody response.
In the follow up study, the effectiveness of lower doses of Tat coated on NPs and
adjuvanted with Alum in generating Tat specific antibodies was evaluated. Lipid A with
1 μg of Tat was used as a positive control. The results (Figure 4.2) indicated that Tat (1
μg) coated NPs were able to generate significantly higher IgG levels at all time points
tested compared to both Alum groups and the NP group receiving the lower dose of Tat.
These data combined with IgG results from the first study suggest that the total serum
anti-Tat IgG levels are similar with immunization doses of 1 μg or 5 μg of Tat coated on
NPs, however, doses of less than 1 μg of Tat, cause a significant decrease in the anti-Tat
IgG levels. More importantly, the data taken together demonstrate that the Tat-coated
NPs were capable of generating stronger and more robust humoral immune responses at
lower doses of antigen compared to Tat adjuvanted with Alum.
To evaluate the type of response (Th1- or Th2-type) that was generated using NPs
compared to the other adjuvants, both Tat-specific IgG2a and IgG1 titers were
determined using Tat anti-sera from the first study evaluating 1 μg and 5 μg Tat. The
Tat-specific IgG2a and IgG1 titers along with the mean IgG2a/IgG1 ratio are presented in
Figure 4.3. Significantly lower Tat-specific IgG2a titers were produced using 1 μg Tat
adjuvanted with Alum compared to Tat (1 μg) coated NPs and the mean IgG2a/IgG1
ratios were lower for both Alum groups compared to the NP groups. Interestingly, CFA,
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a strong adjuvant for Th1 responses in mice, produced similar Tat-specific IgG2a levels
as Tat coated NPs or Tat (5 μg) adjuvanted with Alum. This high level of IgG2a seen
with all groups may be attributed to Tat, which has been demonstrated to enter the MHC
class I pathway and enhance Th1 responses [366,367]. These results are consistent with a
greater stimulation of Th1 responses by NPs compared to Alum.

Tat-specific antibody epitope mapping
The Tat used in this study only corresponds to the first 72 aa acids of Tat, which
is encoded by the first exon of the tat gene. Tat anti-sera collected from both studies
were analyzed to determine reactivity to overlapping 15-mer peptides spanning aa 1-83 of
the Tat sequence. Table 4.3 presents the reactivity pattern for anti-sera collected from
each animal for each Tat immunized group in Study 1. Sera from all animals recognized
aa 1-15 or 5-19, corresponding to the N-terminal region of Tat. In addition, the sera from
Tat immunized mice also recognized aa 45-59 and 49-63, corresponding to the basic
region of Tat; however, this was to a lesser degree than recognition of the N-terminal and
was only observed in some of the animals.

Interestingly, Tat-coated NPs which

demonstrated the highest total serum Tat-specific IgG titers also demonstrated the
strongest reactivity in both the N-terminal and basic regions. Moreover, the strong
reactivity to both the N-terminal and basic regions of Tat is maintained using 1 μg of Tatcoated NPs compared to the Alum groups. In fact, Tat (1 μg) coated on NPs showed
stronger reactivity in the basic region of Tat compared to Tat (5 μg) adjuvanted with
Alum. Similarly, evaluation of the Tat anti-sera from Study 2 demonstrated strong
reactivity of 1 μg Tat-coated NPs compared to Alum at both the N-terminus and basic
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region (Table 4.4). Although the sera from both positive controls in the two studies, CFA
and Lipid A, demonstrated reactivity across the entire Tat sequence analyzed, the
strongest recognition was in the N-terminal and basic regions of the protein.
These data are in agreement with the antibody epitopes reported for Tat (aa 1-86)
in different species [387,412-414].

Sera from healthy and HIV-infected volunteers

immunized with a Tat-toxoid vaccine reacted primarily with the N-terminus (aa 1-24) and
the basic domain (aa 46-60) of Tat [387]. Moreover, sera from mice, rabbits, macaques
and humans immunized with recombinant Tat, synthetic Tat, Tat toxoid or Tat peptides
demonstrated reactivity to N-terminus and basic domains of Tat [413]. While both the Nterminal and basic regions of Tat are highly conserved among different HIV-1 subtypes
[414], the recognition of the basic region may be of particular importance since it
mediates the cellular uptake and nuclear localization of Tat [360]. Thus, generating
antibodies that strongly recognize this region is advantageous for inhibiting Tat-mediated
HIV-gene expression in infected cells. It is important to note that that the strongest
reactivity in the basic domain in the Tat immunized animals was produced by the NP
groups, suggesting that NPs may be effective at enhancing immune responses to this
region.

Inhibition of Tat-mediated LTR-transactivation
Extracellular Tat has been demonstrated to enter HIV-infected cells and promote
gene expression [358,359]. Tat mediates transactivation of HIV-1 via the long-terminal
repeat promoter by migrating from the cell cytoplasm into the cell nucleus and binding to
the Tat responsive element, TAR region [18]. Thus, neutralization of extracellular Tat
may be crucial in preventing spread of HIV infection and slowing the progression on to
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disease. The anti-sera from Tat immunized mice were evaluated for extracellular Tat
neutralization activity using SVGA cells (an astrocytic cell line) transfected with pHIVCAT plasmid. Sera from the naïve group were used as controls and the percent inhibition
in CAT expression for each group compared to the naïve group is presented in Figure 4.4.
All groups demonstrated significantly higher Tat neutralizing antibody compared to the
naïve sera.

As shown, the anti-sera from Tat (5 μg) coated NPs group produced

significantly higher inhibition in CAT expression compared to all groups. Nonetheless,
the other groups also demonstrated ability of the anti-sera to neutralize extracellular Tat.
These data suggest that neutralizing antibodies to Tat (1-72) can be generated with the
various adjuvants employed. Interestingly, Moreau et al. have reported that only antisera reacting with the N-terminal and basic regions of Tat were able to block Tatmediated LTR-transactivation [413].

In the present studies, a correlation between

reactivity in these regions of Tat and ability to block extracellular Tat entry into cells was
not observed. All the anti-sera were able to neutralize extracellular Tat to some degree
regardless of the Tat epitopes recognized in the peptide ELISA. However, Tat (5 μg)
coated on NPs which demonstrated the strongest reactivity to the basic region in the
peptide ELISA also demonstrated the highest neutralization activity in the LTRtransactivation assay. Moreover, this group also demonstrated the strongest reactivity in
the basic region of Tat, which may be of significant importance in preventing entry of Tat
and thus, Tat-mediated LTR-transactivation. Differences observed between the results
obtained in this study compared to those observed by Moreau et al. could be due to a
number of factors. First, different cell types were used in the two studies which may
affect the sensitivity of the assay. Second, the present studies used the first exon of Tat
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(aa 1-72) for the LTR-transactivation assay whereas Moreau et al. used full length Tat (aa
1-86), which has been shown to enter cells more efficiently than Tat (1-72). Third, the
Tat concentrations employed in the present LTR-transactivation studies are
approximately 80-fold greater than those reported by Moreau et al. Fourth, Tosi et al.
have shown that only the monomeric form of exogenous Tat is able induce LTRtransactivation and took significant precautions using high concentrations of DTT to
inhibit oligomer formation [415]. Thus, taken together these differences may offer some
explanation as to why a correlation was not observed between the reactivities of the antisera in the N-terminal and basic regions of Tat and the neutralization activity in the LTRtransactivation assay. Further work to optimize the LTR-transactivation assay using a
HeLa cell line and a difference source of extracellular Tat are on going in our laboratory.
Preliminary results, presented in Chapter 8, demonstrate that improved sensitivity in the
assay can be obtained with these modifications.
It is well recognized that there is an urgent need for a safe and effective vaccine
against HIV. Numerous failures to neutralize the virus using envelope-based vaccines
have caused researchers to look at alternative avenues to provide some protection or to
slow down the progression of the disease in HIV-infected patients by the development of
therapeutic vaccines. One of the requirements for an effective HIV vaccine will be that
the antigen is conserved among the different viral subtypes. Thus, many researchers are
investigating the potential of HIV regulatory proteins Nef, Rev, and Tat, which are
expressed early in the life cycle and are also fairly well conserved among the different
HIV subtypes, as alternative targets for vaccine development [406,416,417]. Several
studies have demonstrated the importance of Tat in the virus life cycle and demonstrated
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that anti-Tat antibodies [373,374,376] and CTL responses [377,378] correlate inversely
with disease progression, making Tat an attractive candidate for HIV vaccine
development.
In conclusion, we previously reported that anionic NPs were effective for
enhancing immune humoral and cellular immune responses to HIV-1 Tat [253].

The

present studies further demonstrated the advantages of using NPs over Alum as an
adjuvant for protein based vaccine in that NPs allowed for lower doses of Tat to be
administered. Moreover, Tat-coated NPs were able to generate antibodies that strongly
recognized both the N-terminal and basic regions of the protein. Tat-mediated LTRtransactivation studies also revealed that the antibodies generated with all Tat groups
were able to block Tat entry into cells, with Tat coated NPs showing superior Tat
neutralization activity over other forms of delivery. Together the data presented here
demonstrate the potential of these novel anionic NPs as effective vaccine delivery
systems for enhancing immune responses to HIV-1 Tat-based vaccines and possibly other
HIV protein-based vaccines.
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Table 4.1. Experimental design for mouse immunization study.
Study

Study 1

Study 2

Treatment
Naïve
NPs + Tat
Alum + Tat
CFA + Tat
Naïve
NPs + Tat
Alum + Tat
Lipid A + Tat

Tat
Dose
1 and 5 μg
1 and 5 μg
5 μg
0.2 and 1 μg
0.2 and 1 μg
0.2 and 1 μg
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Immunization
Schedule
Day 0, 21, 28

Sera
Collected
Day 35

Day 0, 14, 28

Day 13, 34, 42

Table 4.2. Physical properties of anionic NPs coated with HIV-1 Tat (1-72).

Sample (n=3)

Mean Size (nm)

Mean Charge (mV)

Anionic NPs

102.5 + 7.6

-55.7 + 0.7

Tat-coated NPs (1:500 w/w)

130.6 + 3.3

-48.6 + 3.7

Tat-coated NPs (1:100 w/w)

110.9 + 3.3

-43.9 + 1.9

Tat-coated NPs (1:20 w/w)

111.6 + 5.1

-43.6 + 1.7
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Table 4.3. Tat anti-sera reactivity to 15-mer Tat peptides in Study 1. All sera were
diluted 1:100. The reactivity of anti-sera from each animal is presented. The value in
parenthesis represents the dose of Tat in μg. *Cutoff = (AVG Naïve response) + (3*SD).
(-) indicates no response – ELISA OD values equal to cutoff/background.
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Table 4.4. Tat anti-sera reactivity to 15-mer Tat peptides in Study 2. All sera from
mice immunized with 1 μg of Tat were diluted 1:100. The reactivity of anti-sera from
each animal is presented. *Cutoff = (AVG Naïve response) + (3*SD). (-) indicates no
response – ELISA OD values equal to cutoff/background.
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Figure 4.1
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Figure 4.1. Study 1: Tat-specific total serum IgG titers. The numbers in parentheses
refer to the dose of Tat. BALB/c mice were immunized on day 0, 21, and 28 with 100
μL of each formulation. Tat-specific total serum IgG Titers were evaluated on day 35 by
ELISA. Data represent the mean ± SD. *p<0.05 compared to all groups.
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Figure 4.2
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Figure 4.2. Study 2: Tat-specific total serum IgG titers. The numbers in parentheses
refer to the dose of Tat. BALB/c mice were immunized on day 0, 14, and 28 with 100
μL of each formulation. Tat-specific total serum IgG Titers were evaluated on day 13, 34,
and 42 by ELISA. Data represent the mean ± SD. *p<0.05 compared to NPs (0.2 μg) and
both Alum groups at all time points; #p<0.05 compared to all groups at all time points.
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Figure 4.3
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Figure 4.3. Tat-specific IgG2a and IgG1 titers. BALB/c mice were immunized on day
0, 21, and 28 with 100 μL of each formulation. The numbers in parentheses refer to the
dose of Tat. Tat-specific serum IgG2a and IgG1 Titers were evaluated on day 35 by
ELISA. The mean IgG2a/IgG1 ratio is indicated on top of the graphed titers for each
group. Data represent the mean ± SD. *p<0.05 compared to NPs (1 μg) group.

99

Figure 4.4
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Figure 4.4. Inhibition of Tat-mediated LTR-transactivation. BALB/c mice were
immunized on day 0, 21, and 28 with 100 μL of each formulation. The numbers in
parentheses refer to the dose of Tat.

Serum from each mouse was evaluated for Tat

neutralizing antibodies using a LTR-transactivation assay. The percent inhibition in CAT
expression for each group is expressed in comparison to naïve sera. Data represent the
mean ± SD. *p<0.05 compared to all groups.
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Chapter 5

Formulation of Toll-like receptor ligands with cationic nanoparticles and in vivo
evaluation using Ovalbumin as a model antigen

5.1

Summary
The use of cationic nanoparticles formulated with immunostimulatory adjuvants

was investigated for obtaining enhancements in immune responses to ovalbumin (OVA)
compared to either nanoparticles or adjuvant alone. More specifically, three Toll-like
receptor ligands were investigated:

lipoteichoic acid (LTA), a synthetic CpG

oligonucleotide (CpG), and a synthetic double-stranded RNA analog (Poly I:C). Initial
studies revealed the strong potency of CpG formulated with nanoparticles for stimulating
cell responses in the lymph nodes 8 days after initial immunization. Based on these data,
further work was carried out to evaluate the humoral immune responses in BALB/c mice
using nanoparticles coated with OVA and CpG. The data demonstrated that more robust
OVA-specific immune responses could be obtained with CpG coated on nanoparticles
compared to either CpG or nanoparticles alone.
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5.2

Introduction
Unlike traditional vaccines such as live attenuated or whole killed pathogens, new

generation vaccines, composed of peptides, proteins or DNA, are considered to be
potentially much safer; however, they produce poor immune responses when
administered alone.

Thus, the use of immunological adjuvants is crucial with new

generation vaccines to elicit stronger, more robust immune responses. Of particular
importance is the choice of adjuvant used with the antigen, as the adjuvant can greatly
influence the type of immune response generated, biasing towards either a Th1/cellular or
Th2/humoral type response. For example, aluminum-based mineral salts such as Alum
produce strong humoral responses but Alum is considered a weak adjuvant for mediating
cellular responses [134]. In contrast, bacterial derived products such as Lipid A typically
bias the immune response towards a cellular or Th1 type response [64]. Therefore, the
key to eliciting optimal immune responses with new generation vaccines may lie in the
selection of an appropriate adjuvant or combination of adjuvants.
While many new adjuvants have been explored and evaluated in clinical trials, the
majority of adjuvants have been proven to be too toxic to be used in routine human
vaccination. Alum continues to be the only approved adjuvant for use in human vaccines
in the United States [2]. It is well recognized that in order to conquer emerging chronic
infections, such as HIV, safer and more effective adjuvants that produce cellular in
addition to humoral immune responses will be necessary [77].
Adjuvants can be broadly classified as immunostimulatory or particulate,
including particulate delivery systems. Immunostimulatory adjuvants function mainly at
the cytokine level, enhancing the immune responses via activation and up regulation of
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co-stimulatory molecules on antigen presenting cells (APCs).

Immunostimulatory

adjuvants derived from bacterial components, such as lipopolysaccharides and
lipoproteins, are recognized by Toll-like receptors (TLRs) expressed on antigen
presenting cells and mediate enhancement in immune responses through activating the
innate immune system [418]. Presently, ten TLRs have been identified, denoted TLR1 to
TLR10, and ligands that bind to most of these receptors have been identified [57]. For
example, the well-investigated immunostimulant lipopolysaccharide is reported to bind to
TLR4, whereas lipoproteins bind to TLR2. Moreover, the cooperation of different TLRs
in recognition of microbes has been reported.

One example reported includes the

cooperation of TLR2 with TLR1 [419] and TLR6 [420] in recognition and innate
immune responses to pathogens. An additional feature of TLRs is their differential
expression on different dendritic cell subtypes [269]. Furthermore, TLRs are expressed
either on the cell surface (TLR1, 2, 4-5, 11) or intracellularly (TLR3, 7-9) [83].
In contrast to immunostimulatory adjuvants, particulate delivery systems are
thought to mediate their effects through enhanced delivery and uptake by APCs [1].
Particulate systems are naturally targeted for uptake by APCs due to the similarity in
sizes compared to pathogens [125].

The use of immunostimulatory adjuvants in

combination with particulate delivery systems has been of great interest in obtaining
more robust enhancements in immune responses to antigens [4,92,257,421,422].
Particulate

delivery

systems

offer

numerous

advantages

for

delivery

of

immunostimulatory adjuvants including: 1) reducing the toxicity or side effects of the
immunostimulant by providing controlled delivery or release [255], 2) allowing for lower
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doses of immunostimulant to be used by enhancing uptake into APCs [263], and 3)
biasing immune responses toward cellular/Th1 type with particulate systems [99,394].
To this end, our laboratory has reported on the preparation of nanoparticles (NPs)
from oil-in-water microemulsion precursors and reported on initial studies demonstrating
the application of these NPs for enhancing immune responses to plasmid DNA [14,15],
cationized β-galactosidase protein [16], and the HIV-1 Tat protein [253]. These NPs are
approximately 100 nm in size and have the advantage of being prepared in a single step,
one vessel process with relative ease in modifying the physical characteristics of the
particles by using appropriate surfactants. More importantly, the oil phase used for
preparation of these NPs is comprised of cetyl alcohol and polysorbate 60, both which are
found in many pharmaceutical products and are biocompatible [251].

The present

studies investigated the potential application of these NPs formulated with three different
TLR ligands for enhancing immune responses to a model antigen, ovalbumin (OVA). To
formulate with cationic NPs, three negatively charged TLR ligands were used: Poly I:C, a
synthetic analog of double-stranded RNA (dsRNA) that binds to TLR3; lipoteichoic acid
(LTA), a cell wall component from gram positive bacteria that binds to TLR2; and CpG
oligonucleotide (CpG), a synthetic 20-mer oligonucleotide containing unmethylated CpG
motifs typically present in bacterial DNA that bind to TLR9.
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5.3

Materials and methods

Materials
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of
20:1), was purchased from Spectrum (New Brunswick, NJ). Cetyl trimethyl ammonium
bromide (CTAB), PBS/Tween 20 buffer, bovine serum albumin (BSA), ovalbumin grade
VI (OVA), and mannitol were purchased from Sigma Chemical Co. (St. Louis, MO).
Brij 78 was purchased from Uniqema (New Castle, DE).

Sheep anti-mouse IgG,

peroxidase-linked species specific F(ab’)2 fragment was purchased from Amersham
Pharmacia Biotech (Piscataway, NJ). Goat anti-mouse IgG2a and IgG1 horseradish
peroxidase (HRP) conjugates were purchased from Southern Biotechnology Associates,
Inc. (Birmingham, AL). Tetramethylbenzidine (TMB) substrate kit was purchased from
Pierce (Rockford, IL).

RPMI 1640, 10% heat-inactivated fetal calf serum, Hanks

Balanced Salt Solution (HBSS), HEPES, L-glutamine, penicillin, and streptomycin were
from GIBCO (Carlsbad, CA). The TLR ligands: murine CpG oligodeoxynucleotide
(ODN 1826: 5’-tcc atg acg ttc ctg acg tt-3’), synthetic dsRNA (Poly I:C), and
Lipoteichoic acid (LTA) were purchased from Invivogen (San Diego, CA). Incomplete
Freund’s adjuvant, mycobacterium tuberculosis and 2-mercaptoethanol were purchased
from Fisher Scientific (Hampton, NH). For in vivo studies, Female BALB/c mice (8-10
weeks old) obtained from Harlan Sprague-Dawley Laboratories (Indianapolis, Indiana)
were used. Unless stated otherwise, all water used in experiments was filtered (0.2 μm)
deionized water.
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Preparation of cationic NPs
Nanoparticles from oil-in-water microemulsion precursors were prepared as
described previously with slight modification [14,15]. Briefly, 2 mg of emulsifying wax
and 3.5 mg of Brij 78 was melted and mixed at ~60-65oC. Water (980 μL) was added to
the melted wax and surfactant while stirring to form an opaque emulsion. Finally, 20 μL
of CTAB (50 mM) was added to form clear microemulsions at 60-65oC. The
microemulsions were cooled to room temperature while stirring to obtain solid NPs
(2 mg/mL).

The final concentration of components in the NP suspension was

emulsifying wax (2 mg/mL), Brij 78 (3 mM), and CTAB (1 mM). The NP sizes were
measured using a Coulter N4 Plus Sub-Micron Particle Sizer (Coulter Corporation,
Miami, FL) at 90o. The overall charge of the NPs was measured using Malvern Zeta
Sizer 2000 (Malvern Instruments, Southborough, MA).

Coating of the cationic NPs with OVA and TLR ligands
Varying amounts of OVA were added to NPs (1000 μg/mL) in 5% (v/v) mannitol.
The suspension was vortexed gently and placed on a horizontal shaker at room
temperature for a minimum of 30 min to allow for coating. A similar procedure was
followed to coat the TLR ligands on cationic NPs. For formulations where TLR ligands
and OVA were coated on NPs, the required amount of OVA was first coated on the NPs
followed by coating with the ligand as described above. The coated NPs were diluted
appropriately in water for measuring the size and charge of the particles.
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Mouse immunization study evaluating cationic NPs coated with TLR ligands and
OVA
Mice (n=5/group) were immunized (s.c.) once, on day 0, with 100 μL of NPs,
OVA-coated NPs, OVA- and LTA-coated NPs, OVA- and Poly I:C-coated NPs, OVAand CpG-coated NPs, and OVA adjuvanted with complete Freund’s adjuvant (CFA).
The doses were as follows: 5 μg of OVA; 50 μg of TLR ligand; and 100 μg of cationic
NPs. The immune responses in draining lymph nodes (brachial, axillary and inguinal)
were assessed on day 8.

Lymphocyte proliferation assay for day 8 harvested lymph nodes
The draining lymph nodes collected for each mouse were prepared individually
and stimulated in triplicate with media, Con A (2 μg/mL), or OVA (50 μg/mL). Briefly,
single cell suspensions were prepared by teasing the lymph nodes apart in 1X Hanks
Balanced Salt Solution (HBSS). Single cell suspensions were transferred into 15 mL of
1X HBSS in a centrifuge tube and spun down at 1,500 rpm for 10 min at 4oC. The cells
were resuspended in RPMI 1640 (supplemented with 10% heat-inactivated fetal calf
serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL streptomycin,
50 μM 2–mercaptoethanol). The cells (5x105 cells/well) were incubated with media, Con
A, or OVA at 37oC, 7% CO2 for 4 days and then pulsed with 1 μCi of 3H-thymidine and
incubated for an additional 24 hr at 37oC, 7% CO2. The cells were harvested and counted
on day 5 to measure T cell proliferation.
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Mouse immunization study with cationic NPs coated with CpG and OVA
Mice (n=4-5/group) were immunized (s.c.) on day 0 and day 14 with either CpGcoated NPs, OVA adjuvanted with CpG, OVA-coated NPs or CpG- and OVA-coated
NPs. CpG was coated on NPs at a 1:10 w/w and the dose of CpG or OVA given to
animals was 10 μg and 5 μg, respectively. As a positive control, mice were immunized
with 50 μg of OVA adjuvanted with CFA on day 0. On day 14, mice were bled via tail
vein prior to boosting and blood was collected into Microtainer tubes (BD) and sera were
separated according to manufacturer’s instructions.

On day 28, mice were bled by

cardiac puncture and sera were separated. All collected sera were stored at -20oC.
Spleens were harvested and used for splenocyte proliferation assay.

Determination of antibody titers
OVA-specific serum IgG, IgG1 and IgG2a antibody titer were determined using
an ELISA. Briefly, 96-well plates (Costar) were coated with 100 μL of OVA (10 μg/mL
in 0.05 M sodium carbonate-bicarbonate buffer, pH 9.6) overnight at 4oC. The plates
were blocked for 1 hr at 37oC with 200 μL of 4% BSA prepared in PBS/Tween 20. The
plates were then incubated with 50 μL per well of mouse serum diluted appropriately in
4% BSA/PBS/Tween 20 for 2 hr at 37oC. The plates were washed with PBS/Tween 20
and incubated with 50 μL/well anti-mouse IgG HRP F(ab’)2 fragment from sheep
(1:3000 in 1% BSA/PBS/Tween 20) for 1 hr at 37oC. For IgG1 and IgG2a determination,
the plates were similarly incubated with goat anti-mouse IgG1-HRP or goat anti-mouse
IgG2a-HRP diluted 1:8000 (1% BSA/PBS/Tween 20). After washing the plates with
PBS/Tween 20, the plates were developed by adding 100 μL of TMB substrate and
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incubating for 30 min at RT. The color development was stopped by the addition of
100 μL of 2 M H2SO4 and the OD at 450 nm was read using a Universal Microplate
Reader (Bio-Tek Instruments, Inc.). The OD at 450 nm versus log serum dilution for
each animal was plotted and fit to a four parameter logistic equation using GraphPad
Prism software. The titer was defined as the anti-sera dilution giving 0.5*ODmax.

Splenocyte proliferation assay
The spleens were crushed in 1X HBSS using a stomacher homogenizer for 60s at
normal speed to obtain single cell suspensions and the suspensions were then transferred
into centrifuge tubes. Red blood cells were lysed adding 1X ACK buffer (156 mM
NH4Cl, 10 mM KHCO3 and 100 μM EDTA) and incubating for 1-2 min at RT.

The

cells were spun down at 1500 rpm, 4oC for 10 min. Supernatants were decanted and the
cells were washed 2 more times with 1X HBSS. The cells were resuspended in RPMI
1640 (supplemented with 10% heat-inactivated fetal calf serum, 1 mM HEPES, 2 μM Lglutamine, 10 U/mL penicillin, 100 U/mL streptomycin, 50 μM 2–mercaptoethanol). For
splenocyte proliferation assay, cells (5x105 cells/well) were added to a 96-well plate and
incubated in triplicate with media, Con A (2 μg/mL), or OVA (50 μg/mL) at 37oC, 7%
CO2 for 4 days. The cells were pulsed with 1 μCi of 3H-thymidine on day 4 and
incubated for an additional 24 hr at 37oC, 7% CO2.
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Statistical analysis
Statistical analysis was performed using one-way analysis of variances (ANOVA)
followed by pair-wise comparisons using Tukey’s multiple comparison test using
GraphPad Prism software.
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5.4

Results and discussion

Preparation and characterization of cationic NPs coated with OVA and TLR
ligands
The preparation of NPs from warm oil-in-water microemulsion precursors has
previously been reported by our laboratory [15,16]. These NPs are approximately 100
nm in size and have the advantage of being prepared in a single step, one vessel process
with relative ease in modifying the physical characteristics of the particles by using
appropriate surfactants. More importantly, the oil phase used for preparation of these
NPs is comprised of cetyl alcohol and polysorbate 60, both which are found in many
pharmaceutical products and are biocompatible [251].
The NPs used in these present studies were stabilized by the inclusion of Brij 78
and made to be positively-charged by the use of the cationic surfactant CTAB. The net
charge of the NPs prior to coating with OVA or TLR ligands was approximately +50 mV
(Figure 5.1). OVA, a negatively charged protein, was expected to be coated on the
surface of the NPs via ionic interactions. As demonstrated in Figure 5.1, there was a net
decrease in the overall charge with increasing concentrations of OVA adsorbed to the
surface of the NPs. At a protein concentration of 50 μg/mL, approximately 95% of OVA
was estimated to be coated on the NPs using SDS-PAGE densitometry (data not shown).
At this concentration of OVA, it was expected that there was an excess of NPs as the net
charge of the OVA-coated NPs was still positive and thus, allowed for the adsorption of
TLR ligands via the negative charges of the molecules. In the present studies, the
adsorption of TLR ligands on NPs led to a further decrease in the charge, resulting in an
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overall negative charge for the particles (Table 5.1).

The coating of CpG did not

significantly affect the nanoparticle particle size; however, the coating with LTA and
Poly I:C resulted in an increase in the mean particle sizes to around 300 and 200 nm,
respectively.

Lymphoproliferative responses to OVA using TLR ligand-coated NPs
Initial in vivo studies were carried out to evaluate the ability of cationic NPs
coated with three different negatively charged TLR ligands in providing more robust
immune responses to OVA compared to NPs alone.

The immune responses were

evaluated on day 8 by measuring T cell proliferation in the draining lymph nodes.
Lymph node cell counts on day 8 demonstrated the highest activity with CpG-coated NPs
(Figure 5.2), suggesting that this TLR ligand had extremely potent immunostimulatory
activity compared to the Poly I:C and LTA.

Interestingly, this response was even

stronger than the positive control CFA. As expected, the OVA-specific proliferative
responses demonstrated the strongest responses with the CFA positive control (Figure
5.3). All NP groups with OVA demonstrated positive OVA-specific responses, with the
OVA-coated NPs showing the strongest response. However, the responses with the NP
groups were modest compared to the CFA. It is possible that day 8 may not be optimal
for evaluating the T cell responses. Nonetheless, these data demonstrate the potential
application of NPs with or without TLR ligands for enhancing immune responses to
OVA. The results suggested that CpG was a potent immunostimulatory adjuvant when
coated on cationic NPs compared to Poly I:C and LTA, and was chosen for further work
with NPs. Moreover, the use of CpG has been of great interest to numerous researchers.
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The potent activity of CpG does pose potential side effects such as enlarged spleen and
lymph nodes, which have been reported in literature to be dose-dependent [108,109].
Thus, the use of cationic NPs coated with CpG may have the advantage in minimizing
these side effects by enhancing the adjuvant activity of CpG and allowing for lower doses
of CpG to be used. In fact, recent reports demonstrated that PLGA nanoparticles were
able to effectively reduce the doses of CpG required for obtaining more robust immune
responses to tetanus toxoid compared to CpG in saline [263].

Immune response to OVA
In vivo studies in BALB/c mice were carried out to investigate the use of cationic
NPs as potential delivery systems to improve the adjuvant effect of CpG and thus, obtain
significant enhancements in the immune responses to OVA. Mice were immunized with
either OVA-coated NPs (NPs+OVA), OVA mixed with CpG (CpG+OVA), or OVA- and
CpG-coated NPs (NPs+CpG+OVA). As a positive control, mice were immunized with
OVA adjuvanted with CFA. Sera collected from mice were analyzed for total OVAspecific IgG at 2 weeks post initial immunization and 2 weeks post second immunization.
As expected, animals immunized with OVA (50 μg) adjuvanted with CFA (a 10-fold
higher dose than all other groups) resulted in the highest total IgG titers at both time
points (Figure 5.4). More importantly, 3-4-fold higher IgG titers were observed at both 2
and 4 weeks using NPs coated with both CpG and OVA compared to CpG with OVA or
NPs coated with OVA alone. There were no significant differences at either time point in
the IgG titers of the CpG with OVA group compared to OVA-coated NP group. Also,
the CpG-coated NP control group did not result in significant OVA-specific IgG
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compared to naïve animals (data not shown). The data suggest that NPs coated with CpG
and OVA can result in robust enhancements in the humoral immune response. These
results are consistent with reports from Singh et al. who demonstrated that the immune
responses to HIV antigens using microparticles coated with CpG are more effective at
enhancing immune responses than either adjuvant alone [398]. Surprisingly, this study
demonstrated greatest OVA-specific proliferative responses with the NP group (Figure
5.5). This is in line with the initial study; however, it is unclear why the positive control
group CFA did not produce a positive response in the assay.
As mentioned earlier, there have been several reports on the use of CpG in
shifting the immune response to antigens from a Th2 to a Th1 type response
[105,107,159]. The presence of Th1/cellular response can be inferred by measuring the
production of different IgG isotypes, as this is directly under the influence of cytokines
secreted by T helper cells. Th1 responses are characterized by production of IFN-γ,
which promotes production of IgG2a isotype, whereas Th2 responses produce IL-4 which
promotes the presence of the IgG1 isotype [423]. Although no significant differences
existed among the groups for the OVA-specific IgG2a titers in this study, there is a shift
in the type of immune response generated using NPs coated with CpG compared to NPs
alone (Figure 5.6). It is likely that the route of immunization and dose of CpG and/or the
antigen may influence these types of responses. Interestingly, Weeratna et al. have
reported that the intramuscular route (i.m.) is superior to the subcutaneous route (s.c.) in
obtaining optimal adjuvant activity with CpG [424]. Nonetheless, Samuel et al. have
reported significant reduction in the CpG dose can be obtained using nanoparticles after
subcutaneous injection [111,263].

However, the CpG was entrapped inside the
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nanoparticles with the antigen, which may allow for slow release of the antigen at the
injection site. Moreover, the antigen in this case is tetanus toxoid and the dose and
effectiveness of adjuvant, i.e. CpG, may be dependent on the antigen. Samuel et al. also
used C57BL/6 mice in their studies, which have been reported to express higher levels of
TLR9 compared to BALB/c mice, hence affecting the IL-12 production and Th1
responses in the two strains of mice in response to CpG adjuvant [425]. In fact, this
difference in the two strains of mice was suggested to be the underlying cause of the
higher susceptibility of BALB/c mice to Listeria monocytogenes infection compared to
C57BL/6 mice [425]. Therefore, the data with the current strategy in this study does
suggest that NPs can be used for enhancing the adjuvant effect with CpG; however,
further studies evaluating the route of immunization, CpG and antigen doses, as well as
different antigens may be necessary to truly reveal the range of enhancements in immune
responses that can be achieved with these NPs.
As the field moves toward an era where well-defined antigenic components are
becoming more attractive candidates for vaccines, there is an urgent need for more
effective and safer adjuvants to aid in generating cellular and humoral immune responses
to these antigens. Toxicity is one of the greatest barriers in the development of new
adjuvants for use in routine human vaccination. These studies highlight the potential of
NPs for enhancing immune responses to protein-based vaccines. In addition, the use of
an optimal murine CpG coated on NPs was shown to generate more robust immune
responses than either adjuvant alone, further illustrating the potential of these NPs as
adjuvants.

Although some concern has been raised that CpG use may generate

autoimmune diseases due to over stimulation of the innate immune system, repeated
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doses administered in vivo in mice and non-human primates to date have shown no
toxicity. More importantly, the use of CpG have been evaluated in hundreds of human
subjects in Phase I clinical trials and no adverse reactions due to CpG have been reported
[110]. In fact, Phase I clinical trials have demonstrated that hepatitis B surface antigen
(HBsAg) adjuvanted with CpG resulted in stronger, more robust immune responses
compared to the HBsAg alone [94,112]. The strength of the immune response generated
by each CpG oligonucleotide can vary and the optimal sequences differ from species to
species. However, optimal CpG oligonucleotides have been identified for a number of
different species including mice, rabbit, sheep, goat, cattle, swine, horse, rhesus monkey,
chimpanzee, and humans [111].
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Table 5.1. Physical properties of cationic NPs coated with TLR ligands and OVA.

Sample
(n=3)

Mean Size
(nm)

Mean
Charge
(mV)

NPs

111.9 ± 5.4

48.1 ± 1.6

NPs + OVA

116.7 ± 5.9

41.8 ± 1.9

NPs + OVA + LTA

299.1 ± 3.4

-35 ± 6

NPs + OVA + Poly I:C

220 ± 1.8

-30 ± 10

NPs + OVA + CpG

107.1 ± 1.1

-26.0 ± 3

All OVA formulations were prepared at a concentration of 50 μg/mL OVA and
1000 μg/mL cationic NPs. All TLR ligands were present at a concentration of
500 μg/mL.
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Figure 5.1.

Physical characterization of cationic NPs coated with increasing

concentrations of OVA. The particle size ( ) and charge (♦) of cationic NPs (Ctrl) and
OVA-coated on cationic NPs are shown. Data reported are the mean ± S.D. (n=3).
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Figure 5.2
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Mean number of cells recovered from the draining lymph nodes.

Brachial, axillary and inguinal lymph nodes were collected from mice 8 days after
immunization with the appropriate formulations. The data represent the mean number of
cells ± S.D. (for n=5/group). *p<0.05 compared to all groups.
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Figure 5.3
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Figure 5.3. T cell proliferation in draining lymph nodes on day 8. Single cell
suspensions of the draining lymph nodes were stimulated for 4 days with Con A (2
μg/mL) or OVA (50 μg/mL). The cells were evaluated for 3H-thymidine incorporation
on day 5. The data represent the mean ± S.D. (for n=5/group). *p<0.05 compared to
naïve group for OVA-stimulated cells; #p<0.05 compared to naïve group for Con A
stimulated group; ap<0.05 for NPs+OVA group compared to NPs+OVA+LTA.
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Figure 5.4
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Figure 5.4. OVA-specific serum IgG titers at 2 weeks and 4 weeks post initial
immunization. Mice were immunized on day 0 and 14 with OVA (5 μg) adjuvanted
with CpG, OVA (5 μg) coated on NPs (100 μg) or OVA (5 μg) and CpG (10 μg) coated
on NPs (100 μg). As a positive control, OVA (50 μg) adjuvanted with CFA was injected
on day 0 only. Titers reported are the mean ± S.D. (n=4-5). * indicates that the titers are
significantly higher compared to CpG group and NPs group.
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Figure 5.5
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Figure 5.5. OVA-specific proliferative responses in spleen on day 5. Spleens were
harvested four weeks post initial immunization and single cell suspensions of the spleen
were stimulated with OVA for 4 days. The incorporation of 3H-thymidine was evaluated
on day 5. The data represent the mean ± S.D. (for n=4-5/group). *p<0.05 compared to
all groups.
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Figure 5.6
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Figure 5.6. OVA-specific serum IgG1 and IgG2a titers. The IgG1 and IgG2a titers in
sera were analyzed at four weeks post initial immunization. The mean IgG2a to IgG1
ratio for each group is indicated on top of the graphed titers. Data for each group
represents the mean ± S.D. (n=4-5).
.
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Chapter 6

Mechanistic investigation of immune response enhancement using nanoparticles

6.1

Summary
Nanoparticles prepared from oil-in-water microemulsion precursors have been

shown to be effective for enhancing immune responses to pDNA and protein-based
vaccines in mice. The in vitro and in vivo studies in this chapter were carried out to
assess the mechanism(s) by which nanoparticles may be enhancing immune responses.
In vitro studies demonstrated that nanoparticles were taken up efficiently by murine
bone-marrow derived dendritic cells (BMDDCs) and the presence of nanoparticles
intracellulary was confirmed by confocal microscopy. Furthermore, the release of proinflammatory cytokines from human dendritic cells and BMDDCs was not observed after
incubation with nanoparticles for 24 hr; however, nanoparticles coated with the
immunostimulatory adjuvant, CpG, resulted in the release of IL-12, which was higher
than the cytokine levels with CpG alone. Adoptive transfer experiments using cells from
OT-1 mice, MHC class I restricted Ovalbumin (OVA) transgenic mouse model,
demonstrated higher proliferation of the OT-1 cells using OVA-coated nanoparticles
compared to OVA, especially at lower doses of OVA. Taken together, these data suggest
that nanoparticles may be enhancing immune responses by promoting uptake of antigen
by antigen presenting cells and by facilitating the delivery of antigen into MHC class I
restricted antigen presentation pathway.
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6.2

Introduction
The need for safer, more effective adjuvants is clearly recognized for

development of vaccines comprised of proteins, peptides and pDNA [4,5,218,426]. One
of the major limitations in development of vaccines is their toxicity or adverse side
effects [134]. Many of the adjuvants evaluated have been empirically chosen for use and
the mechanisms by which these adjuvants enhance immune responses are not fully
understood and continue to be evaluated. For example, although Alum has been used in
routine human vaccination for over 70 years, the exact mechanism of immune response
enhancement has not been fully elucidated [67]. There are several proposed mechanisms
for the immune response enhancement using Alum and it is possible that each
contributes, at least in part, to stimulating stronger immune responses to the antigen in
vivo. The following have been proposed for immune response enhancement with Alum:
enhancement of uptake of associated antigen into antigen presenting cells (APCs),
formation of depot at the site of injection and in macrophages present in muscle, local
inflammatory response due to necrosis at injection site possibly resulting in activation of
APCs and stimulating release of cytokines [66-69].
Studies over the last several years with various adjuvants have allowed for broad
classification of adjuvants depending on their mode of action [1,64]. The first class of
adjuvants, immunostimulatory adjuvants, functions mainly at the cytokine level
enhancing immune responses via activation and up regulation of co-stimulatory
molecules on APCs. Many of the adjuvants belonging to this class are derived from
bacterial components.

On the contrary, the second class of adjuvants is mainly of

synthetic/chemical nature consisting of particulate systems.
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This class includes

particulate delivery systems, such as microparticles, nanoparticles, and liposomes, and
they are thought to exert their activities by acting as delivery vehicles for the antigens and
promoting the uptake of the antigen by: 1) directly enhancing uptake into APC via
passive and active targeting; and/or 2) forming a depot of the antigen at the site of
injection, providing a slow release and uptake by APCs. Studies with many particulate
delivery systems such as nanoparticles and microparticles have demonstrated that they
are taken up by APCs [239-242,427] and these systems are believed to enhance immune
responses in vivo by promoting the uptake of the associated antigen [4,13]. Moreover, in
one study a modest upregulation in co-stimulatory and MHC class II molecules was also
reported [239], suggesting a possible role of these delivery systems in the maturation of
APCs or enhancement in antigen presentation.
To this end, nanoparticles (NPs) prepared from oil-in-water microemulsion
precursors have been reported to enhance immune responses to pDNA [14,15], cationized
β-galactosidase [16], and HIV-1 Tat [253]. In addition, further enhancements in immune
responses with these NPs were observed by incorporating mannan to target mannose
receptors present on macrophages and dendritic cells (DCs) [14,15].

It was also

demonstrated that the uptake of nanoparticles in macrophages could be enhanced with the
mannan ligand [428]. One of the most potent APCs are DCs and the targeting and
presentation of antigens by DCs is of great interest. The present studies were aimed at
further understanding the mechanism(s) by which NPs enhance immune responses. In
vitro studies were carried out to evaluate the uptake and release of various proinflammatory cytokines from DCs. In addition, an in vivo study using a MHC class I-
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restricted OVA transgenic mouse model was carried out to evaluate the utility of these
NPs in enhancing presentation of exogenous protein via this pathway.
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6.3

Materials and methods

Materials
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of
20:1), Alum and sodium dodecyl sulfate (SDS) were from Spectrum (New Brunswick,
NJ). Cetyl trimethyl ammonium bromide (CTAB), PBS/Tween 20 buffer, bovine serum
albumin (BSA), ovalbumin grade VI (OVA) and Sepharose CL4B were purchased from
Sigma Chemical Co. (St. Louis, MO). Brij 78 was purchased from Uniqema (New
Castle, DE).

TNF-α, IL-1β, and IL-12 ELISA kits were purchased from Pierce

(Rockford, IL). Murine CpG oligodeoxynucleotide (ODN 1826) was purchased from
Invivogen (San Diego, CA).

ScintiVerse liquid scintillation cocktail and 2-

mercaptoethanol was purchased from Fisher Scientific (Hampton, NH).

Prolong®

Antifade kit, Carboxy-fluorescein diacetate, succinimidyl ester (CFSE), and 3,3’dioctadecyloxacarbocyanine perchlorate (DiOC18) were purchased from Molecular
Probes (Eugene, OR).

Biotinylated anti-mouse CD11c primary antibody, and the

monoclonal antibodies, anti-Valpha2 and anti-Vbeta5 were purchased from BD
Bioscience (San Jose, CA). RPMI 1640, 10% heat-inactivated fetal calf serum, Hanks
Balanced Salt Solution (HBSS), HEPES, L-glutamine, penicillin, and streptomycin were
from GIBCO (Carlsbad, CA).

3

H-cetyl alcohol was purchased from Moravek

Biochemicals (Brea, CA). Lysis buffer (5X) was purchased from Promega (Madison,
WI). Lipid A from Salmonella Minnesota R595 (Re) was purchased from List Biological
Laboratories (Campbell, CA).

APC-conjugated Streptavidin was purchased from

eBioscience (San Diego, CA). Unless stated otherwise, all water used in experiments
was filtered (0.2 μm) deionized water.
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Preparation of cationic NPs
Nanoparticles from oil-in-water microemulsion precursors were prepared as
described previously with slight modification [14,15]. Briefly, 2 mg of emulsifying wax
and 3.5 mg of Brij 78 was melted and mixed at ~60-65oC. Water (980 μL) was added to
the melted wax and surfactant while stirring to form an opaque emulsion. Finally, 20 μL
of CTAB (50 mM) or SDS (50 mM) was added to form clear microemulsions at 60-65oC.
The microemulsions were cooled to room temperature, while stirring, to obtain solid NPs
(2 mg/mL).

The final concentration of components in the NP suspension was

emulsifying wax (2 mg/mL), Brij 78 (3 mM), and CTAB or SDS (1 mM). To prepare
neutral NPs, the amount of Brij 78 was increased to 4.6 mg or 4 mM final concentration,
with no additional co-surfactants. The NP sizes were measured using a Coulter N4 Plus
Sub-Micron Particle Sizer (Coulter Corporation, Miami, FL) at 90o. The overall charge
of the NPs was measured using Malvern Zeta Sizer 2000 (Malvern Instruments,
Southborough, MA).

Coating of the cationic NPs with OVA and CpG
Varying amounts of OVA were added to NPs (1000 μg/mL) in 5% (v/v) mannitol.
The suspension was vortexed gently and placed on a horizontal shaker at room
temperature for a minimum of 30 min to allow for coating. A similar procedure was
followed to coat CpG on cationic NPs at a 1:3 w/w ratio. The coated NPs were diluted
appropriately in water for measuring the size and charge of the particles.

129

In vitro generation of murine BMDDCs
Bone marrow cells were obtained by flushing the femurs of BALB/c mice with
1X HBSS. Cells were cultured in 100 mm bacteriological petri dishes at 2 x 105cells/mL
in 10 mL of complete RPMI 1640 medium (supplemented with 10% heat-inactivated
fetal calf serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL
streptomycin, 50 μM 2–mercaptoethanol) containing 20-25 ng/mL GM-CSF at 37oC, 7%
CO2. The cells were supplemented with an additional 10 mL of complete RPMI 1640
with 20-25 ng/mL GM-CSF on day 3. On day 6, 10 mL of supernatant was removed
from each plate and spun down. The cells were resuspended in fresh 10 mL of complete
RPMI 1640 with 20-25 ng/mL GM-CSF and added back to the Petri dishes. Nonadherent to lightly adherent cells were harvested on day 7 and used for in vitro studies.

In vitro uptake of NPs using murine BMDDCs
Cationic (CTAB), anionic (SDS), and neutral (Brij 78) NPs radiolabeled with 3Hcetyl alcohol (50 μCi/mL) were prepared for quantitating uptake of NPs by BMDDCs.
The preparation, entrapment and stability of the radiolabeled NPs has been described
previously [429]. Day 7 harvested BMDDCs were plated in 200 μL of complete RPMI
1640 at 2 x 105 cells/well in 48-well tissue culture plates. After incubating the cells
overnight at 37oC, 7% CO2, the wells were washed once with 500 μL of cold 1X HBSS
and 100 μL of complete RPMI 1640 was added to each well. The radiolabeled NPs were
diluted appropriately in complete RPMI 1640 and 100 μL (equivalent of 1 μg of NPs)
was added to each well and plates were incubated at 37oC, 7% CO2 for 1, 2, 4, 6 and 12
hr. As a control, cells were incubated at 4oC for 1, 2 and 4 hr. At each time point, the
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media containing radiolabeled NPs was removed and the cells were washed three times
with 400 μL of 1X cold PBS. The cells were lysed with 100 μL of 1X lysis buffer with
one freeze thaw cycle at -20oC.

The lysed cells were collected and counted in

ScintiVerse liquid scintillation cocktail using a Beckman LS 6500 scintillation counter
(Fullerton, CA).

Confocal microscopy of BMDDCs incubated with fluorescent NPs
Fluorescent NPs were prepared by using 2% w/w DiOC18. Briefly, 40 μl of
DiOC18 (1 mg/ml stock in chloroform) was added to a vial containing 2 mg of
emulsifying wax and 3.5 mg of Brij 78. The vial was mixed at ~60-65oC allowing for all
solvent to be evaporated. After complete evaporation of the solvent, 1 ml of water was
added to the vial at 60-65oC and NPs were formulated as described above. Unentrapped
DiOC18 was separated from the NPs by gel permeation chromatography using a
Sepharose CL4B packed column (15 x 70 mm) with 0.01 M PBS, pH 7.4 as the mobile
phase.

Purified NPs were used further for in vitro studies with BMDDCs.

Immunofluorescence staining was used to visualize the uptake of NPs by DCs.
BMDDCs were seeded into sterile Petri dish at concentrations 4 x 105 cells/mL and
incubated with 2 or 10 μg/mL of fluorescent NPs at 37oC, 7% CO2 in the dark. After
incubating for 24 hr, the cells were washed with 1X PBS to remove excess NPs. DCs
were stained by labeling the cells with biotinylated anti-mouse CD11c primary antibody
followed by labeling with APC-conjugated Streptavidin. Cells were washed with 1X PBS
after staining, fixed on a glass slide using 2% formaldehyde for 15 min at room
temperature in the dark, and mounted using Prolong® Antifade kit. Cells were visualized
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using Leica Laser scanning confocal microscope equipped with Argon laser (488 nm
green), Krypton laser (568 nm red), and HeNe laser (633 far red) using Leica confocal
software.

In vitro stimulation of with monocyte derived dendritic cells (MDDCs) with NPs
Immature human MDDCs (5x105 cells/well) were plated in triplicate in 48-well
plates and incubated for 24 hrs at 37oC, 5% CO2 with media alone (X-Vivo 15
supplemented with 10% FBS, 1% penicillin-streptomycin, 20 ng/mL GM-CSF, and
10 ng/mL IL-4) or in the presence of Alum, anionic NPs, or Lipid A at concentrations of
10, 50, and 100 μg/mL. The supernatants collected at 24 hr and assessed for TNF-α, IL1β, and total IL-12 release by ELISA.

In vitro stimulation of murine BMDDCs
BMDDCs (2x105 cells/well) were plated in triplicate in a 96-well plate and
incubated overnight at 37oC, 5% CO2. The cells were further incubated with varying
concentrations of cationic NPs, Lipid A, CpG, or CpG coated on cationic NPs (1:3 w/w)
for 24 hr and supernatants were collected. The size and charge of CpG-coated NPs was
130 ± 15.2 nm and -32 ± 2.2, mV, respectively.

The total IL-12 release in the

supernatants was quantified using ELISA kits.

Adoptive transfer experiments using OT-1 cells
OT-1 T cell receptor transgenic mice expressing a T cell receptor specific for an
ovalbumin peptide presented by the H-2Kb molecule were used in adoptive transfer
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experiments as previously described [430]. Briefly, spleen and lymph node cells from
OT-1 mice were labeled with CFSE and transferred into C57BL/6 mice (Jackson
Laboratories, Bar Harbor, ME) such that each mouse received 2.5 x 106 OVA-specific T
cells. After 24 hr, mice (n=3/group) were immunized subcutaneously on the back and
flanks with various concentrations of OVA alone or OVA-coated NPs. Three days
following immunization, cells were isolated from draining lymph nodes and stained with
monoclonal antibodies to the transgenic T cell receptor (anti-Valpha 2 and anti-Vbeta 5)
and analyzed by three-color flow cytometry.

133

6.4

Results and discussion

In vitro uptake
Particulate delivery systems are thought to enhance immune responses mainly by
promoting uptake or delivery of the associated antigen into APCs, such as DCs. To this
end, Singh et al. speculated that the enhanced immune responses obtained with the
immunostimulatory adjuvant CpG coated on cationic microparticles may be due to
enhanced delivery and uptake of both coated CpG and antigen into APCs [398]. In vitro
studies with PLGA microparticles [241] and nanoparticles [239,240,431] demonstrated
that the particles are taken up by DCs. Consequently, the uptake also resulted a modest
increase in the expression of MHC class II and co-stimulatory molecules with the
nanoparticles [239]; however, this was not observed with microparticles.

It was

suggested that particle size may have an effect on inducing the expression of these
molecules [239].
In the present studies, the uptake of NPs prepared from microemulsion precursors
were evaluated using BMDDCs. To determine the extent of uptake, radiolabelled NPs
with varying charges were incubated with BMDDCs and the associated radioactivity was
measured over time.

Figure 6.1 demonstrates that significantly more NPs were

associated with BMDDCs at 37oC than at 4oC, suggesting active internalization. There is
some association of the particles to the cells at 4oC probably due to adsorption of the NPs
to the cell surface. In addition, Figure 6.2 confirms that all NPs, regardless of charge,
were taken up by BMDDCs, with approximately 50-70% of the NPs taken up over 12 hr.
The uptake of cationic NPs was found to be significantly higher than anionic and neutral
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NPs between 4 and 12 hr. Interestingly, there was a linear increase in the number of
particles taken up over 6 hr, after which there appeared to be a reduction in the uptake as
indicated by the plateau around the 12 hr time point. This highly efficient uptake of NPs
is clearly evident in Figure 6.3, where BMDDCs incubated with fluorescent labeled NPs
demonstrate that the NPs, indicated by green fluorescence, are taken up and located
intracellulary in DCs, outlined by red fluorescence.

In vitro evaluation of anionic NPs using human MDDCs
In vitro data indicate that the NPs are taken up into DCs. To further evaluate if
NPs are immunostimulatory after taken up by DCs, anionic NPs were incubated with
human DCs for 24 hr and the supernatants were analyzed for three pro-inflammatory
cytokines, IL-12, TNF-α, and IL-1β. Lipid A, an immunostimulatory adjuvant, was used
a positive control in these studies and Alum, which is a humoral immune response
mediator was also included for comparison. As shown in Figure 6.4 at the 10 μg/mL
concentration of adjuvant, the positive control Lipid A, but not Alum or anionic NPs,
caused significant release of IL-12 (a Th1 promoting cytokine), TNF-α and IL-1β from
human DCs.

Furthermore, Lipid A caused a dose-dependent release of the pro-

inflammatory cytokines at the higher concentrations used; however, the anionic NPs and
Alum treated cells did not cause release of pro-inflammatory cytokines at the higher
concentrations (data not shown). These data suggest that NPs are not immunostimulatory
and do not enhance immune responses via the release of pro-inflammatory cytokines.
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In vitro stimulation using murine BMDDCs
CpG has been shown to induce maturation and activation BMDDCs resulting in a
release of several pro-inflammatory cytokines including IL-12 [97]. It has been reported
that CpG treated DCs had an enhanced ability to activate T cells, which was significantly
diminished in DCs derived from IL-12 knockout mice.

This suggested that CpG-

mediated IL-12 release from DCs plays a significant role in enhancement of Th1/cellular
immune responses [432]. Since the receptor for CpG, TLR9, is located intracellularly, it
has to be first taken up into BMDDCs where CpG can then bind to the TLR9 initiating
the signaling cascade to cause IL-12 secretion. Thus, it was expected that there would be
significantly higher IL-12 release by BMDDCs if the uptake of CpG was enhanced using
cationic NPs. As shown in Figure 6.5, cationic NPs did not stimulate significant release
of IL-12 from BMDDCs confirming that NPs by themselves have no significant
immunostimulatory activity. However, cationic NPs coated with CpG resulted in IL-12
in a dose-dependent manner that was similar to Lipid A (positive control). There was a
significant amount of IL-12 release compared to unstimulated cells at a CpG or Lipid A
dose of greater than 50 ng/mL. NPs coated with CpG resulted in higher IL-12 release
compared to CpG alone and this was statistically significant at a dose of 100 ng/mL of
CpG. These data in combination with the uptake data suggest that NPs functioned to
enhance delivery, causing enhanced uptake of CpG by BMDDCs and therefore, allowing
for more of the oligodeoxynucleotide to be available intracellulary to bind to TLR9 and
causing enhanced IL-12 release. Interestingly, Kwon et al. reported over a 10-fold
increase in IL-12 release from BMDDCs after incubating with CpG coated on acid
degradable nanoparticles [431] and in comparison, the enhancements in IL-12 release in
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the present studies were only modest. Several factors may influence these discrepancies.
First, the BMDDCs used by Kwon et al. were derived from C57BL/6 mice and reports
suggest that these mice express TLR9 to a greater extent compared to BALB/c mice
[425]. More importantly, BMDDCs are derived from primary cultures of cells from
femurs of mice and several factors including the age of mice, the method used for
generation of DCs, and the composition of the cultures at time of use may have an effect
on the results. Taken together, these factors may allow for more efficient stimulation of
BMDDCs at lower concentrations of CpG than were obtained with our experiments. An
additional concern during these in vitro experiments is the presence of FBS in the media,
which may disrupt electrostatic interactions between the cationic particle and CpG,
possibly causing at least some of the CpG to dissociate from the NPs.

This would be

less of a concern in the in vivo situation when the formulation is injected into the
subcutaneous space.

Other factors that may also be of critical consideration is in

identifying greater differences in IL-12 release such as the time of incubation/stimulation
and the source of CpG.

OT-1 cell proliferation in adoptive transfer experiments
One of the major goals in vaccine development is to stimulate CD8+ T cell
responses by presentation of antigen on MHC class I molecules. To determine the extent
to which antigens coupled to NPs stimulate CD8+ T cells in vivo, we utilized an adoptive
transfer system with transgenic T cells from the OT-1 mouse, which express a class I
restricted receptor specific for OVA presented by the H-2Kb class I molecule. OT-1 cells
were labeled with CFSE and transferred into normal C57BL/6 mice. After 24 hr, the
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mice were immunized with OVA alone (no adjuvant) or OVA-coated NPs.

Flow

cytometry was performed on day 3 to assess the extent of cell division by measuring
CFSE dye dilution in the draining lymph nodes, which is a direct measure of the degree
of antigen recognition.

All of the OT-1 cells in the control, unimmunized mice,

remained CFSE bright indicating no cell division. In contrast, OT-1 T cells from mice
immunized with OVA alone or OVA-coated NPs showed extensive CFSE dye dilution
indicating strong cell division in the draining lymph nodes. These responses were at a
plateau between 10 and 20 μg of OVA coated on NPs, as there were no significant
differences in the T cell proliferation with a decrease in the antigen dose by one-half.
However at the lowest dose evaluated, mice immunized with OVA-coated NPs showed
significantly more cell division than OVA alone, indicating that OVA coated on NPs is
superior to an equivalent concentration of soluble OVA in terms of stimulation of CD8+
T cells (Figure 6.6 and 6.7). These results demonstrate that NPs can facilitate the entry of
coated proteins into the MHC class I processing pathway resulting in enhanced
presentation to CD8+ T cells in vivo. This enhanced presentation via the MHC class I
pathway is thought to be due to enhanced delivery into DCs, which are able to crosspresent exogenous antigens and are the primary cells involved in stimulation of T cells
[74]. Moreover, these results are in agreement with the in vitro results using CpG coated
NPs demonstrating that NPs were effective at enhancing delivery of the coated molecule.
Studies evaluating CpG-coated NPs, lower doses of OVA with and without NPs, and
time points of immunization in the adoptive transfer experiments will be helpful in
further elucidating mechanism(s) of immune response enhancement.
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Taken together, these studies demonstrate that NPs prepared from oil-in-water
microemulsions are effective systems for enhancing delivery of the associated antigen or
immunostimulatory adjuvant into DCs. It is hypothesized that this enhanced delivery
causes the significant enhancements observed with antigen coated on NPs in vivo.
However, the uptake and fate of NPs in vivo need to be further evaluated to further
characterize their mechanism(s).

In vitro studies suggest that NPs do not enhance

immune responses by release of cytokines; however, in vivo cell death by necrosis or
apoptosis after injection may contribute to the immune response generation and will need
to be further investigated.
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Figure 6.1
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Figure 6.1.

Uptake of 3H-NPs by BMDDCs at 37oC versus 4oC.

BMDDCs

(1x106/mL) were incubated for various times with 1 μg of 3H-NPs prepared using various
surfactants, CTAB, SDS, and Brij 78, to obtain cationic, anionic, and neutral NPs,
respectively. NPs were incubated with BMDDCs at 4oC as a control to distinguish
association with the cells versus uptake at 37oC. *indicates p<0.05 at 37oC compared to
4oC at 1-4 hr by Students t-test.
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Figure 6.2
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Figure 6.2. Uptake of 3H-NPs by BMDDCs at 37oC. BMDDCs (1x106/mL) were
incubated for various times with 1 μg of 3H-NPs prepared using various surfactants,
CTAB, SDS, and Brij 78, to obtain cationic, anionic, and neutral NPs, respectively. Data
reported are the mean ± S.D. (n=3). *p<0.05 for CTAB NPs compared to SDS and Brij
78 NPs.
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Figure 6.3

A

B

A
Optically sectioned

C

D

Figure 6.3. Laser-scanning confocal microscopy images of fluorescent NPs present
intracellularly in DCs. DCs were visualized by staining with biotinylated anti-mouse
CD11c primary antibody and APC-conjugated Streptavidin secondary antibody (red).
NPs were labeled with DiOC18 (green). All images were obtained at 100X magnification.
A) Whole DC confocal image of BMDDCs incubated with 2 μg/ml fluorescent NPs. B)
Optically sectioned DC confocal image of BMDDCs incubated with 2 μg/ml fluorescent
NPs. C) Whole DC confocal image of BMDDCs incubated with 10 μg/ml fluorescent
NPs. D) Optically sectioned DC confocal image of BMDDCs incubated with 10 μg/ml
fluorescent NPs.
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Figure 6.4.
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Pro-inflammatory cytokine release from human MDDCs.

Day 7

MDDCs (1x106/mL) were cultured with media or 10 μg/mL Alum, anionic NPs, or Lipid
A for 24 hr at 37oC, 5% CO2. Pro-inflammatory cytokines were assessed in 24 hr
supernatants by ELISA. TNF-α levels for Lipid A were >1050 pg/mL. Data reported are
the mean ± S.D. (n=3). *p<0.05 compared to all other groups.
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Figure 6.5
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Figure 6.5. IL-12 release from BMDDCs after in vitro stimulation. Day 7 BMDDCs
(1x106/mL) were cultured in complete RPMI 1640 alone (BMDCCs) or with cationic
NPs, CpG, CpG coated on NPs (NPs+CpG) or Lipid A (positive control).

Total IL-12

release from cells was measured in 24 hr supernatants by ELISA. NP concentrations
used were 3.35 times that indicated for CpG or Lipid A. Data represents the mean ± S.D.
(n=3). Experiment was performed in duplicate with similar trends and data shown here is
representative of one experiment. *p<0.05 for CpG-coated NPs compared to CpG alone
by Students t-test.
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Figure 6.6
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Figure 6.6. Flow cytometry histograms comparing OVA-coated NPs to soluble OVA
for stimulating a CD8+ T cell clonal expansion in vivo. The flow cytometry histograms
from a representative mouse of the CFSE fluorescence of cells expressing the Valpha 2,
Vbeta 5 T-cell receptor. The left-most peak represents endogenous Valpha 2, Vbeta 5
positive T-cells in the B6 mice and thus are CFSE negative. The cells in peak M1
represent OT-1 cells that have not divided while cells in peak M2 represent OT-1 cells
that have undergone various numbers of cell divisions.
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Figure 6.7
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Figure 6.7. OVA-coated NPs are superior to soluble OVA at stimulating a CD8+ T
cell clonal expansion in vivo. The percent cell division (mean +/- S.D.) of the OT-1
cells was determined by calculating the number of cells under marker M2 as a percent of
the total cells under marker M1 + M2. *p<0.05 compared to OVA by Student’s t-test.
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Chapter 7
Preparation and characterization of nickel nanoparticles for enhanced immune
responses to his-tag HIV-1 Gag p24

7.1

Summary
Particulate delivery systems have been widely investigated for obtaining

enhanced immune responses to protein-based vaccines.

Previous reports from our

laboratory have demonstrated that anionic or cationic nanoparticles prepared from oil-inwater microemulsion precursors can be used to enhance immune responses to antigens
coated on the surface of the particle by charge interactions. A stronger interaction of the
antigen to the surface of nanoparticles may provide greater association of antigen with
the particles in vivo and prove beneficial in further enhancing the immune responses.
The purpose of these studies was to prepare nanoparticles with a small amount of surfacechelated nickel to enable stronger interactions with histidine-tagged (his-tag) proteins.
The surface-chelated Ni nanoparticles were shown to bind to his-tag green fluorescent
protein and his-tag HIV-1 Gag p24. Furthermore, his-tag Gag p24 bound to the nickel
nanoparticles resulted in significant enhancements in humoral responses, including IgG2a
responses, compared to the protein adjuvanted with Alum or coated on the surface of
negatively charged nanoparticles.
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7.2

Introduction
The need for improved adjuvants for enhancing immune responses to protein-

based vaccines is widely recognized [2,7,59,60,94,433-435]. Presently, Alum continues
to be the only approved adjuvant for routine human vaccination in the U.S [3]. However,
there has been considerable interest in the development of particulate delivery systems
for enhancing immune responses with protein-based vaccines over the past few years
[4,6,8,172,198,263,436]. In fact, both PLGA microparticles and liposomes are currently
under clinical evaluation with potential HIV and hepatitis vaccines, respectively [77,94].
Particulate delivery systems are attractive as they offer numerous advantages such as the
ability to: control the release of the antigen [202,230,232], target the delivery of antigen
to antigen presenting cells (APCs) [169,283,296], and incorporate immunostimulatory
adjuvants for synergistic enhancements in immune responses [79,257,260]. Moreover,
particulate delivery systems are of similar sizes as naturally occurring pathogens and
considered to be rapidly taken up by APCs, leading to increased accumulation of the
associated protein inside the cell [125].
Particulate delivery systems for protein-based vaccine applications have most
often utilized entrapment of the antigen within the particle for obtaining enhanced
immune responses [8,213,214,216,217,437]. Although effective, concerns associated
with this approach include protein instability and entrapment efficiency. For example,
the protein stability is of significant concern with the most often investigated PLGA
microparticles [235]. The protein degradation can occur during the entrapment by
conditions such as the presence of organic solvents, during freeze drying, and also by the
acidic environment created by polymer degradation in vivo [229].
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Moreover, low

entrapment of the protein and instability of the delivery system are challenges faced with
using liposomal systems.

Alternatively, the use of charged particles has been

investigated for coating antigens to the particle surface by ionic interactions and thus,
enhancing immune responses to the coated antigen in vivo [9,235,237,248,398].
Negatively charged PLGA microparticles have been shown to enhance immune responses
to HIV-1 Gag p55 [238]. To this end, reports from our laboratory have demonstrated the
potential of charged nanoparticles (NPs) prepared from oil-in-water microemulsion
precursors for enhancing immune responses with cationic proteins such as βgalactosidase [16] and HIV-1 Tat protein [253,438], and with the anionic model antigen
ovalbumin (OVA) as shown in Chapter 5.
Several studies suggest that the higher uptake of antigens into APCs using
particulate delivery systems may result in enhanced immune response to associated
antigens in vivo [239-242]. Studies in our laboratory suggest that NPs are taken up
effectively in vitro by DCs and that the enhanced delivery of associated antigen or
molecules, at least in part, contributes to the enhanced immune responses observed in
vivo [439]. It is important to note that these are simply antigens coated on charged
particles and some dissociation of the coated protein from the particle may occur in vivo
due to other charged molecules present, resulting in a decreased accumulation in APCs.
It is hypothesized that increasing the affinity of the antigen for the particles could allow
even more of the antigen accumulate in the APCs compared to antigen coated on the
surface of the NPs and thus, enabling greater enhancements in immune responses in vivo.
The attachment of proteins and antibodies to particulate delivery systems has been
investigated extensively by covalent linkages that involve the use of sulfhydryl-, amine-

149

and carboxyl-reactive moieties on the protein or the particle [440-443]. However, these
approaches are often cumbersome and require the use of activating or reducing agents. In
addition, these methods have the potential for causing protein degradation during
attachment, random or multiple point attachment of the protein, and quite often, low
coupling efficiencies are obtained. An alternative approach that takes advantage of
affinity interactions has been extensively used for purification of recombinant proteins
[444-447]. This approach exploits the interaction between chelated divalent metal ions
such as nickel, copper, or cobalt and a short sequence of histidine residues (4 to 10
repeating units) added to the N- or C-terminus of the protein, referred to as histidine-tags
(his-tag). These purification methods generally involve immobilizing the metal ion onto
the column packing material using a chelating agent such as nitrilotriacetic acid (NTA)
[444]. In the case of Cu2+ and Ni2+ which have six coordination sites, NTA forms a
strong complex with four of the metal sites, leaving two additional sites for interaction
with the his-tag present on the protein [445]. Moreover, the interaction of his-tags with
NTA-Ni has been reported to be equivalent or stronger than that of antibody interactions
(10-6 to 10-9), with a dissociation constants (Kd) in the range of 10-6 to 10-13 M at pH 7-8
depending on the protein and location of the his-tag on the protein [448,449]. The
binding is reversible by competing off with excess imidazole (> 100 mM) or by lowering
the pH which results in release of the his-tag protein due to protonation of electron
donating histidine groups (pKa = 6.0).

In addition to its extensive use in protein

purification, the use of NTA-Ni has been also reported for immobilization of his-tag
proteins onto surfaces for structural and functional studies [450] and for studying protein
interactions by flow cytometry [449]. More recently, hydrophobized NTA-Ni ligand
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integrated in the liposomal lipid bilayer was reported for attaching his-tag peptides and
proteins on the surface [451] and for targeting the uptake of entrapped antigen to DCs via
surface immobilization of his-tag antibodies for DC-specific receptors [290].
The interaction of chelated Ni with his-tag proteins for enhancing immune
responses to antigens with particulate delivery systems would be advantageous since it is
simple, applicable to a wide range of proteins, and offers stronger interactions between
the particle and antigen compared to conventional charged particles, consequently
allowing for higher accumulation of the antigen inside the cell.

Once the antigen is

taken up into the cells, it can also be released because the interactions weaken in the
acidic environment of the lysosomes. Therefore, the present studies were aimed at
investigating the preparation of NPs with a small amount of surface-chelated nickel for
binding to his-tag proteins. In addition, the utility of these NPs for enhancing the
immune responses to protein-based vaccines was evaluated in vivo using his-tag HIV-1
Gag p24 protein (his-tag p24).
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7.3

Materials and methods

Materials
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of
20:1) and Alum were purchased from Spectrum (New Brunswick, NJ).

Phosphate

buffered saline, pH 7.4 (PBS), PBS, pH 7.4 with 0.05% Tween 20 (PBS/Tween 20),
bovine serum albumin (BSA), and Sepharose CL4B were from Sigma Chemical Co. (St.
Louis, MO). Brij 78 was purchased from Uniqema (New Castle, DE). Sheep anti-mouse
IgG, peroxidase-linked species specific F(ab’)2 fragment was purchased from Amersham
Pharmacia Biotech (Piscataway, NJ).

IFN-γ ELISA kit, streptavidin-horseradish

peroxidase (Sv-HRP) and biotinylated rat anti-mouse IgG1 and IgG2a monoclonal
antibodies

were

from

BD

Biosciences

Pharmingen

(San

Diego,

CA).

Tetramethylbenzidine (TMB) substrate kit and HisGrab™ nickel-coated plates were
purchased from Pierce (Rockford, IL).

Microcon® YM-100, CentriPlus® YM-100,

certified nickel standard (Claritas® certified reference material), nitric acid (trace metal
grade), and 2-mercaptoethanol were purchased from Fisher Scientific (Hampton, NH).
RPMI 1640, 10% heat-inactivated fetal calf serum, Hanks Balanced Salt Solution
(HBSS), HEPES, L-glutamine, penicillin, and streptomycin were from GIBCO
(Carlsbad, CA). 1,2-dioleoyl-sn-glycero-3-[(N-(5-amino-1-carboxypentyl)iminodiacetic
acid)succinyl] nickel and

ammonium salt,

DOGS-NTA-Ni

and

DOGS-NTA,

respectively, were purchased from Avanti Polar Lipids (Alabastar, AL).

PVDF

membranes, 15% Tris-HCl SDS-PAGE gels, and Immun-star HRP substrate kit were
from Bio-Rad (Hercules, CA). Histidine-tag HIV-1 Gag p24 (his-tag p24) was obtained
through the Centralised Facility for AIDS Reagents supported by EU Programme
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EVA/MRC and the UK Medical Research Council (donated by Dr. I. Jane). For in vivo
studies, female BALB/c mice (6-8 weeks old) were obtained from Harlan SpragueDawley Laboratories (Indianapolis, IN).

Preparation of NPs with surface-chelated Ni
Nanoparticles were prepared from oil-in-water microemulsion precursors using
emulsifying wax as the oil phase and Brij 78 as the surfactant. In a 7 mL glass vial, 2 mg
of emulsifying wax and 3.5 mg (3 mM) of Brij 78 was added. To this vial, 10.6 μL (0.1
mM) of DOGS-NTA-Ni (10 mg/mL stock in chloroform) was added and the chloroform
was evaporated on a hot plate (~60-65oC) while stirring. Water (1000 μL) was added to
the vial at 60-65oC and the contents of the vial were mixed on the hot plate to form clear
microemulsions. NPs were obtained by cooling the vials to room temperature while
stirring. NPs of similar composition but without Ni were prepared in the same manner
using 0.1 mM of DOGS-NTA lipid instead, referred to as NTA-NPs. The NPs were
characterized by measuring their size using a Coulter N4 Plus Sub-Micron particle sizer
(Coulter Corporation, Miami, FL) at 90o and charge, using a Malvern Zeta Sizer 2000
(Malvern Instruments, Southborough, MA).

Binding of his-tag p24 and initial in vivo studies
For the initial studies, his-tag p24 was bound to the surface-chelated Ni
nanoparticles (Ni-NPs) at a 1:10 w/w ratio in PBS, pH 7.4 at 4oC overnight. The
effectiveness of these formulations was evaluated in vivo using BALB/c mice (n=5-6 per
group). The animals were dosed on day 0 and day 14 with his-tag p24 bound to Ni-NPs,
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adjuvanted with Alum, or as a control coated on NTA-NPs. All mice were given 100 μL
s.c. injections on the back containing 2.5 μg of his-tag p24 and 25 μg of the NPs or
Alum. The mice were bled by cardiac puncture on day 28 and the sera were separated
and stored at –20oC for antigen-specific IgG analysis.

Determination of his-tag p24-specifc total IgG levels
His-tag p24-specific serum IgG levels were determined using an ELISA. The
plates (96-well Costar plates) were coated with 50 μL of his-tag p24 (5 μg/mL in PBS,
pH 7.4) overnight at 4oC. The plates were blocked for 1 hr at 37oC with 200 μL of 4%
BSA prepared in PBS/Tween 20. The plates were then incubated with 50 μL per well of
mouse serum diluted at 1:100 and 1:1000 in 4% BSA/PBS/Tween 20 for 2 hr at 37oC.
The plates were washed with PBS/Tween 20 and incubated with 50 μL/well anti-mouse
IgG HRP F(ab’)2 fragment from sheep (1:3000 in 1% BSA/PBS/Tween 20) for 1 hr at
37oC. After washing the plates with PBS/Tween 20, the plates were developed by adding
100 μL of TMB substrate and incubating for 30 min at RT. The color development was
stopped by the addition of 100 μL of 2 M H2SO4 and the OD at 450 nm was read using a
Universal Microplate Reader (Bio-Tek Instruments, Inc., Winooski, VT).

Optimization of Ni-NP formulation for binding to his-tag proteins using his-tag GFP
To further optimize the binding of Ni-NPs to his-tag p24, studies evaluating the
entrapment and binding ratios to a model protein, his-tag green fluorescent protein (GFP)
were carried out. Excess DOGS-NTA-Ni was separated from the Ni-NPs using a gravity
packed Sepharose CL4B gel permeation chromatography (GPC) column (15 x 70 mm).
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Briefly, 200 μL of the Ni-NPs was passed down the GPC column using PBS, pH 7.4 as
the mobile phase. Fractions (1 mL) were collected and the fractions containing the NPs
were used for binding to his-tag GFP. To determine the optimal binding ratios, his-tag
GFP was mixed with the GPC-purified Ni-NPs at a 1:16.9 and 1:33.7 w/w ratios in PBS,
pH 7.4 at 4oC overnight. Free protein was separated from bound protein by passing
through the Sepharose CL4B column using PBS, pH 7.4 as the mobile phase. Fractions
collected (1 mL) were analyzed by fluorescence to determine the percent of his-tag GFP
bound to Ni-NPs. The stability of the binding at 1:33.7 w/w ratio at 37oC in PBS, pH 7.4
was evaluated by removing aliquots at over 4 hr and passing through the GPC column.
The fluorescence associated in fraction 1-12 was measured and particle sizes were
measured using fraction 4. The fluorescence was measured using a Hitachi F-2000
fluorescence spectrophotometer (Fairfield, OH) with the excitation and emission
wavelengths set at 395 nm and 508 nm, respectively.

Optimization of his-tag p24 binding to Ni-NPs
The Ni-NPs were purified by GPC as described and further reacted with the histag p24 at 1:8.85, 1:17.7, 1:35.4, and 1:70.8 w/w ratios to determine the optimal binding
conditions. Unlike his-tag GFP, the binding of his-tag p24 to the Ni-NPs cannot be
assessed directly. Therefore, after GPC purification, fractions 7-13 were evaluated for
the presence of free protein by ELISA. The NP containing fractions, fractions 3 to 5,
were combined, concentrated using Microcon® YM-100 ultracentrifuge devices and
analyzed by western blot.
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ELISA for analysis of free his-tag p24
To detect the free his-tag p24 eluting from GPC column, a qualitative ELISA
method was developed using HisGrab™ nickel-coated plates. Samples (100 μL) were
added to the plate and incubated for 1 hr at room temperature (RT) while shaking. The
wells were washed 3 times with PBS/Tween 20 and blocked with 200 μL of 1% fetal
bovine serum (heat inactivated) in PBS/Tween 20 for 1 hr at RT. The wells were washed
3 times with PBS/Tween 20 and incubated with for 1 hr at RT with 100 μL of His-tag
p24 anti-sera (from initial studies) at 1:1000 in the blocking solution. The wells were
washed again and incubated for 1 hr with 100 μL of anti-mouse IgG HRP F(ab’)2
fragment from sheep diluted at 1:3000 in the blocking solution. After washing the wells
with PBS/Tween 20, they were developed by incubating with 100 μL of TMB substrate
for 30 min at RT and the color development was stopped by the addition of 100 μL of 2
M H2SO4. The OD at 450 nm was measured using a plate reader.

Western blot analysis for his-tag p24 bound to Ni-NPs
The concentrated NP fractions after GPC purification along with various amounts
of his-tag p24 as controls were loaded on 15% Tris-HCl SDS-PAGE gels using Bio-rad
power supply (200 V constant for 45 min). A semi-dry transfer of the proteins from the
SDS-PAGE gel onto a PVDF membrane was performed using Trans-Blot semi dry
transfer cell (Bio-rad) using the Bio-rad power supply (15 V, 120 mA, 400 W for 24
min). The membrane was blocked for 1 hr with 4% BSA prepared in PBS/Tween 20 and
then incubated with a 1:1000 dilution of his-tag p24 anti-sera from the initial experiment
for 2 hr. Finally, the membrane was incubated with a 1:5000 anti-mouse IgG HRP
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F(ab’)2 fragment from sheep for 1 hr.

All antibodies were diluted in 4% BSA in

PBS/Tween 20. All steps were performed with shaking at RT and three to five washings
for 5 min using PBS/Tween 20 were included in between each step. The protein on the
membrane was detected using the Immun-star HRP substrate kit and the membrane was
exposed using a Kodak Image Station 2000 mm (New Haven, CT) and analyzed using
Kodak 1D software.

Atomic emission spectroscopy for quantitating the surface-chelated Ni on NPs
Atomic emission spectroscopy (AES) using inductively coupled plasma as the
excitation source was used to quantify Ni present on the Ni-NPs before and after GPC
purification. The method parameters set on the Varian Vista-PRO CCD simultaneous
ICP-OES instrument (Palo Alto, CA) were as follows: plasma flow at 15.0 L/min;
auxillary flow at 1.50 L/min; nebulizer flow at 0.90 mL/min; sample uptake 30 sec; rinse
time 10 sec; and pump rate 15 rpm. Yttrium was used as an internal standard for
correction as needed. The Ni was detected at 216.55 and 231.604 nm and the final results
were calculated based on an average of both wavelengths. The data was collected and
analyzed by Vista-PRO ICP software v.4.1.0. All samples and standards were prepared
using 5% nitric acid. A standard curve for Ni was prepared from 10 to 200 ppb Ni. For
quality control purposes, independent Ni standards at 20 and 100 ppb were prepared and
analyzed prior to sample analysis.

The acceptance criteria for the quality control

standards were based on greater 90% of theoretical Ni concentration. To determine the
recovery of Ni from the NP matrix, 0.4 and 2.0 mg of NTA-NPs were spiked with 10 and
50 ppb of Ni and analyzed for Ni content. For quantitation of Ni on the Ni-NPs, the NPs
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were purified by GPC to obtain a total of 2.0 mg of purified NPs and fractions 3-6 were
collected.

The combined fractions were further desalted and concentrated using

CentriPlus® YM-100 ultracentrifuge devices to a final volume of 1 mL and diluted in
nitric acid for analysis.

In vivo assessment of optimized his-tag p24 bound to Ni-NPs
BALB/c mice (n = 6-8 per group) were immunized (s.c.) on day 0 and day 14
with 100 μL of his-tag p24 bound to GPC purified Ni-NPs, coated on NTA-NPs, or
adjuvanted with Alum. As an additional control, his-tag p24 bound to unpurified Ni-NPs
were also assessed. The dose of his-tag p24 was 2.5 μg and of the NPs or Alum was 88.5
μg. On day 28, mice were bled by cardiac puncture; the sera were collected and stored at
-20oC for IgG analysis. The spleens for were collected and pooled for each group for
splenocyte proliferation and IFN-γ release assays.

His-tag p24-specific antibody isotype analysis
His-tag p24 specific IgG1 and IgG2a levels were determined using an ELISA
procedure similar to that described for total IgG levels. Briefly, the plates were coated
with 50 μL of his-tag p24 (1 μg/mL in PBS, pH 7.4) overnight at 4oC. The plates were
blocked with 4% BSA in PBS/Tween 20 for 1 hr at 37oC. The sera (50 μL) diluted at
1:1000 in the blocking solution were added to the wells and incubated for 1 hr at RT.
The plates were incubated with 50 μL of IgG1 or IgG2a diluted at 1:5000 in blocking
solution for 1 hr at RT and finally with Sv-HRP diluted at 1:4000 in blocking solution for
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30 min at RT. The plates were washed 3-5 times with PBS/Tween 20 in between each
step. The plates were developed and read as described for the total IgG levels.

Splenocyte proliferation and IFN-γ release assay
The spleens were crushed in 1X Hanks Balanced Salt Solution (HBSS) using a
stomacher homogenizer for 60 s at normal speed to obtain single cell suspensions and the
suspensions were then transferred into centrifuge tubes. Red blood cells were lysed
adding 1X ACK buffer (156 mM NH4Cl, 10 mM KHCO3 and 100 μM EDTA) and
incubating for 1-2 min at RT. The cells were spun down at 1500 rpm, 4oC for 10 min.
Supernatants were decanted and the cells were washed 2 more times with 1X HBSS. The
cells were resuspended in RPMI 1640 (supplemented with 10% heat-inactivated fetal calf
serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL streptomycin,
50 μM 2–mercaptoethanol). For splenocyte proliferation assay, cells (5x105 cells/well)
were added to a 96-well plate and incubated with media, Con A (2 μg/mL), or his-tag p24
(1 μg/mL) at 37oC, 7% CO2 for 4 days. The cells were pulsed with 1 μCi of 3Hthymidine on day 4 and incubated for an additional 24 hr at 37oC, 7% CO2. The cells
were harvested on filters and counted on day 5 to measure T cell proliferation. To
measure IFN-γ release from stimulated splenocytes, parallel 48-well plates were set up
using 1x106 cells/well in 400 μL of media and stimulated as described for the
proliferation assay. The supernatants were collected at 72 hr and stored at -80oC for IFNγ analysis by ELISA.
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Statistical analysis
Statistical analysis was performed using one-way analysis of variances (ANOVA)
followed by pair-wise comparisons using Tukey’s multiple comparison test using
GraphPad Prism software.

160

7.4

Results and discussion

Preparation of Ni-NPs and initial in vivo study with Ni-NPs
NPs prepared from oil-in-water microemulsion precursors have been reported
from our laboratory [15,16,249]. These NPs offer great versatility in entrapment of
ligands and molecules and can be easily engineered to be neutral, anionic, or cationic
based on the appropriate choice of surfactant(s). In these studies, neutral NPs were
prepared using non-ionic emulsifying wax as the oil phase and the neutral surfactant Brij
78. To further incorporate a small amount of surface-chelated nickel, the use of the lipid
DOGS-NTA-Ni (Figure 7.1) was explored. The hydrophobic portion of this molecule is
thought to be entrapped within the oil phase, exposing the NTA-Ni portion on the surface
of the NPs for interaction with the histidine-tag on protein. The Ni-NPs prepared were
approximately 150 nm in size with a slightly negative charge (-30 to -20 mV). Based on
theoretical calculations, these Ni-NPs were initially bound to his-tag p24 at a 1:10 w/w
ratio for initial in vivo evaluation to determine the applicability of this technology for
further development. The binding of his-tag p24 to the Ni-NPs was confirmed by SDSPAGE (data not shown). The use of DOGS-NTA entrapped in NPs was also investigated
to control for non-specific adsorption of the protein on the surface of the NPs. The
carboxylic groups of the NTA are thought to give the NPs a net negative charge and
could allow his-tag p24, a cationic protein, to be coated on the surface of the particles.
As shown in Figure 7.2, the Ni-NPs resulted in a significant enhancement in the antibody
responses compared to both Alum and NTA-NPs. These initial studies were very
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encouraging in that they demonstrated that superior humoral responses could be obtained
with these Ni-NPs compared to the conventional coated NPs and Alum.

Ni-NP formulations optimized and characterized with his-tag GFP
Based on the promising results obtained with the initial in vivo studies, further
work to optimize and characterize the Ni-NPs using his-tag GFP was performed. The use
of this protein offered numerous advantages in optimizing the formulations such as ease
of detection by fluorescence, direct quantitation of the protein bound to the NPs and
released from the NPs. In addition, GFP is similar in molecular weight, 28 kDa for GFP
versus 24 kDa for Gag p24, to the Gag p24 used in the in vivo studies. Separation of histag GFP bound to Ni-NPs from unbound his-tag GFP was achieved using a gravity
column packed with Sepharose CL4B resins. The eluent from the GPC purification can
be fractionated (1 mL) and based on the particle size intensity and fluorescence intensity
measurements, NPs and protein associated with NPs were found to elute in fractions 3 to
6, where as free protein eluted in later fractions, 8 to 12 (Figure 7.3). Moreover, during
these binding studies, it was discovered that the Ni-NP formulation contained some
unentrapped DOGS-NTA-Ni, which could also be separated from the NPs by GPC since
it elutes mostly in Fractions 7-9 (Figure 7.4). Thus, GPC purification with a Sepharose
CL4B column allowed efficient separation of the unentrapped lipid from Ni-NPs and for
separating unbound his-tag protein from the Ni-NP bound protein. As shown in Figure
7.4, the GPC purification of excess lipid from Ni-NPs resulted in a higher amount of histag protein being bound to the surface of the NPs and subsequently, GPC purification of
NPs was performed prior to reacting with his-tag proteins.
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The binding of his-tag GFP with Ni-NPs was evaluated at two ratios and it was
found that at a 1:33.7 w/w ratio of his-tag GFP to Ni-NPs, greater than 80% of the protein
was bound to the surface of the NPs (Figure 7.5).

Furthermore, to determine the

specificity of the binding, GPC purified NTA-NPs were mixed with his-tag GFP at a
1:33.7 w/w ratio and the binding was evaluated. As shown in Figure 7.6, only 7% of the
protein was associated with the NTA-NPs and the majority of the protein eluted in later
fractions, where free protein is expected to elute, suggesting that the binding to the NiNPs was stronger and more specific than simple adsorption on the surface of the
particles. The binding of his-tag GFP to Ni-NPs was found to be stable as determined by
particle size and binding efficiency over 4 hr in PBS, pH 7.4 (Figure 7.7). Furthermore,
his-tag GFP bound to Ni-NPs at 1:33.7 w/w ratio was stable at 4oC, with comparable
binding efficiency on day 7 as the initial day of preparation (data not shown).

Entrapment efficiency of DOGS-NTA-Ni in NPs based on Ni
The amount of DOGS-NTA-Ni entrapped in NPs was calculated indirectly by
quantitating the amount of Ni associated with the NPs before and after GPC purification
using AES. The molar ratio of Ni chelated with DOGS-NTA is 1:1, therefore the
entrapment efficiency of the lipid can be calculated based on the Ni. As controls, the
amount of Ni present in NTA-NPs was evaluated and the recovery of Ni from this matrix
was also determined using NTA-NPs. As expected, no Ni was detected in the control
NTA-NP preparations. In addition, the spike-recovery studies suggested that the Ni
could be recovered from the NP matrix, with greater than 80% recovery at the highest
amount of NPs evaluated (Table 7.1). Based on the amount of Ni associated with NPs
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before and after GPC purification in four independent Ni-NP preparations, it was
calculated that approximately 5% of the lipid initially used in the formulation was
entrapped within the NPs (Table 7.2). Furthermore, using these results, it was calculated
that there was about a 3-fold excess of Ni present on the NPs at the 1:33.7 w/w ratio of
his-tag GFP to NPs. Interestingly, increasing the protein to NP ratio from 1:16.9 to
1:33.7 w/w only resulted in a slight increase in binding efficiency (Figure 7.5) from about
70% to 80%. This combined with the fact that there is still a 3-fold excess of Ni on the
NPs at the higher binding ratio suggests that there may have been some steric hindrance
preventing accessibility to at least some of the Ni present on NPs for binding to the
protein.

Optimized Ni-NP formulations with his-tag p24
Based on the binding studies for his-tag GFP with Ni-NPs, the optimal binding
ratios of his-tag p24 to Ni-NPs was evaluated for further use in in vivo studies.
Evaluating the binding of his-tag p24 was more challenging because, unlike GFP, it could
not be assessed directly on Ni-NPs. To determine the optimal binding ratios, the relative
amounts of unbound his-tag p24 were detected using ELISA (Figure 7.8) and the
fractions containing Ni-NPs were analyzed for presence of bound his-tag p24 by western
blot (Figure 7.9). The western blot was further analyzed by densitometry and the results
suggested that approximately 80% of the protein was associated with the Ni-NPs at ratios
greater that 1:35.4 w/w. Thus, for further in vivo evaluation the 1:35.4 w/w ratio was
used to prepare the formulation with Ni-NPs and with control NTA-NPs.
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In vivo results using optimized Ni-NP formulations with his-tag p24
Initial in vivo studies demonstrated the potential of Ni-NPs for enhancing humoral
immune responses to his-tag p24. However, these formulations were not optimized and
some of the protein could have been associated with excess, unentrapped lipid instead of
NPs, leading to suboptimal in vivo responses. The goal of this follow up in vivo study
was to confirm that humoral immune responses could be obtained with the optimized
formulations of Ni-NPs and to further evaluate the cellular immune responses. Mice
were immunized with his-tag p24 bound to Ni-NPs, coated on NTA-NPs or adjuvanted
with Alum. In addition, the use of unpurified Ni-NPs was also investigated to control for
the immune responses that may have been enhanced by unentrapped lipid reacted with
his-tag p24. At the 1:1000 serum dilution, significantly higher his-tag p24- specific IgG
levels were detected using the Ni-NPs compared to all groups (Figure 7.10). Moreover,
NTA-NPs, Alum, and unpurified Ni-NP groups were statistically insignificant compared
to the naïve group.

Interestingly, the unpurified Ni-NPs demonstrated similar potency

in generating antibodies as the NTA-NPs and Alum, but significantly less compared to
the purified Ni-NPs. It is hypothesized that his-tag p24 would interact with unentrapped
lipid, which exists freely in solution, in micelles, or loosely adsorbed on the NP surface,
to a greater extent because the Ni would be more accessible for interactions compared to
the Ni-chelated to lipid which is entrapped in the NPs. Thus, while there may be some
enhancement in antigen uptake and subsequently antibody production with the unpurified
Ni-NP formulation, the results demonstrate that they are less effective compared to the
responses that can be generated with the antigen being bound to the Ni on the NPs.
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Moreover, these data support that protein bound to Ni-NPs was superior to Alum and
NTA-NPs in enhancing humoral immune responses to his-tag p24.
The cellular immune responses in these studies were evaluated by splenocyte
proliferation and IFN-γ release assays. Splenocytes from immunized mice that were
stimulated in vitro with his-tag p24 demonstrated significantly higher proliferation with
all groups compared to naïve group, with the exception of the unpurified Ni-NPs group
(Figure 7.11). In addition, the IFN-γ released from the stimulated splenocytes showed a
similar trend in that all groups, except the unpurified Ni-NPs, produced significantly
higher IFN-γ compared to the naïve group (Figure 7.12).

However, the IFN-γ release

was only modest with both the Ni-NP and Alum groups (cytokine levels in the picogram
per mL range). It is interesting to note that although weak antibody responses could be
generated with the unpurified Ni-NPs, this group did not induce strong cellular responses
as demonstrated by both the splenocyte proliferation and IFN-γ release assays. This
could be due to very little antigen actually being bound to the Ni on the NPs because of
binding with the more accessible unentrapped lipid, as discussed above. Alternatively,
the dose of DOGS-NTA-Ni given with these NPs is higher than that of the purified NiNPs and could have an affect on the immune responses. Therefore, further assessment
various doses of Ni-NPs would be beneficial in elucidating the effect of Ni on the
immune responses and the optimal doses for enhancing both cellular and humoral
immune responses. It is important to note that based on the AES characterization of NiNPs, the dose of Ni administered to mice in each 100 μL injection in the purified Ni-NPs
was 20 ng. This amount of Ni is significantly lower than the levels of Ni that have shown
adverse effects in mice [452-455]. To provide additional perspective, the average human
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diet is estimated to contain 0.15 mg Ni per day and drinking water alone contains 0.001
to 0.01 mg Ni per Liter [456]. Thus, the dose of Ni used in these studies was considered
to be within the tolerable range.
An additional indicator of the type of immune response generated (i.e. Th1 or
Th2) are the serum isotype levels, IgG1 versus IgG2a. During an immune response, the
release of Th1 or Th2 cytokines will affect the production of these antibodies. BALB/c
mice normally produce antibodies of IgG1 isotype; however, in the presence of Th1 type
immune responses, the cells produce IFN-γ which causes a switch in the isotype
produced to IgG2a. The isotype analysis in these studies revealed that the Ni-NPs
resulted in the highest levels of IgG2a compared to all groups, while the IgG1 levels were
comparable to the other three immunized groups (Figure 7.13).
In conclusion, the preparation of novel NPs containing a small amount of surfacechelated nickel was shown to be effective for enhancing the interaction with his-tag
proteins compared to simple charged particles. This interaction of the antigen to the NiNPs resulted in superior humoral immune responses in vivo compared to protein
adjuvanted with Alum or coated on charged NPs.

Moreover, the Ni-NPs are also

promising for generating Th1 type immune responses. It is hypothesized that the Ni-NPs
enhance immune responses by increasing the interaction of the antigen with the NPs and
allowing for greater amount of the antigen to be taken up into APCs. Although further
studies are necessary to elucidate the exact mechanism(s) of immune response
enhancement, preliminary in vitro data suggests that Ni-NPs do not enhance immune
responses by causing the release of IL-12, a Th1 driving cytokine, from DCs (data not
shown). Taken together, these data demonstrate the potential applications of Ni-NP for

167

vaccine delivery and warrant further investigation of these systems for enhancing cellular
and humoral immune responses to protein-based vaccines.
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Table 7.1. Ni spike and recovery from NTA-NPs. Spike and recovery studies with Ni
were performed at 10 and 50 ppb using 0.4 and 2.0 mg of NTA-NPs. Results shown are
average of n=3.

NTA-NPs

Ni spike

Average
Ni
Recovery
(%)

0.4 mg

10 ppb

102.1

19.0

0.4 mg

50 ppb

104.8

1.8

2.0 mg

10 ppb

87.8

9.6

2.0 mg

50 ppb

89.6

5.1
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Standard
Deviation

Table 7.2. Quantitation of Ni on NP surface before and after GPC purification by
AES. *Values reflect amount of Ni per 2 mg of NPs.
Ni-NP
Preparation

μg
Ni before
GPC*

μg Ni
after
GPC*

1

8.19

0.53

2

7.87

0.38

3

7.82

0.27

4

7.85

0.49

Molecules
Ni per
particle

3557

170

Molecules of Molar ratio
GFP per
of GFP to
particle
Ni

1039

1 to 3

Figure 7.1

Figure 7.1. Structure of DOGS-NTA-Ni. NTA occupies four of the Ni coordination
sites, leaving two unoccupied sites (shown coordinating with water in figure) for
interaction with the histidine residues. (Structure was taken from Avanti Polar Lipids
website: http://www.avantilipids.com/SyntheticNickel-ChelatingLipids.asp).
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Figure 7.2
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Figure 7.2.
immunization.

Gag p24-specific IgG levels in serum at 4 weeks post initial
Mice were immunized with 2.5 μg of his-tag p24 bound to Ni-NPs (25

μg), coated on NTA-NPs (25 μg), or adjuvanted with Alum (25 μg) on day 0 and day 14.
Data for each group represents the mean ± S.D. (n=5-6). *p<0.01 compared to all
groups.
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Figure 7.3. Elution profile of Ni-NPs, his-tag GFP bound to Ni-NPs, and unbound
his-tag GFP on Sepharose CL4B GPC column. Ni-NPs eluted in fraction 3-6 as
determined by particles size intensity. The extent of his-tag GFP bound to Ni-NPs was
determined by separating protein bound to Ni-NPs from free protein, which elutes in
faction 8-12 as determined by fluorescence intensity measurements. Fluorescence of the
protein when bound to Ni-NPs overlaps with correlating particle size intensities in
fraction 3-6.
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Figure 7.4
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Figure 7.4. Separation profiles for his-tag GFP bound to GPC purified Ni-NPs and
unpurified Ni-NPs. Free protein elutes in fraction 8-12, whereas the peak for the protein
bound to unentrapped lipid in unpurified Ni-NPs was shifted to the left to fractions 7-12.
The binding efficiency of his-tag GFP to Ni-NPs was increased by first separating the
unentrapped lipid from the NPs by GPC.
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Figure 7.5
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Figure 7.5. GPC purification profiles for his-tag GFP bound to Ni-NPs at 1:16.9
and 1:33.7 w/w ratios of protein to Ni-NPs. The binding of his-tag GFP to Ni-NPs was
evaluated at the ratios indicated by separating free protein from protein bound to Ni-NPs
using GPC. At the 1:33.7 w/w ratio, greater than 80% of the protein was associated with
the Ni-NPs.
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Figure 7.6
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Figure 7.6. GPC profile for his-tag GFP mixed with NTA-NPs. His-tag GFP was
incubated with NTA-NPs at 1:33.7 w/w ratio overnight at 4oC in PBS, pH 7.4. The
interaction of the protein with the NPs was evaluated to determine specificity of the
binding with NTA-NPs compared to Ni-NPs. Only 7% of the protein was associated
with the NTA-NPs, based on fluorescence intensity measurements associated with
fractions 3-6. The majority of the protein was detected in later fractions, 8-12, where free
his-tag GFP was expected to elute.
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Figure 7.7. Stability of his-tag GFP bound to Ni-NPs at 37oC in PBS, pH 7.4. Histag GFP was bound to Ni-NPs (1:33.7 w/w) by overnight incubation at 4oC in PBS, pH
7.4. The formulation was then incubated at 37oC to evaluate stability of the interaction
with the Ni-NPs. Aliquots of the formulation were taken at various time points and
passed through a Sepharose CL4B GPC column to evaluate the percent of his-tag GFP
remaining associated with the Ni-NPs. The particle sizes were measured using fraction 4
from the GPC purification.
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Figure 7.8
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Figure 7.8. Free his-tag p24 eluting from GPC column. His-tag p24 was bound to NiNPs at various ratios and the relative amounts of free protein eluting from the Sepharose
CL4B GPC column were traced in the fractions were free protein was expected to elute
using ELISA. Ni-NPs with no protein were run as control with the ELISA to account for
any interference.
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Figure 7.9
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Figure 7.9. Western blot of his-tag p24 bound to Ni-NPs. His-tag p24 was incubated
to Ni-NPs at various ratios and the protein bound to Ni-NPs was separated from free
protein by passing through a Sepharose CL4B GPC column. Fractions 3-5 from the GPC
purification were collected, combined, and analyzed by western blot to determine the
relative amounts of his-tag p24 bound to the Ni-NPs. The lanes correspond to the
following samples: 1) 1:70.8 w/w; 2) 1:35.4 w/w; 3) 1:17.7 w/w; 4) 1:8.85 w/w; 5) NiNPs as control; and lanes 6-9 are 50, 100, 200, and 250 ng of his-tag p24 standards
loaded as controls, respectively. Greater than 80% of the his-tag p24 was bound to the
Ni-NPs at ratios greater than 1:35.4 w/w.
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Figure 7.10
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Figure 7.10. Total serum IgG levels for his-tag p24 immunization with optimized
formulations. Mice were immunized with 2.5 μg of his-tag p24 bound to Ni-NPs (88.5
μg), coated on NTA-NPs (88.5 μg), adjuvanted with Alum (88.5 μg) or mixed with
unpurified Ni-NPs (88.5 μg) on day 0 and day 14. Serum IgG levels were measured on
day 28. Data for each group represents the mean ± S.D. (n=6-8). ap<0.01 compared to
Ni-NP group; bp< 0.001 compared to all groups; cp>0.05 compared to naïve group.
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Figure 7.11
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Figure 7.11. Splenocyte proliferative responses to his-tag p24 on day 5. Mice were
immunized with 2.5 μg of his-tag p24 on day 0 and day 14. Spleens were harvested and
pooled for each group on day 28. Cells (5x105/well) were stimulated with 1 μg/mL histag p24 and the incorporation of 3H-thymidine in cells was evaluated on day 5. The data
represents the mean ± S.D. (n=3). *p<0.05 compared to unstimulated cells.
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Figure 7.12
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Figure 7.12. 72 hr IFN-γ release from stimulated splenocytes. Mice were immunized
with 2.5 μg of his-tag p24 on day 0 and day 14. The spleens were harvested and pooled
for each group on day 28. Cells (1x106) were stimulated with 1 μg/mL his-tag p24 and
the supernatants were evaluated for IFN-γ release at 72 hr by ELISA. The data represents
the mean ± S.D. (n=3). *p<0.05 compared to unstimulated cells.
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Figure 7.13
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Figure 7.13. His-tag p24-specific serum IgG1 and IgG2a levels. Serum IgG isotype
levels were measured on day 28 by ELISA using a 1:1000 serum dilution. Data for each
group represents the mean ± S.D. (n=6-8).
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p<0.001 compared to all groups; bp>0.05

Chapter 8

In vivo immune responses to Tat coated on different anionic nanoparticle
formulations

8.1

Summary
Anionic nanoparticles can be prepared from oil-in-water microemulsion

precursors using emulsifying wax as the oil phase and sodium dodecyl sulfate (SDS) as
the surfactant. The stability of these anionic nanoparticles in buffered solutions was
improved by the inclusion of the co-surfactant Brij 78. The studies in this chapter were
carried out to evaluate the immune responses to nanoparticles prepared using different
surfactant compositions.

Three anionic NP formulations were prepared using the

following composition of surfactants: 15 mM SDS, 15 mM SDS/1 mM Brij 78 and 1 mM
SDS/3 mM Brij 78. These nanoparticle formulations were coated with the cationic HIV1 Tat protein and evaluated in vivo. No significant differences in the humoral immune
responses were generated among all the Tat-coated nanoparticle formulations evaluated.
Moreover, an improved LTR-transactivation assay demonstrated that significant Tatneutralizing antibodies were generated with all formulations evaluated. For the cellular
responses, some differences were observed in an initial study using a 1 μg Tat dose;
however, no significant differences among the groups were detected in a follow up study
using a 5 μg Tat dose. Taken together, these data suggest that the composition of
surfactants used to prepare the anionic nanoparticles do not have a significant influence
on the immune responses generated to HIV-1 Tat protein.
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8.2

Introduction
Nanoparticles prepared from oil-in-water microemulsions precursors have been

reported to enhance cellular and humoral immune responses to pDNA- and protein-based
vaccines [14-16,46,253]. These nanoparticles (NPs) are prepared using emulsifying wax
as the oil phase and appropriate surfactants to obtain particles with the desired surface
properties. For example, cationic surfactants such as cetyl trimethyl ammonium bromide
(CTAB) can be used to obtain net positively charged particles and surfactants with a
negative charge such as sodium dodecyl sulfate (SDS) can be used to obtain anionic
particles. These particles with different surface properties can be further used to coat
anionic or cationic molecules and/or proteins on the NP surface for enhanced immune
responses compared to the protein alone or adjuvanted with Alum.
Previous studies in our laboratory have shown that anionic NPs prepared using 15
mM SDS as the surfactant generate superior cellular and humoral immune responses to
β-galactosidase [16] and HIV-1 Tat protein [253]. However, these NPs were also shown
to contain an excess amount of the SDS surfactant, which could be removed by
purification using gel permeation chromatography (GPC) [16]. In a more recent study,
the use of sterically stabilized NPs prepared using 1 mM SDS/3 mM B78 was
investigated with Tat as it allowed for preparation of net negatively charged NPs with a
minimal amount of excess SDS present [438]. In our studies, this is advantageous
because it avoids the need for GPC purification and estimating the dose of NPs used for
in vivo studies. Moreover, these NPs coated with Tat demonstrated superior humoral
immune responses compared to Alum.
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To evaluate if anionic NPs prepared from different surfactant compositions could
influence the type of immune responses generated to the coated antigen in vivo, anionic
NPs having different surfactant compositions were investigated. Anionic NPs were
prepared using emulsifying wax as the oil phase and the following surfactant
combinations: 1) 15 mM SDS/1 mM Brij 78; 2) 1 mM SDS/3 mM Brij 78; and 3) 15
mM SDS. All anionic NP formulations were coated with HIV-1 Tat protein and the Tatspecific cellular and humoral immune responses were evaluated to identify differences in
the NP formulations.
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8.3

Materials and methods

Materials
Emulsifying wax, comprised of cetyl alcohol and polysorbate 60 (molar ratio of
20:1) and sodium dodecyl sulfate (SDS), were purchased from Spectrum (New
Brunswick, NJ). PBS/Tween 20 buffer, bovine serum albumin (BSA), Sephadex G75
and mannitol were purchased from Sigma Chemical Co. (St. Louis, MO). Brij 78 was
purchased from Uniqema (New Castle, DE). Sheep anti-mouse IgG, peroxidase-linked
species specific F(ab’)2 fragment was purchased from Amersham Pharmacia Biotech
(Piscataway, NJ).

Goat anti-mouse IgG2a and IgG1 horseradish peroxidase (HRP)

conjugates were purchased from Southern Biotechnology Associates, Inc. (Birmingham,
AL). IFN-γ ELISA kit was from BD Biosciences Pharmingen (San Diego, CA).
Tetramethylbenzidine (TMB) substrate kit was purchased from Pierce (Rockford, IL).
Centricon® YM-50 ultracentrifuge devices were from Fisher Scientific (Hampton, NH).
HIV-1 Clade B consensus Tat peptides (15 aa) were obtained through the AIDS Research
and Reference Reagent Program (Division of AIDS, NIAID, NIH, Bethesda, MA).
Recombinant HIV-1 Tat (1-72 aa) was prepared as previously described [362].

Preparation of anionic NPs
NPs from oil-in-water microemulsion precursors were prepared as previously
described with slight modification [16,253]. The composition of the various formulations
is described in Table 8.1.

For formulations incorporating Brij 78 (B78), 4 mg of

emulsifying wax and appropriate amount of Brij 78 was melted and mixed at ~60-65oC.
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Deionized and filtered (0.2 μm) water was added to the melted wax and surfactant while
stirring to form an opaque suspension. Finally, an appropriate volume of sodium dodecyl
sulfate (50 mM) was added to form clear microemulsions at 60-65oC.

The

microemulsions were cooled to room temperature while stirring to obtain NPs (2
mg/mL). The NP sizes were measured using a Coulter N4 Plus Sub-Micron Particle
Sizer (Coulter Corporation, Miami, FL) at 90o. The overall charge of the NPs was
measured using Malvern Zeta Sizer 2000 (Malvern Instruments, Southborough, IL).

GPC to remove excess surfactant in anionic NP formulations
Previously, it was demonstrated that there was an excess of surfactant present
when formulating NPs with 15 mM SDS [16]. This excess surfactant was shown to be
separated from the NPs by passing through a GPC column packed with Sephadex G75
(15 x 75 mm). Therefore, to remove excess surfactant from the NPs prepared in this
study, 300 μL of the NP formulation was passed through a Sephadex G75 column and the
fractions containing the NPs (fraction 3-5) were collected for further use in coating with
Tat. The GPC purification was also performed on the 1 mM SDS/3 mM B78 NPs to
serve as an additional control in the in vivo experiments.

All purifications were

performed three times to obtain a total of 1.8 mg of purified NPs and the fractions
collected from the GPC purifications were further concentrated using Centricon® YM-50
ultracentrifuge devices to obtain NPs at a final concentration of 2 mg/mL.
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Coating of the anionic NPs with Tat
To prepare formulations for in vivo analysis, Tat, at a final concentration of 10 or
50 μg/mL, was added to the appropriate NP formulations (1000 μg/mL) in 5% (v/v)
mannitol. The suspensions were vortexed gently and placed on a horizontal shaker at
room temperature for a minimum of 30 min to allow for coating. The coated NPs were
diluted appropriately in de-ionized water for measuring the size and charge of the
particles.

Mouse immunization study
Two animal studies were carried out to determine the immune response to Tat
coated on various anionic NP formulations. A summary of the experimental design is
presented in Table 8.2. For both studies, female BALB/c mice (8-10 weeks old) obtained
from Harlan Sprague-Dawley Laboratories (Indianapolis, Indiana) were immunized
subcutaneously with 100 μL of the formulations. In the first study (study 1), mice were
dosed three times at 2 week intervals with 1 μg of Tat coated on anionic NPs that had
been purified by GPC or with 1 μg Tat coated on unpurified NPs (100 μg) prepared using
1 mM SDS/3 mM B78. The dose of anionic NPs for the GPC purified formulations was
also estimated to be about 100 μg. The IgG responses were monitored by collecting sera
via tail-vein bleed prior to boosting with Tat-coated NPs. On day 42, mice were bled by
cardiac puncture and sera were separated. All sera collected were stored at -20oC. In
addition, spleens were harvested from all mice and pooled for each group for splenocyte
proliferation and IFN-γ release assays. In the second study (study 2), a similar protocol
was followed except a 5 μg dose of Tat was evaluated with the anionic NP formulations
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and the spleens in the study 2 were collected on day 42 and prepared individually for
splenocyte proliferation and IFN-γ release assays.

Determination of antibody titers
Tat-specific serum IgG, IgG1 and IgG2a antibody titers were determined using an
ELISA. This procedure is described in detail in Chapter 4 of the dissertation.

Tat anti-sera recognition of N-terminal and basic regions of Tat protein
Tat anti-sera in the first study were tested by ELISA to determine reactivity to the
N-terminal and basic regions of Tat. The ELISA procedure is described in detail in
Chapter 4.

LTR-transactivation assay
The LTR-transactivation assay was performed essentially as described in Chapter
4 with the following modifications. First, HeLa cell lines transfected with pHIV-CAT
were used for the assay. Secondly, supernatant containing Tat released from HeLa cell
lines (transfected with a Tat plasmid) was used as the source for extracellular Tat. The
Tat-contatining supernatants were diluted at 1:40 and incubated with the sera for the
assay. Sera were diluted at 1:10, 1:50, 1:250, and 1:1250 to evaluate for Tat-neutralizing
antibodies.
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Splenocyte proliferation and IFN-γ release assays
The spleens were crushed in 1X Hanks Balanced Salt Solution (HBSS) using a
stomacher homogenizer for 60 s at normal speed to obtain single cell suspensions and the
suspensions were then transferred into centrifuge tubes. Red blood cells were lysed
adding 1X ACK buffer (156 mM NH4Cl, 10 mM KHCO3 and 100 μM EDTA) and
incubating for 1-2 min at RT. The cells were spun down at 1500 rpm, 4oC for 10 min.
Supernatants were decanted and the cells were washed 2 more times with 1X HBSS. The
cells were resuspended in RPMI 1640 (supplemented with 10% heat-inactivated fetal calf
serum, 1 mM HEPES, 2 μM L-glutamine, 10 U/mL penicillin, 100 U/mL streptomycin,
50 μM 2–mercaptoethanol). In Study 1, for the splenocyte proliferation assay, cells
(5x105 cells/well) were added to a 96-well plate and incubated with media, Con A (2
μg/mL), Tat (0.1 and 1 μg/mL) or pooled 15-mer Tat peptides (10 μg/mL each peptide)
at 37oC, 7% CO2 for 4 days. The cells were pulsed with 1 μCi of 3H-thymidine on day 4
and incubated for an additional 24 hr at 37oC, 7% CO2. The 15-mer Tat peptides were
pooled as follows: Set 1 = aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa 17-31, 21-35, 25-39: Set
3 = 29-43, 33-47, 37-51; Set 4 = aa 41-55, 45-59, 49-63, 53-67; Set 5 = 57-71, 61-75, 6579, 69-83.

To measure IFN-γ release from stimulated splenocytes, parallel 48-well

plates were set up using 1x106 cells/well in 400 μL of media and stimulated as described
for the proliferation assay. The supernatants were collected at 72 hr and stored at -80oC
for IFN-γ analysis by ELISA.
For study 2, the splenocyte proliferation and IFN-γ release assays were carried out
as described as above. The IFN-γ assay was set up in parallel to splenocyte proliferation
assay using 96-well plates using 5 x 105 cells/well.
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Statistical analysis
Statistical analysis was performed using one-way analysis of variances (ANOVA)
followed by pairwise comparisons with Tukey’s multiple comparison test, when
appropriate, using GraphPad Prism software.
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8.4

Results and discussion

Preparation and characterization of Tat coated anionic NPs
Previously our laboratory reported on the preparation of anionic NPs from
microemulsions precursors using 15 mM SDS as the anionic surfactant. These NPs were
demonstrated to effective enhance immune responses to a model protein, β-galactosidase
[16], and HIV-1 Tat [253]. Further work with this system revealed that upon removal of
excess surfactant from this formulation, the NPs were unstable in buffered solutions. To
further stabilize these systems, the used of B78 as a co-surfactant was investigated and it
was found that at least 1 mM of B78 was required to provide stable NPs in buffered
solutions (data presented in Appendix B). In addition, it was found that NPs prepared
using various compositions of surfactant (Table 8.1) resulted in sizes of around 100-150
nm with a net charge of approximately -60 mV (Table 8.3). Upon GPC purification to
remove excess surfactant all formulations retained a net negative charge, with the 1 mM
SDS/3 mM B78 having a slightly lower zeta potential.

Coating the NPs with an

increasing concentration of Tat resulted in a decrease in the overall charge of the
particles; however, the Tat-coated NPs continued to have a net negative charge possibly
due to the exposed negatively charged amino acids of the protein or due to an excess
amount of anionic NPs present.

Immune responses to Tat coated on anionic NPs: Study 1
In vivo responses to the different anionic NPs were evaluated in BALB/c mice to
identify if using different surfactant compositions would affect the cellular and/or
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humoral immune responses generated to Tat. As shown in Figure 8.1, there were no
significant differences in the Tat-specific antibody titers produced at all time points
assessed.

Moreover, the evaluation of IgG1 and IgG2a antibody titers did not

demonstrate any significant differences in the formulations (Figure 8.2). These data
combined suggest that the different formulations were equally effective at generating
humoral immune responses and Th1 type immune responses, as indicated by the IgG2a
production with the various formulations.
Previous results with Tat coated on anionic NPs (1 mM SDS/3 mM Brij 78)
demonstrated that the anti-sera from Tat immunized animals produced antibodies with
specificity in the N-terminal and basic regions of the protein [438]. To further assess the
different anionic formulations in their ability to produce antibodies to Tat specific for
these regions, the anti-sera collected in Study 1 was evaluated for binding to 15-mer Tat
peptides covering the N-terminal and basic regions of Tat. As shown in Table 8.4, all
groups contained antibodies that recognized these regions of Tat and no obvious
differences due to the different formulations of NPs were noted.
The Tat-neutralizing antibodies generated using different anionic NP formulations
were assessed using an LTR-transactivation assay. In the previous study presented in
Chapter 4, modest Tat-neutralizing activity was demonstrated with all Tat anti-sera
compared to literature reports. This was speculated to be due to differences in assay
conditions and thus, further work to optimize the LTR-transactivation assay was carried
out. In attempt to improve the assay, two modifications were made to the existing LTRtransactivation assay: 1) HeLa cells transfected with pHIV-CAT were used instead of the
SVGA cells, and 2) Tat-containing supernatants replaced the use of recombinant Tat as
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the source for extracellular protein in the assay. Using this modified assay, the sera from
all Tat-immunized groups demonstrated the ability to neutralize extracellular Tat as
shown in Figure 8.3. More importantly, the Tat-neutralizing activity was retained at
higher serum dilutions, which was not possible in the assay described in Chapter 4.
Therefore, the altered conditions improved the sensitivity of the assay and studies to
further optimize the assay are ongoing.
To evaluate cellular immune responses, the spleens were pooled and stimulated
with 0.1 and 1.0 μg/mL Tat or with pooled 15-mer Tat peptides. No significant Tatspecific splenocyte proliferative responses compared to the naïve group were detected at
a concentration of 0.1 μg/mL Tat (Figure 8.4). However, at Tat concentration of 1.0
μg/mL, significantly higher Tat-specific proliferation was seen with all NP groups
compared to the naïve group.

In addition, the Tat-specific splenocyte proliferative

response with the 15 mM SDS group was significantly higher than both of the 1 mM
SDS/3 mM B78 groups (p<0.05).

Tat has been observed to induce non-specific

proliferation of naïve cells as seen in Figure 8.4. This has also been reported by other
groups [412]. Thus, the use of pooled 15-mer Tat peptides was also evaluated in effort to
identify the appropriate sequence(s) for future assays. As shown in Figure 8.5, the
strongest response compared to the naïve group was observed with peptide set 5, which
included the C-terminus peptides for Tat; however, no significant differences were
observed among the test groups.
The IFN-γ release from stimulated splenocytes was evaluated in 72 hr
supernatants by ELISA. Once again, Tat-induced non-specific IFN-γ release in naïve
cells, proving it difficult to assess cellular responses with the test groups (Figure 8.6).
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The strongest IFN-γ release was observed with the 1 mM SDS/3 mM B78 control (Ctrl)
and 15 mM SDS NP groups using the 1.0 μg/mL Tat concentration. Moreover, IFN-γ
release from splenocytes stimulated with the pooled 15-mer Tat peptides demonstrated
strongest responses with the 15 mM SDS NP group with set 4 and 5 as shown in Figure
8.7; however, it should be noted that the IFN-γ release was quite modest compared to that
obtained with Tat protein. In addition, non-specific IFN-γ release from naïve cells
stimulated with peptide set 5 was also observed. Taken together, these data suggested
that while no differences existed in the humoral immune responses to the various
formulations, potential differences in the cellular responses (IFN-γ release) to Tat using
the different formulations may exist and were further evaluated in a second study.

Immune responses to Tat coated on anionic NPs: Study 2
Based on the immune responses results from Study 1, a second study to evaluate
the immune responses to Tat was carried out with these three formulations: 15 mM
SDS/1 mM B78; 1 mM SDS/3 mM B78 (unpurified control); and 15 mM SDS. In this
study, purification of 1 mM SDS/3 mM B78 was not included because of the lack of
significant differences between this group and the control group in the first study. In the
second immunization study, a higher dose of Tat, 5 μg, was used for evaluating Tatspecific cellular responses to enable easier identification of differences among the NP
groups. As observed in Study 1, no significant differences were observed in the Tatspecific IgG titers on day 42 (Figure 8.8). Furthermore, the splenocyte proliferation
assay demonstrated Tat-specific proliferation with all groups including the naïve group
making it difficult to point out any differences among the groups (Figure 8.9).
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Surprisingly, no proliferation to any of the pooled Tat peptide sets was observed with the
groups and in the IFN-γ release assay only one animal from the 1 mM SDS/3 mM B78
group demonstrated a strong response after stimulation with all of the pooled Tat peptide
sets (data not shown).

The IFN-γ release data also did not show any significant

differences among the groups, and non-specific IFN-γ release after stimulation with the
Tat protein in the naïve group was observed (Figure 8.10).
In summary, previous reports from our laboratory have demonstrated that anionic
NPs were effective at enhancing the immune responses to protein-based vaccines. In the
present studies, further work was carried out to evaluate if any differences in the cellular
and/or humoral immune responses could be identified using anionic NPs of varying
surfactant composition. Based on the data from two in vivo studies using 1 and 5 μg of
Tat coated on these various anionic NP formulations, no significant differences in the
humoral responses were observed. Likewise, all NP formulations used were effective at
generating neutralizing antibodies to Tat as demonstrated by the improved LTRtransactivation assay. Overall, the cellular responses to the anionic NPs also did not
show strong differences. However, there were numerous challenges faced with assessing
cellular immune responses to the Tat protein. For example, Tat demonstrates mitogenic
activity in the cellular assays. The use of Tat peptides was also investigated but it was
difficult to identify the optimal regions to include in future studies and further studies
optimizing the cellular assays to evaluate Tat-specific responses are necessary.

197

Acknowledgements
I would like to thank Dr. Avindra Nath’s laboratory at John’s Hopkins University for
performing the LTR-transactivation assay. I would also like to thank Martin Ward in Dr.
Woodward’s laboratory for his help with the in vivo studies.

Copyright © Jigna D. Patel 2006

198

Table 8.1. Composition of anionic NP formulations.

Formulation

Brij 78 (mg)

Volume of
50 mM SDS
(μL)

DI Water
(mL)

15 mM SDS

0

600

1.4

15 mM SDS/1 mM Brij 78

2.3

600

1.4

1 mM SDS/3 mM Brij 78

6.9

40

1.96
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Table 8.2. Experimental conditions for mouse immunization studies.

Study

Study 1

Study 2

Formulation
Naïve
15 mM SDS
15 mM SDS/1 mM B78
1 mM SDS/3 mM B78
1 mM SDS/3 mM B78
(unpurified Control)
Naïve
15 mM SDS
15 mM SDS/1 mM B78
1 mM SDS/3 mM B78
(unpurified Control)

Tat
Dose
1 μg
1 μg
1 μg

Immunization
Schedule
-

Day 0, 14, 28

Sera
Collected

Day 13, 35, 42

1 μg
5 μg
5 μg
5 μg

200

Day 0, 14, 28

Day 42

Table 8.3. Physical characteristic of anionic NP formulations.
Before GPC
Formulation

15 mM SDS
15 mM SDS/1 mM B78
1 mM SDS/3 mM B78

201

1 mM SDS/3 mM B78
(unpurified Control)

Mean size
(nm)
113.3
± 13.3
121.4
± 10.1
147.9
± 10.9
147.9
± 10.9

Mean
Charge
(mV)
-64.6
± 1.8
-61.3
± 1.9
-61.2
± 3.6
-61.2
± 3.6

The mean sizes and charges ± S.D. (n=3) are shown.
*represents mean ± S.D. (n=2).

After GPC

150.6
± 5.4
145.9
± 11.4
172.4
± 9.9*

Mean
Charge
(mV)
-63.2
± 2.0
-63.9
± 3.6
-43.3
± 5.5*

-

-

Mean size
(nm)

Tat Coated
(10 μg/mL)
Mean
Mean size
Charge
(nm)
(mV)
119.7
-58.9
± 9.8
± 6.2
130.7
-62.0
± 10.5
± 4.3
146.7
-44.4
± 13.3
± 5.8
151.27
-53.8
± 20.8
± 3.3

Tat Coated
(50 μg/mL)
Mean
Mean
Charge
size (nm)
(mV)
114.8
-51.1
± 19.4
± 2.3
122.2
-51.7
± 0.3
± 2.6
-

-

153.4
± 14.9

-46.5
± 1.4

Table 8.4. Tat anti-sera reactivity to N-terminal and basic regions of Tat. All sera
from Study 1 were diluted 1:100. The reactivity of anti-sera from each animal is
presented. *Cutoff = (AVG Naïve response) + (3*SD). (-) indicates no response –
ELISA OD values equal to cutoff/background.
Tat Peptide

aa 1-15

aa 5-19

aa 9-23

aa 45-59

aa 49-63

15 mM SDS/1 mM B78
1

1.880

2.887

-

-

-

2

1.998

2.831

0.509

0.358

0.423

3

2.743

2.862

-

-

-

4

-

-

-

0.286

0.314

5

1.073

1.355

0.184

-

-

6

0.884

2.515

0.187

-

-

7

2.691

2.656

0.168

-

0.227

1 mM SDS/3 mM B78
1

0.847

0.749

0.183

-

0.235

2

1.118

2.042

2.837

-

-

3

2.183

1.010

0.181

-

-

4

2.526

2.515

-

0.472

0.388

5

0.397

1.515

0.231

0.356

0.305

6

1.363

1.695

-

-

0.32

1

1.407

2.267

0.234

0.593

0.341

2

2.443

2.630

0.447

-

-

3

2.984

2.708

0.192

-

0.551

4

2.423

2.875

0.167

-

0.274

5

2.457

2.465

-

-

-

6

2.715

2.565

1.734

-

-

7

0.680

1.392

0.194

-

0.254

15 mM SDS

1 mM SDS/3 mM B78 Ctrl
1

2.520

2.999

1.356

-

-

2

1.726

2.89

0.685

-

0.351

3

1.609

2.523

0.215

-

-

4

-

0.790

0.200

-

0.228

5

0.368

1.440

-

-

-

6

1.110

1.468

-

-

-

7

2.984

3.047

-

-

-

8

2.934

2.531

0.172

0.275

0.228

Cutoff*

0.31

0.18

0.16

0.27

0.20
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Figure 8.1

Total Serum IgG Titer

100000

10000
Day 13
Day 35

1000

Day 42

100

15 mM SDS

1 mM SDS/3 mM B78 Ctrl

1 mM SDS/3 mM B78

15 mM SDS/1 mM B78

10

Figure 8.1. Tat-specific serum IgG titers. BALB/c mice were immunized (s.c.) on day
0, 14, and 28 with 1 μg of Tat coated on the anionic NPs (100 μg). Sera were collected
and analyzed by ELISA at various time points. Data represent the mean ± S.D. (n=6-8).
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Figure 8.2

Total Serum Titer
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Figure 8.2. Tat-specific IgG1 and IgG2a titers. BALB/c mice were immunized (s.c.)
on day 0, 14, and 28 with 1 μg of Tat coated on the anionic NPs (100 μg). Tat-specific
serum IgG1 and IgG2a titers were evaluated on day 42 by ELISA.

The mean

IgG2a/IgG1 ratio is indicated on top of the graphed titers for each group. Data represent
the mean ± S.D. (n=6-8).

204

Figure 8.3

Relative CAT activity
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Figure 8.3.

15 mM SDS

1mM SDS/3 mM B78 Ctrl

1mM SDS/3mM B78

15mM SDS/1 mM B78

Naive

0.00

Neutralizing activity of Tat anti-sera using an improved LTR-

transactivation assay. BALB/c mice were immunized on day 0, 14, and 28 with 1 μg
of Tat-coated NPs and sera were collected on day 42. Serum from each mouse was
diluted as indicated in the figure legend and evaluated for Tat neutralizing antibodies
using an optimized LTR-transactivation assay. The relative amounts of CAT expression
determined using an ELISA. Data represents mean ± SD (n = 6-8). *p<0.05 compared to
naïve group; ap<0.05 compared to 1mM SDS/3mM B78 and 15mM SDS group; bp<0.05
compared to 1mM SDS/3mM B78 and 15mM SDS group; cp<0.05 compared to 15 mM
SDS group.
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Figure 8.4

17500
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Figure 8.4. Splenocyte proliferation on day 5. BALB/c mice (n=6-8 per group) were
immunized (s.c.) on day 0, 14, and 28 with 1 μg of Tat coated on the anionic NPs (100
μg) and spleens were harvested and pooled for each group on day 42. Single cell
suspensions of the spleen were stimulated with Con A or Tat for 4 days and the
incorporation of 3H-thymidine was evaluated on day 5. The data represent the mean ±
S.D. (n=3). *p<0.01 compared to naïve group; #p<0.05 compared to the Ctrl and 1 mM
SDS/3 mM B78 group.
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Figure 8.5
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Figure 8.5. Splenocyte proliferative responses to 15-mer Tat peptides. BALB/c mice
(n=6-8 per group) were immunized (s.c.) on day 0, 14, and 28 with 1 μg of Tat coated on
the anionic NPs (100 μg) and spleens were harvested and pooled for each group on day
42.

Single cell suspensions of the spleen were stimulated with pooled 15-mer Tat

peptides for 4 days. The incorporation of 3H-thymidine was evaluated on day 5. Set 1 =
aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa 17-31, 21-35, 25-39; Set 3 = 29-43, 33-47, 37-51;
Set 4 = aa 41-55, 45-59, 49-63, 53-67; Set 5 = 57-71, 61-75, 65-79, 69-83.
represent the mean ± S.D. (n=3). *p<0.05 compared to naïve group.
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The data
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IFN-γ (pg/mL)

Figure 8.6

Figure 8.6. INF-γ release from Tat stimulated splenocytes. BALB/c mice (n=6-8 per
group) were immunized (s.c.) on day 0, 14, and 28 with 1 μg of Tat coated on the anionic
NPs (100 μg) and spleens were harvested and pooled for each group on day 42. Single
cell suspensions of the spleen were stimulated with Tat for 72 hr and the IFN-γ release in
the supernatants was quantitated by ELISA. The data represent the mean ± S.D. (n=3).
*p<0.001 compared to naïve group; #p<0.05 compared to naïve group.
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Figure 8.7
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Figure 8.7. INF-γ release from splenocytes stimulated with 15-mer Tat peptides.
BALB/c mice (n=6-8 per group) were immunized (s.c.) on day 0, 14, and 28 with 1 μg of
Tat coated on the anionic NPs (100 μg) and spleens were harvested and pooled for each
group on day 42. Single cell suspensions of the spleen were stimulated in triplicate with
pooled 15-mer Tat peptides and the supernatants were pooled at 72 hr from triplicate
wells and the assayed for IFN-γ by ELISA. Set 1 = aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa
17-31, 21-35, 25-39; Set 3 = 29-43, 33-47, 37-51; Set 4 = aa 41-55, 45-59, 49-63, 53-67;
Set 5 = 57-71, 61-75, 65-79, 69-83.

The data represent the mean ± S.D. (n=2). ap<0.01

compared to all groups; bp<0.001 compared to all groups; cp<0.001 compared to all
groups.
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Figure 8.8
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Figure 8.8. Tat-specific serum IgG titers. BALB/c mice were immunized (s.c.) on day
0, 14, and 28 with 5 μg of Tat coated on the anionic NPs (100 μg). Sera were collected
and analyzed by ELISA at various time points. Data represent the mean ± S.D. (n=6-8).
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Figure 8.9
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Figure 8.9. Splenocyte proliferation on day 5. BALB/c mice were immunized (s.c.)
on day 0, 14, and 28 with 5 μg of Tat coated on the anionic NPs (100 μg) and spleens
were harvested on day 42. Single cell suspensions of the spleen were stimulated in
triplicate for 4 days. The incorporation of 3H-thymidine was evaluated on day 5. Set 1 =
aa 1-15, 5-19, 9-23, 13-27; Set 2 = aa 17-31, 21-35, 25-39; Set 3 = 29-43, 33-47, 37-51;
Set 4 = aa 41-55, 45-59, 49-63, 53-67; Set 5 = 57-71, 61-75, 65-79, 69-83.
represent the mean ± propagated error. (n=6-8).
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The data

Figure 8.10
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Figure 8.10. IFN-γ release from Tat stimulated splenocytes. BALB/c mice (n=6-8)
were immunized (s.c.) on day 0, 14, and 28 with 5 μg of Tat coated on the anionic NPs
(100 μg) and spleens were harvested on day 42. Single cell suspensions of the spleen
were stimulated with Tat (1.0 μg/mL) for 72 hr and the IFN-γ release in the supernatants
was quantitated by ELISA. The graph show IFN-γ release from stimulated splenocytes
for each mouse in the group and the horizontal line represents the mean for each group.
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Chapter 9

Summary and conclusions

The purpose of the studies presented herein was to investigate the potential of
nanoparticles for enhancing immune responses to the HIV-1 proteins, Tat and Gag p24.
The hypotheses driving this research were that: 1) mice dosed with anionic nanoparticles
coated with HIV-1 proteins would result in enhanced humoral and cellular immune
responses compared to those dosed with protein adjuvanted with Alum, 2) increasing the
affinity of the protein antigen for the nanoparticles would result in a more stable
attachment and lead to a corresponding enhancement in the immune responses in vivo
compared to antigens coated on anionic nanoparticles by charge interaction, and 3) mice
dosed with nanoparticles co-formulated with protein antigen and an immunostimulatory
molecule would produce enhanced immune responses compared those dosed with protein
antigen with either nanoparticles or immunostimulatory molecule alone.
In these studies, anionic NPs were prepared from oil-in-water microemulsions
using emulsifying wax as the oil phase and Brij 78 and SDS as the surfactants. The
overall composition of surfactants used to prepare the anionic NPs did not significantly
affect the immune responses generated to Tat. Anionic NPs coated with HIV-1 Tat were
demonstrated to generate superior immune responses compared to Tat adjuvanted with
Alum. A dose-response study with Tat demonstrated that NPs were able to generate
comparable levels of Tat-specific IgG titers using a 1 and 5 μg Tat dose, whereas Alum
resulted in significantly lower IgG titers at the lower dose of Tat. To determine the
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antibody epitopes generated, the Tat anti-sera was evaluated for recognition to 15-mer
Tat peptides by ELISA. It was found that the Tat anti-sera from immunized animals
reacted greatest with the N-terminal and basic regions of the protein, which is consistent
with literature reports [387,412-414]. The NP groups demonstrated higher levels of
antibodies recognizing the basic region compared to Alum. Moreover, the anti-sera from
Tat-immunized mice were capable of blocking extracellular Tat in a LTR-transactivation
assay.
To investigate the potential of these NPs for synergistic enhancements in immune
responses with immunostimulatory molecules, cationic NPs were prepared and
formulated with three different immunostimulatory molecules. These molecules are TLR
ligands and were expected to enhance immune response via stimulation of the innate
immune system. The cationic NPs were coated with the immunostimulatory molecules,
LTA, CpG, and Poly I:C, and evaluated for immune responses generated to OVA. From
these studies, CpG demonstrated the greatest immunostimulatory activity and further in
vivo evaluation demonstrated that CpG coated NPs resulted in significant enhancements
in the OVA-specific antibody titers compared to either adjuvant alone.
To gain an understanding of the mechanism(s) by which nanoparticles may be
enhancing immune responses to the associated antigens, two studies were carried out. In
the in vitro studies, the uptake of NPs into DCs and consequently, the release of proinflammatory cytokines were evaluated. These studies demonstrated that NPs were taken
by into DCs and accumulated intracellularly in the cytoplasm.

Analysis of pro-

inflammatory cytokines after 24 hr incubation of NPs with DCs demonstrated that the
NPs did not cause release of any significant levels of TNF-α, IL-1β or IL-12.
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Furthermore, significant enhancements in IL-12 release were observed after incubating
the CpG coated NPs with DCs compared to CpG alone. These in vitro studies suggested
that NPs were enhancing the uptake of the associated molecule into DCs and this
mechanism, at least in part, contributes to the enhancements in immune responses
observed in vivo.
In the second study, the extent to which antigens coupled to NPs stimulated CD8+
T cells in vivo were evaluated by performing an adoptive transfer of transgenic T cells
from the OT-1 mouse into C57BL/6 mice. The OT-1 transgenic mouse model expresses
a class I restricted receptor specific for OVA presented by the H-2Kb class I molecule.
These studies demonstrated that NPs significantly enhanced the uptake of the associated
protein into the MHC class I processing pathway and thus, resulted in enhanced
presentation to CD8+ T cells in vivo compared to soluble OVA.

This enhanced

presentation via the MHC class I pathway was thought to be due to enhanced delivery of
coated OVA into DCs compared to soluble OVA.
These in vitro and in vivo data together suggest that NPs enhance immune
responses primarily through enabling greater accumulation of the associated antigen into
DCs compared to soluble antigen. The NPs investigated so far have taken advantage of
coating the antigen on the surface through simple ionic interactions. It was hypothesized
that by increasing the affinity of the antigen for the NPs, a greater accumulation of the
antigen into DCs can be achieved and this would result in further enhancements in the
immune responses compared to the surface coated antigen on anionic NPs. For this, NPs
containing a small amount of surface-chelated Ni were prepared and shown to bind to
his-tag proteins with more strongly compared to NPs prepared without the Ni.
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Furthermore, in vivo evaluation of his-tag Gag p24 bound to Ni-NPs generated superior
IgG responses, including IgG2a, compared to protein adjuvanted with Alum or coated on
the surface of NPs.
In conclusion, these studies highlight the potential applications of NPs prepared
from oil-in-water microemulsion precursors for enhancing immune responses to both
HIV-1 Tat and Gag p24. Of significant importance is the demonstration that the 72 aa
Tat protein was effective at generating antibodies that recognized the same regions of the
protein when compared to the full-length Tat protein (1-86 or 1-101) [387,412-414].
Many researchers believe that a Tat-based vaccine may play a vital role in controlling the
disease progression [346,368,400]. To this end, the use of the full-length Tat protein as a
potential HIV vaccine has been investigated [384]. However, some reports suggest that
the full-length Tat is immunosuppressive. As an alternative, one group has reported on
the use of Tat-toxoid as a potential Tat vaccine [457]. A previous study in our laboratory
demonstrated that Tat (1-72) is not immunosuppressive [253] and the studies presented
here further confirm the ability to generate antibodies to both the N-terminal and basic
regions, which is consistent with literature reports using the full-length Tat protein. In
addition, the antibodies to Tat (1-72) are able to neutralize extracellular Tat as
demonstrated by the LTR- transactivation assays. Therefore, the use of Tat (1-72) coated
on NPs in a potential HIV vaccine may be a good alternative to the current approaches
with the full-length Tat protein or Tat-toxoid.
A significant contribution in the advancement of delivery systems for proteinbased vaccines was further demonstrated through the development of a simple and rapid
approach for attaching protein antigens to the surface of NPs via surface-chelated nickel.
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Several studies, including those presented herein, suggest that particulate delivery
systems may result in enhanced immune responses in vivo due to the higher uptake of
antigen associated with the particles [239,427]. However, the conventional approach of
coating the protein antigen on a charged particle, while effective at enhancing immune
responses, may be inefficient or sub-optimal due to possible dissociation of some of the
antigen from the particle after in vivo administration. Typical approaches utilized for
attachment of antibodies or proteins to particles often require activating agents or
multiple steps and pose challenges in obtaining high conjugation yields.

As an

alternative, the studies presented in this dissertation demonstrated that NPs containing a
small amount of surface-chelated nickel could be prepared.

The Ni-NPs provide a

relatively simple approach for attaching protein antigens containing his-tag on the surface
of the NPs. More importantly, this technology may be widely applicable to protein-based
vaccines because the interaction uses a simple histidine tag that could be incorporated in
the expression vector during the protein production process.
Although the studies presented here illustrate the potential applications of NPs for
HIV-1 protein-based vaccines, more experiments to further characterize and optimize
these systems will be necessary. The studies presented in this dissertation were based on
using the in vivo immune responses as the end point; however, minimal work was carried
out to correlate the effect of formulation parameters on the in vivo immune responses. It
must be recognized that several steps are involved between the protein formulation with
the NPs and the in vivo responses that may prove to be critical in the generating the
immune responses but are missing in the work presented here. For example, the protein
stability and release, as well as the uptake of the associated antigen by DCs using both
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the charged NPs and Ni-NPs are critical parameters to evaluate. These types of in vitro
studies may provide clues for further improvements that could be made in the
formulations, which may lead to greater enhancements in the cellular and humoral
immune responses. Moreover, additional in vitro studies investigating the expression of
co-stimulatory molecules on DCs and the processing and presentation of antigens on DCs
may provide insight into the possible mechanisms by which NPs are enhancing the
immune responses in vivo.
While in vitro studies may provide a basic understanding of mechanistic
processes, ultimately in vivo studies will be necessary to providing a greater
understanding of the possible functions of NPs. Along these lines, the fate of the protein
associated with the NPs after in vivo administration would provide a greater
understanding of their role in stimulating immune responses.

Additional studies

evaluating the responses occurring at the site of injection, i.e. inflammation, may reveal
other contributing mechanisms through which NPs enhance the immune responses to
antigens.

Furthermore, if the uptake of the NPs is found to be critical in enhancing the

immune responses, exploring the use of a DC-targeting ligand may also provide
additional benefits in improving the immune responses to the antigen. Combined these
additional studies may reveal further improvements or alternative formulation approaches
that could be investigated for building better nanoparticle-based delivery systems for
HIV-1 protein-based vaccines.
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Appendices

This section contains the following information and additional experiments:

•

Appendix A: Structures and physical properties for various materials used in the
dissertation

•

Appendix B: Preparation and characterization of sterically stabilized anionic
nanoparticles for delivery of HIV-1 Tat and Gag proteins

•

Appendix C:

Synthesis of mannopentaose targeting ligand and in vitro

evaluation
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Appendix A

Figure A1

(OCH2CH2)XOH

HO(CH2CH2O)W
O

CH(OCH2CH2)YOH

O

CH2(OCH2CH2)Z -O-C-CH2 (CH2)15CH3
Polysorbate 60 (Polyoxyethylene 20 sorbitan monostearate);
W+X+Y+Z = 20; Mw 1312; HLB 14.9

CH3 (CH2)14CH2OH
Cetyl Alcohol; Mw 242; m.p. 49oC

Figure A1.

Structure and properties of emulsifying wax.

comprised of cetyl alcohol and polysorbate 60 in a 20:1 molar ratio.
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Emulsifying wax is

Figure A2

CH3 (CH2)17 (OCH2CH2)20OH
Polyoxyethylene 20 Stearyl Ether (Brij® 78); Mw 1150;
m.p. 38oC; HLB 15.3

CH3(CH2)11 SO4Na
Sodium Dodecyl Sulfate (SDS); Mw 288; HLB 40

CH3(CH2)15N(CH3)3Br
Cetyl Trimethyl Ammonium Bromide (CTAB); Mw 364.5; HLB 10

Figure A2. Structure and physical properties of surfactants used for preparing
nanoparticles. Neutral, anionic, and cationic nanoparticles were prepared using Brij 78,
SDS, and CTAB, respectively.
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Figure A3

3,3'-dioctadecyloxacarbocyanine perchlorate (DiOC18); Mw 881.72
Ex: 484 nm and Em: 501nm

Figure A3. Chemical structure and physical properties of DiOC18. This green
fluorescent marker was used for labeling nanoparticles for confocal microscopy studies
looking

at

nanoparticle

uptake

into

BMDDCs.

http://probes.invitrogen.com/servlets/structure?item=275)
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Appendix B

Preparation and characterization of sterically stabilized anionic nanoparticles for
delivery of HIV-1 Tat and Gag Proteins

B.1

Preparation of sterically stabilized anionic NPs
Anionic NPs have been previously prepared in Dr. Mumper’s laboratory from

microemulsion precursors [16]. Briefly, the microemulsions were prepared at 50-55°C
by forming a homogeneous slurry of emulsifying wax (comprised of 20:1 cetyl
alcohol/polysorbate 60) in water followed by the addition of sodium dodecyl sulfate
(SDS) at a final concentration of 15 mM to result in the formation of stable, clear
systems.

The mircoemulsion systems were cooled to room temperature while stirring to

form NPs of approximately 100 nm in size. Excess surfactant was removed by gel
permeation chromatography (GPC) using a Sephadex G75 column (15 mm x 70 mm) and
the particle size was measured by photon correlation spectroscopy (PCS) using a Coulter
N4 Plus Particle Sizer at 90° for 60 s.
Initial stability studies of these anionic NPs prepared from 15 mM SDS revealed
that the particles aggregated at 25°C in 150 mM sodium chloride (NaCl) (Figure B1). To
sterically stabilize these NPs, the use of Brij 78 as a co-surfactant was investigated. The
anionic NPs were prepared as stated above using concentrations of 0.5 to 1 mM Brij 78.
NPs were further purified by GPC to remove the excess surfactant and then evaluated in
150 mM NaCl at 25°C to determine the concentration of Brij 78 required for stabilization
of the particles. As shown in Figure B1, a minimum of 0.5 mM Brij 78 was required to
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stabilize the NPs under the conditions tested. Anionic NPs prepared using 0.5 and 1.0
mM of Brij 78 were further evaluated at 37°C in simulated biological media. Anionic
NPs prepared with 1.0 mM Brij 78 were found to be stable in 150 mM NaCl, 10 mM
phosphate buffered saline (PBS) pH 7.4, 10% (v/v) fetal bovine serum (FBS) in 150 mM
NaCl and 10% (w/v) lactose at 37°C (Figure B2). In addition, characterization of these
anionic NPs prepared using 15 mM SDS and 1 mM Brij 78 by Transmission Electron
Microscopy (TEM) revealed that the particles were approximately 50 to 100 nm in size
with spherical morphology (Figure B3). This formulation was chosen for further work
for coating with the HIV-1 protein antigens.
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Figure B1

2000

Particle Size (nm)

1600

0 mM B78

1200

0.1 mM B78

800

0.5 mM B78

400
200

1.0 mM B78

100

0
GPC

0 hr

1 hr

2 hr

Figure B1. Stability of GPC purified anionic NPs in 150 mM NaCl at 25oC. All NPs
were prepared using 15 mM SDS and varying concentrations of Brij 78 (B78) as
indicated on the graph. The formulations were passed through a GPC column to remove
excess surfactant and the size after purification (GPC) was measured. The stability of the
particles was determined over 2 hr in 150 mM NaCl by measuring the size and 0 hr on
graph indicates the sized immediately after adding the NaCl. Data represents mean ±
S.D. (n=3).
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Figure B2
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Stability of anionic NPs in simulated biological media at 37oC.

Negatively charged NPs were prepared using emulsifying wax as the oil phase and 15
mM SDS and 1 mM Brij 78 as the surfactants. NPs were purified by GPC to remove any
excess surfactant and stability of the particles was evaluated based on particle size
measurements. Data represents mean ± SD (n=3).
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Figure B3

Figure B3. TEM of anionic NPs. Anionic NPs prepared using 15 mM SDS and 1 mM
Brij 78 surfactants were purified by GPC.
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B.2

Preparation and characterization of HIV-1 Tat-coated NPs
Anionic NPs were purified by GPC to remove excess surfactant, and filtered

through a 0.2 μm filter. A volume of 200 μL of the purified NPs (~40 μg) was gently
mixed at varying concentrations of Tat for 1 hr at room temperature. The adsorption of
Tat on the surface of NPs was verified by measuring the overall charge (Figure B4) using
a Zeta Sizer 2000 from Malvern Instruments, Inc. and TEM analysis of the Tat-coated
NPs suggested that the particles retained a spherical shape and ~100 nm size (Figure B5).
As expected, an increase in the concentration of Tat adsorbed on the surface of the NPs
resulted in an increase in the overall charge of the NPs (Figure B4) up to a final
concentration of 25 μg/mL, above which a plateau observed. This may be due to the
negative residues in the Tat protein being exposed at the surface of the particle.
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Figure B4. Anionic NPs coated with HIV-1 Tat. The size and charge of the particles
was characterized before (Ctrl) and after coating with increasing concentrations of Tat.
Data represents mean ± SD (n=2).
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Figure B5

Figure B5. TEM of HIV-1 Tat-coated NPs. Anionic NPs were prepared using 15 mM
SDS and 1 mM Brij 78 and excess surfactant was separated by GPC. The GPC purified
NPs were coated with Tat (25 μg/mL).
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B.3

Preparation and characterization of HIV-1 Gag-coated NPs
HIV-1 Gag p55 (obtained through the AIDS Research and Reference Reagent

Program, Division of AIDS, NIAID, NIH: HIV SF2 Gag p55 from Chiron Corporation
and the DAIDS) is insoluble in water and most other buffer systems. Therefore, the
protein is supplied in 50 mM sodium phosphate (pH 7.9) with 0.4 M NaCl and 6 M urea.
To coat anionic NPs with Gag p55, first, excess surfactant was removed by GPC using
6 M urea as the mobile phase. The purified NPs were collected and filtered through a
0.2 μm filter, and 200 μL (40 μg) of NPs were gently mixed with 1, 5, and 10 μg of Gag
p55 for 1 hr at room temperature. The coated and uncoated NPs (Ctrl) were centrifuged
at 8000 x g at 20oC using Microcon® YM-100 (Millipore, MWCO 100 kDa)
ultracentrifuge devices to desalt and remove urea by washing three times with water. The
NPs were re-suspended in water (0.2 μm filtered), and characterized by size and charge
(Figure B6). The adsorption of Gag p55 on the NPs was also confirmed by TEM (Figure
B7), where small, 50 nm size particles formed by Gag p55 were shown to be adsorbed on
anionic NPs.
NPs coated with Gag p55 were analyzed using SDS-PAGE and densitometry to
quantify the amount of protein adsorbed on the surface. Samples and standards were
loaded on pre-cast Novex® 4-20% Tris-Glycine gradient gels and were run under
reducing conditions at 125V for 90 min. The gels were developed by silver staining,
photographed using GeneSnap, and analyzed by densitometry using GeneTools software.
For densitometry, five standards (100, 200, 300, 500, and 700 ng of Gag p55) were run
on each gel along with the samples.

The amount of protein in all samples was

calculated from the standard curve and the coating efficiency for Gag p55 was
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determined using these results. The percent of protein adsorbed after ultrafiltration was
calculated based on the initial (before ultrafiltration) concentration of Gag p55 for NPs
having a final protein concentration of 25 μg/mL and 50 μg/mL. For NPs coated with
Gag p55 at a final concentration of 5 μg/mL, the samples were below detection limit;
thus, the sample was only analyzed after ultrafiltration and the percent of protein
adsorbed was calculated based on the theoretical concentration. As shown in Figure B8,
approximately 100% of the protein was adsorbed on the surface of the NPs when the Gag
p55 was at a final concentration of 5 μg/mL and 25 μg/mL. In contrast, when the Gag
p55 was at a final concentration of 50 μg/mL, only 75% of the protein was adsorbed on
the surface of NPs. Gag p55 coated NPs were found to be stable (as determined by
retention in particle size) for up to 60 min in 150 mM NaCl, 10 mM PBS, 10% (v/v)
FBS, and 10% (w/v) lactose at 37oC (data not shown).
As mentioned above, the use of Gag p55 provides some difficulties in handling
the protein since it is insoluble and must be dissolved in 6M urea. As a result, the urea
must be removed. This poses potential difficulties in carrying out in vivo studies for
immunization with protein adjuvanted with Alum. For further studies, the use of Gag
p24, which is positively-charged and water-soluble, was investigated. More importantly,
it has been previously shown that Gag p24 is highly conserved and leads to cross-reactive
CTL responses [353,354,356]. After GPC purification of the NPs, 1, 5, and 10 μg of Gag
p24 (Trinity Biotech; Carlsbad, CA) were gently mixed with approximately 40 μg of NPs
for 1 hr at room temperature. The size and charge of Gag p24-coated NPs is presented in
Figure B9.

The overall charge of the NPs becomes more positive with increasing

concentrations of Gag p24, confirming adsorption to the surface of NPs. As seen with
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Tat, a plateau in the charge of the NPs results above a Gag p24 concentration of
25 μg/mL thought to be possibly due to negatively charged residues of the protein being
exposed on the surface of the NPs.
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Figure B6. Anionic NPs coated with HIV-1 Gag p55. The size and charge of the
particles was characterized before (Ctrl) and after coating with increasing concentrations
of Gag p55. Data represents mean ± SD (n=2).
.
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Figure B7

Figure B7. TEM of HIV-1 Gag p55-coated NPs. Anionic NPs were prepared using 15
mM SDS and 1 mM Brij 78 and excess surfactant was separated by GPC. The GPC
purified NPs were coated with Gag p55 (25 μg/mL). Gag p55 forms small particles of
approximately 50 nm in size as shown on the overlayed TEM. Thus, the smaller particles
adsorbed on the larger size particles were confirmed to be Gag p55.
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Figure B8. Coating efficiency of HIV-1 Gag p55 on anionic NPs. The amount of Gag
p55 associated with the NPs was determined by SDS-PAGE/densitometry.
represent mean ± S.D. (n=2-6).
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Figure B9. Anionic NPs coated with HIV-1 Gag p24. The size and charge of the
particles was characterize before (Ctrl) and after coating with increasing concentration of
Gag p24. Data represents mean ± SD (n=2).
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B.4

Immune responses to HIV-1 Tat- and Gag p24-coated NPs
BALB/c mice (n=5-6/group) were immunized intramuscularly (i.m., 50 μL per

gastrocnemius muscle) on day 0 and day 20 with 2.5 μg Tat or Gag p24 adjuvanted with
Alum (Spectrum) or 2.5 μg Tat or Gag p24 coated on NPs. In this study, Alum was used
as a positive control for a Th2 type immune response. The sera from all mice were
collected on day 36 for further assessment of humoral immune responses generated in the
various groups. The Tat- and Gag p24-specific serum IgG levels, determined by ELISA,
are shown in Figure B10 and B11, respectively.
The IgG antibody responses from the Tat-immunized mice were stronger than the
Gag p24-immunized mice, which may be indicative of the higher immunogenicity of Tat
compared to Gag p24. However, in both the Tat- and Gag p24-immunized mice, the
antibody levels for mice immunized using NPs versus Alum, a control for Th2 type
immune response, were comparable and statistically insignificant. This demonstrates the
potential of anionic NPs for producing similar enhancements in immune responses to the
approved Alum adjuvant after i.m. administrations. However, previous results using
anionic NPs coated with the model antigen β-galactosidase suggests that NPs produced
superior immune responses to Alum after subcutaneous (s.c.) immunization.

The

differences in the responses with NPs obtained in the two studies may be antigen specific
or may indicate that the s.c. route may be better compared to i.m. for generating immune
responses with the NPs.
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Figure B10
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Figure B10. Tat-specific total serum IgG levels on day 36. Mice were immunized
with 2.5 μg of Tat coated on anionic NPs or adjuvanted with Alum on day 0 and day 20
by 50 μL injection into each gastrocnemius muscle. Data represent mean ± S.D. (n=5-6).
*p<0.05 compared to naïve group by ANOVA.
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Figure B11
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Figure B11.

Gag p24-specific total serum IgG levels on day 36.

Mice were

immunized with 2.5 μg of Gag p24 coated on anionic NPs or adjuvanted with Alum on
day 0 and day 20 by 50 μL injection into each gastrocnemius muscle. Data represent
mean ± S.D. (n=5-6). *p<0.05 compared to naïve group by ANOVA.
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B.5

Conclusions
These studies demonstrated that simple anionic NPs prepared using 15 mM SDS

could be stabilized by inclusion of Brij 78. Furthermore, the resulting anionic NPs could
be coated with HIV-1 Tat, Gag p55, and Gag p24. The in vivo immune responses to Tatand Gag p24-coated NPs demonstrated that these systems were similar in enhancing
immune responses compared to protein adjuvanted with Alum after i.m. immunization.
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Appendix C

Synthesis of mannopentaose targeting ligand and in vitro evaluation

The mannose receptor (MR) has been utilized for targeting antigens to DCs and
thus, obtaining enhanced immune responses [275]. Many groups have investigated the
use of hydrophobized mannan for enhancing immune responses to antigens [15,282,283].
Mizuochi et al. have investigated various oligosaccharide ligands and demonstrated that
hydrophobized mannopentaose (Figure C1) attached to the surface of liposomes
generated enhanced cellular responses compared uncoated liposomes [283,285]. Thus,
the use of hydrophobized mannopentaose was further investigated as a potential targeting
ligand for increasing NPs uptake in vitro into DCs.
The conjugation of mannopentaose to the lipid, 1,2-dipalmitoyl-sn-glycero-3phosphoethanolamine (DPPE) has been previously described and was followed with
minor modifications [458]. Briefly, 7.7 mg of DPPE (Avanti Polar Lipids; Alabaster,
AL) was reacted with 1.2 mg mannopentaose (Sigma; St. Louis, MO) in 1.5 mL of
chloroform/methanol (1:1 v/v) at 60°C for 2 hr in an 8 mL glass vial with a Teflon coated
cap. Sodium cyanoborohydride was added after 2 hr and the reaction was allowed to
proceed at 60oC.

The progress of the reaction was monitored by thin layer

chromatography using chloroform/methanol/water 105:100:28 (v/v/v) using orcinol
reagent (Fisher; Hampton, NH) to visualize the mannopentaose and the lipid conjugate.
The reaction was stopped when the mannopentaose was undetectable by TLC (~5 days).
The product was purified by column chromatography using silica gel 60 (EM Science;
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Gibbstown, NJ) with the following solvent systems (all indicate volume to volume
ratios):

1) 1:1 chloroform/methanol; 2) 11:9:2 chloroform/methanol/water; and 3)

10:10:3 chloroform/methanol/water.

The eluent from the column was fractionated,

checked for presence of the lipid-mannopentaose conjugate by TLC, and the fractions
positive for conjugate were combined and the solvent was evaporated. The product was
confirmed to be DPPE-mannopentaose by mass spectrometry with the molecular ion peak
present at 1504 m/z (Figure C2).
To determine if the DPPE-mannopentaose could serve as a targeting ligand to
enhance the uptake of NPs into BMDDCs, radiolabeled anionic NPs using Brij 78 and
SDS (3 mM and 1 mM, respectively) as the surfactant were prepared with 1 to 10% w/w
of DPPE-mannopentaose. BMDDCs were confirmed to express the mannose receptor by
flow cytometry (Figure C3). The uptake by BMDDCs of the DPPE-mannopentaose NPs
was compared to the anionic NPs (B78/SDS) at 37oC.

As a control, the various

formulations were also incubated with BMDDCs at 4oC to differentiate the binding
versus active uptake expected at 37oC and significantly accumulation of all NP
formulations was observed at 37oC compared to 4oC (data not shown). As shown in
Figure C4, there were no significant differences in the uptake of the particles with
inclusion of DPPE-mannopentaose over the 4 hr evaluated. It is important to note that
the NPs without the targeting ligand were efficiently taken up by the BMDDCs, with
about 40% accumulation into the cells over the 4 hr. This highly efficient uptake of NPs
may present difficulty in evaluating differences in uptake due to the targeting ligand in
vitro. However, this strategy may be viable in vivo and may cause enhanced immune
responses since there are other cells present and the presence of the ligand may facilitate
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targeting and higher uptake into DCs versus other cell types. Alternatively, it is possible
that the ligand on the NPs is not accessible for interaction with the mannose receptor on
the BMDDCs. This may be evaluated by inclusion of a hydrophilic spacer such as
polyethylene glycol between the lipid and mannopentaose moieties to allow for more
flexibility and accessibility for interaction with the receptor.
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Figure C1

Figure C1. Structure of DPPE lipid conjugated to mannopentaose. The molecular
weight of this ligand was calculated to be 1504.70. (Structure from Shimizu et al. [286])
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Figure C2

Figure C2. Mass spectrum for purified DPPE-mannopentaose ligand. The mass
spectrum was obtained in a negative ion mode by MALDI-TOFMS.
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Figure C3

(A)

(B)
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CD11c

Figure C3. Mannose receptor expression on BMDDCs. A) Cells from primary
culture of murine bone-marrow were identified as DCs by staining the cells with CD11c
and MHC I antibodies. The double positive cells, circled, were gated to see expression of
mannose receptor on the BMDDCs. B) Cells were labeled with a murine mannose
receptor antibody (CD206). Double positive cells from (A) that are also positive for
mannose receptor are shown.
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Figure C4. Uptake of radiolabeled NP formulations in BMDDCs. An amount of 1
μg of anionic NP (B78/SDS) or anionic NPs containing 1, 5 and 10% w/w DPPEmannopentaose were incubated with BMDDCs at 37oC. The radioactivity associated
with the cells was measured at the time points shown to evaluate uptake of the various
NP formulations.
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